CUMULATIVE SUPPLEMENT 7
JULY 2015



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

Cumulative Supplement 7

July 2015

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

CUMULATIVE SUPPLEMENT 7
July 2015

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
AGILA SPECIALTIES PRIVATE LTD (AGILA SPECLTS)	MYLAN LABORORATORIES LTD (MYLAN LABS LTD)
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
ONCO THERAPIES LTD (ONCO THERAPIES LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
REDKITT BENCKISER PHARMACEUTICALS INC (RECKITT BENCKISER)	INDIVIOR INC (INDIVIOR INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies

to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2014	MAR 2015	JUN 2015	SEPT 2015	DEC 2015
DRUG PRODUCTS LISTED	16150	16352	16543		
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)	2586 (15.6%)		
MULTISOURCE	13578 (84.1%)	13744 (84.1%)	13957 (84.4%)		
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)	13832 (83.6%)		
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)	125 (0.8%)		
EXCEPTIONS[1]	77 (0.5%)	75 (0.5%)	75 (0.5%)		
NEW MOLECULAR ENTITIES APPROVED	13	22	12		
NUMBER OF APPLICANTS	927	935	957		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN

SOLUTION;IV (INFUSION)

OFIRMEV

	+	MALLINCKRODT IP	1000MG/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Jun	CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL

FIORICET

	@	ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616	001	Nov 09, 1984	Feb	CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

FIORICET W/ CODEINE

AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Jan	CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		SUN PHARM INDS LTD	300MG;30MG	A085868	001		Apr	CAHN
AA			300MG;60MG	A087083	001		Apr	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	+	MIKART	325MG;2.5MG	A040846	001	Jun 09, 2010	Feb	CTEC
	@	SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007	Apr	CAHN

NORCO

AA		ACTAVIS LABS FL INC	325MG;2.5MG	A040148	004	Jul 07, 2014	Feb	NEWA
AA			325MG;5MG	A040148	005	Jul 07, 2014	Feb	NEWA

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

DIAMOX

AB	+	TEVA BRANDED PHARM	500MG	N012945	001		Jun	CAHN

ACETOHEXAMIDE

TABLET;ORAL

ACETOHEXAMIDE

>A>	@	ANI PHARMS INC	250MG	A070869	001	Feb 09, 1987	Jul	CAHN
>A>	@		500MG	A070870	001	Feb 09, 1987	Jul	CAHN
>D>	@	BARR	250MG	A070869	001	Feb 09, 1987	Jul	CAHN
>D>	@		500MG	A070870	001	Feb 09, 1987	Jul	CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP		AKORN INC	6GM/30ML (200MG/ML)	A203173	001	Mar 24, 2015	Mar	NEWA
AP		MYLAN INSTITUTIONAL	6GM/30ML (200MG/ML)	A203624	001	Jun 19, 2015	Jun	NEWA

ACITRETIN

CAPSULE;ORAL

ACITRETIN

AB		SIGMAPHARM LABS LLC	10MG	A204633	001	May 22, 2015	May	NEWA
AB			17.5MG	A204633	002	May 22, 2015	May	NEWA
AB			22.5MG	A204633	003	May 22, 2015	May	NEWA
AB			25MG	A204633	004	May 22, 2015	May	NEWA

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

	+	ASTRAZENECA PHARMS	0.375MG/INH	N202450	001	Jul 23, 2012	Apr	CAHN

ACYCLOVIR

TABLET;ORAL

ACYCLOVIR

AB		SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Apr	CAHN
AB			800MG	A074980	002	Sep 30, 1998	Apr	CAHN

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

EPIDUO FORTE

>A>	+	GALDERMA R AND D	0.3%;2.5%	N207917	001	Jul 15, 2015	Jul	NEWA

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

AP		EUROHLTH INTL SARL	3MG/ML	A076500	001	Jun 16, 2004	Jun	CAHN
	@	WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009	May	DISC

ALBENDAZOLE

TABLET, CHEWABLE;ORAL

ALBENZA

	+	AMEDRA PHARMS LLC	200MG	N207844	001	Jun 11, 2015	Jun	NEWA

ALBUTEROL SULFATE

POWDER, METERED;INHALATION

PROAIR RESPICLICK

	+	TEVA BRANDED PHARM	EQ 0.090MG BASE/INH	N205636	001	Mar 31, 2015	Mar	NEWA

SYRUP;ORAL

ALBUTEROL SULFATE

AA		G AND W LABS INC	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Apr	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED;INHALATION

COMBIVENT

	@	BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996	May	DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

	@	WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012	Feb	DISC

UROXATRAL

AB	+	CONCORDIA PHARMS INC	10MG	N021287	001	Jun 12, 2003	Jun	CAHN

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET;ORAL

TEKAMLO

	@	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545	001	Aug 26, 2010	May	DISC
	@		EQ 150MG BASE;EQ 10MG BASE	N022545	002	Aug 26, 2010	May	DISC
	@		EQ 300MG BASE;EQ 5MG BASE	N022545	003	Aug 26, 2010	May	DISC
	@		EQ 300MG BASE;EQ 10MG BASE	N022545	004	Aug 26, 2010	May	DISC

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

AMTURNIDE

	@	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045	001	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045	002	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 5MG BASE;25MG	N200045	003	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045	004	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 10MG BASE;25MG	N200045	005	Dec 21, 2010	May	DISC

ALMOTRIPTAN MALATE

TABLET;ORAL

ALMOTRIPTAN MALATE

AB		TEVA PHARMS USA	EQ 6.25MG BASE	A078027	001	Jul 07, 2015	Jun	NEWA
AB			EQ 12.5MG BASE	A078027	002	Jul 07, 2015	Jun	NEWA

AXERT

AB		JANSSEN PHARMS	EQ 6.25MG BASE	N021001	001	May 07, 2001	Jun	CFTG
AB	+		EQ 12.5MG BASE	N021001	002	May 07, 2001	Jun	CFTG

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

AB		ROXANE	EQ 0.5MG BASE	A200652	001	May 04, 2015	Apr	NEWA
AB			EQ 1MG BASE	A200652	002	May 04, 2015	Apr	NEWA

LOTRONEX

AB		PROMETHEUS LABS	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Apr	CFTG
AB	+		EQ 1MG BASE	N021107	001	Feb 09, 2000	Apr	CFTG

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

>A>		@ ANI PHARMS INC	0.25MG	A074085	001	Feb 16, 1994	Jul	CAHN
>A>		@	0.5MG	A074085	002	Feb 16, 1994	Jul	CAHN
>A>		@	1MG	A074085	003	Feb 16, 1994	Jul	CAHN
>A>		@	2MG	A074085	004	Feb 26, 1996	Jul	CAHN
>A>	AB	AUROBINDO PHARMA LTD	0.25MG	A203346	001	Jul 31, 2015	Jul	NEWA
>A>	AB		0.5MG	A203346	002	Jul 31, 2015	Jul	NEWA
>A>	AB		1MG	A203346	003	Jul 31, 2015	Jul	NEWA
>A>	AB		2MG	A203346	004	Jul 31, 2015	Jul	NEWA
	AB	NATCO PHARMA LTD	0.25MG	A200739	001	Apr 15, 2015	Mar	NEWA
	AB		0.5MG	A200739	002	Apr 15, 2015	Mar	NEWA
	AB		1MG	A200739	003	Apr 15, 2015	Mar	NEWA
	AB		2MG	A200739	004	Apr 15, 2015	Mar	NEWA
>D>		@ TEVA	0.25MG	A074085	001	Feb 16, 1994	Jul	CAHN
>D>		@	0.5MG	A074085	002	Feb 16, 1994	Jul	CAHN
>D>		@	1MG	A074085	003	Feb 16, 1994	Jul	CAHN
>D>		@	2MG	A074085	004	Feb 26, 1996	Jul	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

	AB	BANNER LIFE SCIENCES	100MG	A078720	001	May 29, 2008	Jan	CAHN

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

		@ G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990	May	CAHN

AMIKACIN SULFATE

INJECTABLE;INJECTION

AMIKACIN SULFATE

		@ IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995	Mar	CAHN
		@	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995	Mar	CAHN

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

>A>	AB	ZYDUS PHARMS USA INC	5MG	A204180	001	Aug 07, 2015	Jul	NEWA

AMINO ACIDS

INJECTABLE;INJECTION

BRANCHAMIN 4% IN PLASTIC CONTAINER

		@ BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984	Feb	DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

		@ BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N020177	001	Oct 23, 1995	Feb	DISC

AMINOCAPROIC ACID

SYRUP;ORAL

AMINOCAPROIC ACID

	AA	VERSAPHARM INC	1.25GM/5ML	A074759	001	Sep 02, 1998	May	CAHN

TABLET;ORAL

AMINOCAPROIC

	AB	VERSAPHARM INC	500MG	A075602	001	May 24, 2001	May	CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

LIMBITROL

>A>		@ HERITAGE PHARMS INC	EQ 12.5MG BASE;5MG	N016949	001		Jul	CAHN
>D>		@ VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949	001		Jul	CAHN

LIMBITROL DS

>A>		@ HERITAGE PHARMS INC	EQ 25MG BASE;10MG	N016949	002		Jul	CAHN
>D>		@ VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949	002		Jul	CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	CHINA RESOURCES	EQ 5MG BASE	A090752	001	Apr 15, 2011	Mar	CAHN
AB		EQ 10MG BASE	A090752	002	Apr 15, 2011	Mar	CAHN
>A> AB	SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015	Jul	NEWA
>A> AB		EQ 5MG BASE	A204900	002	Jul 23, 2015	Jul	NEWA
>A> AB		EQ 10MG BASE	A204900	003	Jul 23, 2015	Jul	NEWA
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007	Apr	CAHN
AB		EQ 5MG BASE	A077974	002	Jul 09, 2007	Apr	CAHN
AB		EQ 10MG BASE	A077974	003	Jul 09, 2007	Apr	CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	LUPIN LTD	5MG;12.5MG;160MG	A200797	001	Jun 03, 2015	May	NEWA
AB		5MG;25MG;160MG	A200797	002	Jun 03, 2015	May	NEWA
AB		10MG;12.5MG;160MG	A200797	003	Jun 03, 2015	May	NEWA
AB		10MG;25MG;160MG	A200797	004	Jun 03, 2015	May	NEWA
AB		10MG;25MG;320MG	A200797	005	Jun 03, 2015	May	NEWA
AB	PAR PHARM	5MG;12.5MG;160MG	A201087	001	Jun 01, 2015	May	NEWA
AB		5MG;25MG;160MG	A201087	002	Jun 01, 2015	May	NEWA
AB		10MG;12.5MG;160MG	A201087	003	Jun 01, 2015	May	NEWA
AB		10MG;25MG;160MG	A201087	004	Jun 01, 2015	May	NEWA
AB		10MG;25MG;320MG	A201087	005	Jun 01, 2015	May	NEWA
AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	May	CAIN
AB		5MG;25MG;160MG	A200435	002	Sep 25, 2012	May	CAIN
AB		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	May	CAIN
AB		10MG;25MG;160MG	A200435	003	Sep 25, 2012	May	CAIN
AB		10MG;25MG;320MG	A200435	004	Sep 25, 2012	May	CAIN
AB	TORRENT PHARMS LTD	5MG;12.5MG;160MG	A201593	001	Jun 04, 2015	May	NEWA
AB		5MG;25MG;160MG	A201593	002	Jun 04, 2015	May	NEWA
AB		10MG;12.5MG;160MG	A201593	003	Jun 04, 2015	May	NEWA
AB		10MG;25MG;160MG	A201593	004	Jun 04, 2015	May	NEWA
AB		10MG;25MG;320MG	A201593	005	Jun 04, 2015	May	NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

	SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Jan	NEWA
		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Jan	NEWA
+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Jan	NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;160MG	A202713	001	Apr 03, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A202713	003	Apr 03, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A202713	002	Apr 03, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A202713	004	Apr 03, 2015	Mar	NEWA
AB	LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Mar	NEWA
AB	MATRIX LABS LTD	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Apr	CAHN
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Apr	CAHN
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Apr	CAHN
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Apr	CAHN
AB	NOVEL LABS INC	EQ 5MG BASE;160MG	A202829	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A202829	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A202829	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A202829	004	Mar 30, 2015	Mar	NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Mar	NEWA

TABLET;ORAL
AMLODIPINE BESYLATE AND VALSARTAN

AB		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Mar NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS
AMMONIA N 13

AP	BIOMEDCL RES FDN	48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)	A204352	001	May 01, 2015	Apr NEWA
	CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539	001	Jun 23, 2015	Jun NEWA
AP	IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Apr NEWA
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015	Jan NEWA
AP	SPECTRON MRC LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr NEWA

AMOXICILLIN

CAPSULE;ORAL
AMOXICILLIN

AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Apr CAHN
AB		500MG	A065016	002	Apr 08, 1999	Apr CAHN

FOR SUSPENSION;ORAL
AMOXICILLIN

@	SUN PHARM INDS LTD	200MG/5ML	A065113	001	Nov 29, 2002	Apr CAHN
@		400MG/5ML	A065113	002	Nov 29, 2002	Apr CAHN

TABLET;ORAL
AMOXICILLIN

AB	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Apr CAHN
AB		875MG	A065059	002	Nov 24, 2000	Apr CAHN

TABLET, CHEWABLE;ORAL
AMOXICILLIN

AB	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Apr CAHN
@		200MG	A065060	001	Nov 29, 2000	Apr CAHN
AB		250MG	A065021	002	Dec 23, 1999	Apr CAHN
@		400MG	A065060	002	Nov 29, 2000	Apr CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Apr CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Apr CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Apr CAHN

TABLET;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

@	SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002	Apr CAHN
AB		875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Apr CAHN

TABLET, CHEWABLE;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Apr CAHN
AB		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Apr CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	COREPHARMA	1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May NEWA

AMPHETAMINE SULFATE

TABLET;ORAL
EVEKEO

	ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Mar CTNA
+		10MG	A200166	002	Aug 09, 2012	Mar CTNA

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL
PROBAMPACIN

@	G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001		Apr CAHN

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

		@ KREMERS URBAN PHARMS	1MG	A091331	001	Jan 05, 2011	Mar	CAHN

ARGATROBAN

INJECTABLE;INJECTION

ARGATROBAN

AP		FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Apr	CDFR

INJECTABLE;IV (INFUSION)

ARGATROBAN

AP		FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Mar	NEWA

ARIPIPRAZOLE

TABLET;ORAL

ABILIFY

AB		OTSUKA	2MG	N021436	006	Nov 15, 2002	Apr	CFTG
AB	+		5MG	N021436	005	Nov 15, 2002	Apr	CFTG
AB	+		10MG	N021436	001	Nov 15, 2002	Apr	CFTG
AB			15MG	N021436	002	Nov 15, 2002	Apr	CFTG
AB			20MG	N021436	003	Nov 15, 2002	Apr	CFTG
AB			30MG	N021436	004	Nov 15, 2002	Apr	CFTG

ARIPIPRAZOLE

AB		ALEMBIC PHARMS LTD	2MG	A202101	001	Apr 28, 2015	Apr	NEWA
AB			5MG	A202101	002	Apr 28, 2015	Apr	NEWA
AB			10MG	A202101	003	Apr 28, 2015	Apr	NEWA
AB			15MG	A202101	004	Apr 28, 2015	Apr	NEWA
AB			20MG	A202101	005	Apr 28, 2015	Apr	NEWA
AB			30MG	A202101	006	Apr 28, 2015	Apr	NEWA
>A> AB		APOTEX INC	2MG	A078583	001	Jul 24, 2015	Jul	NEWA
>A> AB			5MG	A078583	002	Jul 24, 2015	Jul	NEWA
>A> AB			10MG	A078583	003	Jul 24, 2015	Jul	NEWA
>A> AB			15MG	A078583	004	Jul 24, 2015	Jul	NEWA
>A> AB			20MG	A078583	005	Jul 24, 2015	Jul	NEWA
>A> AB			30MG	A078583	006	Jul 24, 2015	Jul	NEWA
AB		HETERO LABS LTD V	2MG	A205064	001	Apr 28, 2015	Apr	NEWA
AB			5MG	A205064	002	Apr 28, 2015	Apr	NEWA
AB			10MG	A205064	003	Apr 28, 2015	Apr	NEWA
AB			15MG	A205064	004	Apr 28, 2015	Apr	NEWA
AB			20MG	A205064	005	Apr 28, 2015	Apr	NEWA
AB			30MG	A205064	006	Apr 28, 2015	Apr	NEWA
AB		TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015	Apr	NEWA
AB			5MG	A078607	002	Apr 28, 2015	Apr	NEWA
AB			10MG	A078608	001	Apr 28, 2015	Apr	NEWA
AB			15MG	A078708	001	Apr 28, 2015	Apr	NEWA
AB			20MG	A078708	002	Apr 28, 2015	Apr	NEWA
AB			30MG	A078708	003	Apr 28, 2015	Apr	NEWA
AB		TORRENT PHARMS LTD	2MG	A201519	001	Apr 28, 2015	Apr	NEWA
AB			10MG	A201519	003	Apr 28, 2015	Apr	NEWA
AB			5MG	A201519	002	Apr 28, 2015	Apr	NEWA
AB			15MG	A201519	004	Apr 28, 2015	Apr	NEWA
AB			20MG	A201519	005	Apr 28, 2015	Apr	NEWA
AB			30MG	A201519	006	Apr 28, 2015	Apr	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

ABILIFY

AB	+	OTSUKA	10MG	N021729	002	Jun 07, 2006	Apr	CFTG
AB			15MG	N021729	003	Jun 07, 2006	Apr	CFTG

ARIPIPRAZOLE

AB		ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015	Apr	NEWA
AB			15MG	A202102	002	Apr 28, 2015	Apr	NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

		@ IGI LABS INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985	Jun	CAHN

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

		FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Jun	CAHN
	+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Jun	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

FIORINAL

AA	+	ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Jan	CAHN

TABLET;ORAL

FIORINAL

	@	ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

FIORINAL W/CODEINE

AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	Jan	CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

NORGESIC

	@	MEDICIS	385MG;30MG;25MG	N013416	003	Oct 27, 1982	Mar	DISC

NORGESIC FORTE

	@	MEDICIS	770MG;60MG;50MG	N013416	004	Oct 27, 1982	Mar	DISC

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

		SANDOZ	385MG;30MG;25MG	A074654	001	Dec 31, 1996	Mar	CTEC
	+		770MG;60MG;50MG	A074654	002	Dec 31, 1996	Mar	CTEC

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA		ACTAVIS LABS FL INC	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar	CAHN

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

	+	BRISTOL MYERS SQUIBB	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015	Jan	NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

>A>	AB	ALVOGEN IPCO SARL	25MG	A073646	001	Jul 31, 1992	Jul	CAHN
>A>	AB		50MG	A072303	001	Jul 15, 1988	Jul	CAHN
>A>	AB		100MG	A072304	001	Jul 15, 1988	Jul	CAHN
		@ DAVA PHARMS INC	25MG	A074099	001	Apr 28, 1992	Jun	DISC
>D>	AB	IPR	25MG	A073646	001	Jul 31, 1992	Jul	CAHN
>D>	AB		50MG	A072303	001	Jul 15, 1988	Jul	CAHN
>D>	AB		100MG	A072304	001	Jul 15, 1988	Jul	CAHN

TENORMIN

	AB	ALVOGEN IPCO SARL	25MG	N018240	004	Apr 09, 1990	Feb	CAHN
	AB		50MG	N018240	001		Feb	CAHN
	AB	+	100MG	N018240	002		Feb	CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

>A>	AB	ALVOGEN IPCO SARL	50MG;25MG	A072301	001	May 31, 1990	Jul	CAHN
>A>	AB		100MG;25MG	A072302	001	May 31, 1990	Jul	CAHN
>D>	AB	IPR	50MG;25MG	A072301	001	May 31, 1990	Jul	CAHN
>D>	AB		100MG;25MG	A072302	001	May 31, 1990	Jul	CAHN

TENORETIC 100

	AB	+ ALVOGEN IPCO SARL	100MG;25MG	N018760	001	Jun 08, 1984	Feb	CAHN

TENORETIC 50

	AB	ALVOGEN IPCO SARL	50MG;25MG	N018760	002	Jun 08, 1984	Feb	CAHN

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		KREMERS URBAN PHARMS	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar	CAHN
AB			EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar	CAHN
AB			EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar	CAHN
AB			EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar	CAHN
AB		SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Apr	CAHN
AB			EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr	CAHN
AB			EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr	CAHN
AB			EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr	CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LIPTRUZET

	@	MERCK SHARP DOHME	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	May	DISC
	@		EQ 20MG BASE;10MG	N200153	002	May 03, 2013	May	DISC
	@		EQ 40MG BASE;10MG	N200153	003	May 03, 2013	May	DISC
	@		EQ 80MG BASE;10MG	N200153	004	May 03, 2013	May	DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB		GLENMARK GENERICS	62.5MG;25MG	A091211	002	Apr 06, 2015	Mar	NEWA

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

AP		AUROBINDO PHARMA LTD	10MG/ML	A206011	001	Apr 08, 2015	Mar	NEWA

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP		AUROBINDO PHARMA LTD	10MG/ML	A206010	001	Apr 08, 2015	Mar	NEWA

ATROPINE SULFATE

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

	+	AKORN	1%	N206289	001	Jul 18, 2014	May	CRLD

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL

MOTOFEN

	+	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002			Feb CAHN

MOTOFEN HALF-STRENGTH

	@	SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001			Feb CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>A>	@	ANI PHARMS INC	0.025MG;2.5MG	A086727	001			Jul CAHN
>D>	@	IVAX PHARMS	0.025MG;2.5MG	A086727	001			Jul CAHN

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)

AVYCAZ

	+	CEREXA INC	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Feb	NEWA

AZELAIC ACID

>A> AEROSOL, FOAM;TOPICAL

>A> FINACEA

>A>	+	BAYER HLTHCARE	15%	N207071	001	Jul 29, 2015	Jul	NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

>A> AB		BRECKENRIDGE PHARMS	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Jul	NEWA

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB		LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	May NEWA
AB			EQ 200MG BASE/5ML	A065488	002	May 15, 2015	May NEWA

INJECTABLE;INJECTION

AZITHROMYCIN

AP		AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A203294	001	Jun 19, 2015	Jun NEWA

TABLET;ORAL

AZITHROMYCIN

AB		LUPIN LTD	EQ 250MG BASE	A065398	001	May 15, 2015	May NEWA
AB			EQ 500MG BASE	A065399	001	May 15, 2015	May NEWA
AB			EQ 600MG BASE	A065400	001	May 15, 2015	May NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL

COLAZAL

>D>	AB	+	SALIX PHARMS	750MG	N020610	001	Jul 18, 2000	Jul CAHN
>A>	AB	+	VALEANT PHARMS INTL	750MG	N020610	001	Jul 18, 2000	Jul CAHN

TABLET;ORAL

GIAZO

>D>		+	SALIX PHARMS	1.1GM	N022205	001	Feb 03, 2012	Jul CAHN
>A>		+	VALEANT PHARMS INTL	1.1GM	N022205	001	Feb 03, 2012	Jul CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB		AMNEAL PHARMS LLC	5MG	A076820	001	Feb 03, 2006	Jan CAHN
AB			10MG	A076820	002	Feb 03, 2006	Jan CAHN
AB			20MG	A076820	003	Feb 03, 2006	Jan CAHN
AB			40MG	A076820	004	Feb 03, 2006	Jan CAHN
AB		SUN PHARM INDS LTD	5MG	A076344	001	Feb 11, 2004	Apr CAHN
AB			10MG	A076344	002	Feb 11, 2004	Apr CAHN
AB			20MG	A076344	003	Feb 11, 2004	Apr CAHN
AB			40MG	A076344	004	Feb 11, 2004	Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	5MG;6.25MG	A077483	001	Sep 08, 2005	Apr CAHN
AB			10MG;12.5MG	A077483	002	Sep 08, 2005	Apr CAHN
AB			20MG;12.5MG	A077483	003	Sep 08, 2005	Apr CAHN
AB			20MG;25MG	A077483	004	Sep 08, 2005	Apr CAHN

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA		APOTEX INC	100MG	A091310	001	Jan 16, 2015	Jan NEWA
AA			200MG	A091310	002	Jan 16, 2015	Jan NEWA
AA		BANNER LIFE SCIENCES	100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA			200MG	A081297	002	Oct 30, 2007	Jan CAHN
>A>	AA	CSPC NBP PHARM CO	200MG	A202765	001	Jul 31, 2015	Jul NEWA
>A>	AA	STRIDES ARCOLAB LTD	100MG	A091133	001	Jul 30, 2015	Jul NEWA
>A>	AA		200MG	A091133	002	Jul 30, 2015	Jul NEWA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

ACANYA

AB		+	DOW PHARM	2.5%;EQ 1.2% BASE	N050819	001	Oct 23, 2008	Jun CFTG

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB			ACTAVIS LABS UT INC	2.5%;EQ 1.2% BASE	A205128	001	Jun 19, 2015	Jun NEWA

ONEXTON

		+	DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Jan CRLD

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

AA		+	KVK TECH	50MG	A090968	001	Jul 20, 2010	Jun CRLD

DIDREX

		@	PHARMACIA AND UPJOHN	50MG	N012427	002		Jun DISC

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

AA		NUVO PHARM INC	0.5MG	A204713	001	Apr 14, 2015	Mar NEWA
AA			1MG	A204713	002	Apr 14, 2015	Mar NEWA
AA			2MG	A204713	003	Apr 14, 2015	Mar NEWA

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		G AND W LABS INC	EQ 0.05% BASE	A071467	001	Aug 10, 1987	Apr CAHN
	@		EQ 0.05% BASE	A071882	001	Jun 06, 1988	Apr CAHN

BETAMETHASONE VALERATE

LOTION;TOPICAL

BETA-VAL

AB		G AND W LABS INC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	Apr CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA		HERITAGE PHARMA	5MG	A091256	001	May 04, 2010	Mar CAHN
AA			10MG	A091256	002	May 04, 2010	Mar CAHN
AA			25MG	A091256	003	May 04, 2010	Mar CAHN
AA			50MG	A091256	004	May 04, 2010	Mar CAHN
AA		LANNETT HOLDINGS INC	5MG	A040703	001	Mar 27, 2008	Feb CMFD
AA			50MG	A040677	001	Mar 27, 2008	Feb CMFD

DUVOID

AA		WELLSPRING PHARM	10MG	A086262	001		Jan CMFD
AA			25MG	A086263	001		May CMFD
AA			50MG	A085882	003		May CMFD

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

AB		BANNER LIFE SCIENCES	75MG	A203174	001	Aug 12, 2014	Jun CMFD
	@		75MG	A203174	001	Aug 12, 2014	Jan CAHN

TARGRETIN

AB	+	VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Jun CTEC

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB		APOTEX INC	50MG	A200274	001	May 21, 2015	May NEWA
AB		STASON PHARMS	50MG	A091011	001	Jun 10, 2015	May NEWA

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT		ALCON RES LTD	0.03%	A202565	001	May 05, 2015	Apr NEWA
>A> AT		APOTEX INC	0.03%	A090449	001	Jul 20, 2015	Jul NEWA
AT	+	LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Apr CTEC
	+		0.03%	A203991	001	Feb 20, 2015	Mar CTEC
AT	+		0.03%	A203991	001	Feb 20, 2015	Feb NEWA

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE;ORAL

PYLERA

>D>	+	FOREST LABS INC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Jul CAHN
>A>	+	FOREST LABS LLC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Jul CAHN

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

ANGIOMAX

AP	+	MEDICINES CO	250MG/VIAL	N020873	001	Dec 15, 2000	Jun CFTG

BIVALIRUDIN

AP		HOSPIRA INC	250MG/VIAL	A090811	001	Jul 14, 2015	Jun NEWA
AP			250MG/VIAL	A090816	001	Jul 14, 2015	Jun NEWA

BOSUTINIB MONOHYDRATE

TABLET;ORAL

BOSULIF

	+	WYETH PHARMS INC	EQ 100MG BASE	N203341	001	Sep 04, 2012	Jun CRLD
			EQ 500MG BASE	N203341	002	Sep 04, 2012	Jun CRLD

>A> BREXPIPRAZOLE

>A> TABLET;ORAL

>A> REXULTI

>A>		OTSUKA PHARM CO LTD	0.25MG	N205422	001	Jul 10, 2015	Jul NEWA
>A>			0.5MG	N205422	002	Jul 10, 2015	Jul NEWA
>A>			1MG	N205422	003	Jul 10, 2015	Jul NEWA
>A>			2MG	N205422	004	Jul 10, 2015	Jul NEWA
>A>			3MG	N205422	005	Jul 10, 2015	Jul NEWA
>A>	+		4MG	N205422	006	Jul 10, 2015	Jul NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMDAY

AT2	+	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	May CTEC

BROMFENAC SODIUM

AT2		APOTEX INC	EQ 0.09% ACID	A202620	001	Jun 23, 2014	May CTEC
AT1	+	COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	May CRLD
AT2		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May CTEC
AT1		PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jan NEWA

BUDESONIDE

AEROSOL, FOAM;RECTAL

UCERIS

	+	VALEANT PHARMS INTL	2MG/ACTUATION	N205613	001	Oct 07, 2014	Apr CAHN

SPRAY, METERED;NASAL

BUDESONIDE

		APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Mar CTEC

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP		EUROHLTH INTL SARL	0.25MG/ML	A079196	001	Apr 30, 2008	Jun CAHN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPRENORPHINE HYDROCHLORIDE

>A> AP		PAR STERILE PRODUCTS	EQ 0.3MG BASE/ML	A206586	001	Jul 28, 2015	Jul NEWA

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	EQ 2MG BASE	A090819	001	Feb 19, 2015	Feb NEWA
AB			EQ 8MG BASE	A090819	002	Feb 19, 2015	Feb NEWA
AB		MYLAN PHARMS INC	EQ 2MG BASE	A201066	001	Mar 06, 2015	Feb NEWA
AB			EQ 8MG BASE	A201066	002	Mar 06, 2015	Feb NEWA
AB		SANDOZ INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	May NEWA
AB			EQ 8MG BASE	A090279	002	Jun 10, 2015	May NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

ZUBSOLV

		OREXO AB	EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jun NEWA

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

		VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008	Feb CAHN
			348MG	N022108	002	Apr 23, 2008	Feb CAHN
	+		522MG	N022108	003	Apr 23, 2008	Feb CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1		PRINSTON INC	100MG	A202304	001	May 26, 2015	May NEWA
AB1			150MG	A202304	002	May 26, 2015	May NEWA
AB1			200MG	A202304	003	May 26, 2015	May NEWA
AB2		SANDOZ INC	150MG	A077475	001	Mar 12, 2008	Mar CAHN

	TABLET, EXTENDED RELEASE;ORAL						
	BUPROPION HYDROCHLORIDE						
	@ WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012		May DISC
	@	150MG	A201331	002	Aug 30, 2012		May DISC
	@	200MG	A201331	003	Aug 30, 2012		May DISC
	BUTABARBITAL SODIUM						
>D>	ELIXIR;ORAL						
>D>	BUTISOL SODIUM						
>D>	+ MEDA PHARMS	30MG/5ML	A085380	001			Jul DISC
>A>	@	30MG/5ML	A085380	001			Jul DISC
	TABLET;ORAL						
	BUTISOL SODIUM						
	@ MEDA PHARMS	50MG	N000793	003			May DISC
	BUTOCONAZOLE NITRATE						
	CREAM;VAGINAL						
	BUTOCONAZOLE NITRATE						
	@ ELAN PHARMA INTL LTD	2%	N019881	001	Feb 07, 1997		May CTNA
	GYNAZOLE-1						
	+ PERRIGO ISRAEL	2%	A200923	001	May 18, 2012		Jun CTNA
	CALCIPOTRIENE						
	CREAM;TOPICAL						
	CALCIPOTRIENE						
AB	GLENMARK PHARMS LTD	0.005%	A205772	001	Jun 09, 2015		May NEWA
	CALCITONIN SALMON						
	INJECTABLE;INJECTION						
	CALCITONIN-SALMON						
	@ IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995		Mar CAHN
	CALCITRIOL						
	CAPSULE;ORAL						
	CALCITRIOL						
AB	BANNER LIFE SCIENCES	0.25MCG	A091174	001	May 24, 2013		Jan CAHN
AB		0.5MCG	A091174	002	May 24, 2013		Jan CAHN
AB	STRIDES PHARMA	0.25MCG	A091356	001	Dec 12, 2014		Jan CAHN
AB		0.5MCG	A091356	002	Dec 12, 2014		Jan CAHN
	INJECTABLE;INJECTION						
	CALCIJEX						
	@ ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986		Jun DISC
	@	0.002MG/ML	N018874	002	Sep 25, 1986		Jun DISC
	CALCITRIOL						
	@ AKORN	0.002MG/ML	A078066	002	Jan 29, 2008		Jun DISC
	@ FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002		Jun DISC
	@	0.002MG/ML	A075836	002	Dec 31, 2002		Jun DISC
	@ FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003		Jun DISC
	@	0.002MG/ML	A075766	002	Feb 20, 2003		Jun DISC
	@ LUITPOLD	0.001MG/ML	A075746	001	Sep 26, 2003		Jun DISC
	@	0.002MG/ML	A075746	002	Sep 26, 2003		Jun DISC
	@ SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006		Jun DISC
	CALCIUM ACETATE						
	CAPSULE;ORAL						
	CALCIUM ACETATE						
AB	LUPIN LTD	EQ 169MG CALCIUM	A202127	001	Jul 09, 2015		Jun NEWA
AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015		Jun NEWA
	TABLET;ORAL						
	CALCIUM ACETATE						
AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015		Jan NEWA
	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE						
	INJECTABLE;INJECTION						
	PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER						
	+ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008		Jan CPOT
	PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER						
	@ GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4	N021703	012	Oct 10, 2008		Jan CPOT

INJECTABLE;INJECTION

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

		GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)				

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Jan CPOT

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jan CPOT

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Jan CPOT

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Jan CPOT

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Jan CPOT

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Jan CPOT

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Jan CPOT

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Jan CPOT

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan CPOT

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan CPOT

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan CPOT

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan CPOT

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan CPOT

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	N/A/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187	N207026	002	Jan 13, 2015	Jan NEWA

	INJECTABLE;INJECTION							
	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER							
		GM/1000ML (5000ML)						
	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER							
+	GAMBRO LUNDIA	3.68GM/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187 GM/1000ML (5000ML)	N	207026	001	Jan 13, 2015	Jan	NEWA
	CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE							
	SOLUTION;IRRIGATION							
	NAVSTEL							
@	ALCON PHARMS LTD	0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N	022193	001	Jul 24, 2008	Jun	DISC
	CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE							
	INJECTABLE;INJECTION							
	PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER							
@	BAXTER HLTHCARE	37MG/100ML;5GM/100ML;30MG/100ML;119MG/100ML;161MG/100ML;94MG/100ML;138MG/100ML	N	017390	001		Mar	DISC
	CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE							
	INJECTABLE;INJECTION							
	PLASMA-LYTE R IN PLASTIC CONTAINER							
@	BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML	N	017438	001		Mar	DISC
	CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE							
	INJECTABLE;INJECTION							
	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER							
+	GAMBRO LUNDIA	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N	207026	002	Jan 13, 2015	Feb	CAIN
	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER							
+	GAMBRO LUNDIA	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187	N	207026	001	Jan 13, 2015	Feb	CAIN
	CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE							
	TABLET;ORAL							
	CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE							
AB	MACLEODS PHARMS LTD	16MG;12.5MG	A	204100	001	Feb 27, 2015	Feb	NEWA
AB		32MG;12.5MG	A	204100	002	Feb 27, 2015	Feb	NEWA
AB		32MG;25MG	A	204100	003	Feb 27, 2015	Feb	NEWA
	CANGRELOR							
	POWDER;IV (INFUSION)							
	KENGREAL							
+	MEDICNES CO	50MG/VIAL	N	204958	001	Jun 22, 2015	Jun	NEWA
	CAPECITABINE							
	TABLET;ORAL							
	CAPECITABINE							
AB	ACCORD HLTHCARE	150MG	A	202593	001	Apr 23, 2015	Apr	NEWA
AB		500MG	A	202593	002	Apr 23, 2015	Apr	NEWA
	CAPTOPRIL							
	TABLET;ORAL							
	CAPOTEN							
@	PAR PHARM	12.5MG	N	018343	005	Jan 17, 1985	May	DISC
@		25MG	N	018343	002		May	DISC
@		50MG	N	018343	001		May	DISC
@		100MG	N	018343	003		May	DISC
	CAPTOPRIL							
>A> @	G AND W LABS INC	12.5MG	A	074433	001	Feb 13, 1996	Jul	CAHN
@		12.5MG	A	074462	001	Feb 13, 1996	Apr	CAHN
>A> @		12.5MG	A	074483	001	Feb 13, 1996	Jul	CAHN
@		12.5MG	A	074590	004	Aug 30, 1996	Apr	CAHN

TABLET;ORAL
CAPTOPRIL

>A>		@		25MG	A074433	002	Feb 13, 1996	Jul CAHN
		@		25MG	A074462	002	Feb 13, 1996	Apr CAHN
>A>		@		25MG	A074483	002	Feb 13, 1996	Jul CAHN
		@		25MG	A074590	002	Aug 30, 1996	Apr CAHN
>A>		@		50MG	A074433	003	Feb 13, 1996	Jul CAHN
		@		50MG	A074462	003	Feb 13, 1996	Apr CAHN
>A>		@		50MG	A074483	003	Feb 13, 1996	Jul CAHN
		@		50MG	A074590	001	Aug 30, 1996	Apr CAHN
>A>		@		100MG	A074433	004	Feb 13, 1996	Jul CAHN
		@		100MG	A074462	004	Feb 13, 1996	Apr CAHN
>A>		@		100MG	A074483	004	Feb 13, 1996	Jul CAHN
		@		100MG	A074590	003	Aug 30, 1996	Apr CAHN
AB	+		MYLAN	100MG	A074434	004	Feb 13, 1996	May CRLD
>D>		@	TEVA	12.5MG	A074433	001	Feb 13, 1996	Jul CAHN
>D>		@		12.5MG	A074483	001	Feb 13, 1996	Jul CAHN
>D>		@		25MG	A074433	002	Feb 13, 1996	Jul CAHN
>D>		@		25MG	A074483	002	Feb 13, 1996	Jul CAHN
>D>		@		50MG	A074433	003	Feb 13, 1996	Jul CAHN
>D>		@		50MG	A074483	003	Feb 13, 1996	Jul CAHN
>D>		@		100MG	A074433	004	Feb 13, 1996	Jul CAHN
>D>		@		100MG	A074483	004	Feb 13, 1996	Jul CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE
TABLET;ORAL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB			G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Apr CAHN
AB				25MG;25MG	A074827	002	Dec 29, 1997	Apr CAHN
AB				50MG;15MG	A074827	004	Dec 29, 1997	Apr CAHN
AB				50MG;25MG	A074827	003	Dec 29, 1997	Apr CAHN

CARBAMAZEPINE
CAPSULE, EXTENDED RELEASE;ORAL
CARBAMAZEPINE

AB			MYLAN PHARMS INC	100MG	A076697	001	May 20, 2011	May CAHN
AB				200MG	A076697	002	May 20, 2011	May CAHN
AB				300MG	A076697	003	May 20, 2011	May CAHN

CARBIDOPA; LEVODOPA
CAPSULE, EXTENDED RELEASE;ORAL
RYTARY

			IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015	Jan NEWA
				36.25MG;145MG	N203312	002	Jan 07, 2015	Jan NEWA
				48.75MG;195MG	N203312	003	Jan 07, 2015	Jan NEWA
	+			61.25MG;245MG	N203312	004	Jan 07, 2015	Jan NEWA

SUSPENSION;ENTERAL
DUOPA

	+		ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015	Jan NEWA

CARISOPRODOL
TABLET;ORAL
CARISOPRODOL

AB			INDICUS PHARMA	250MG	A205126	001	Jul 08, 2015	Jun NEWA
AA				350MG	A205126	002	Jul 08, 2015	Jun NEWA

SOMA

AB	+		MEDA PHARMS	250MG	N011792	004	Sep 13, 2007	Jun CTEC

CARVEDILOL
TABLET;ORAL
CARVEDILOL

		@	HIKMA	3.125MG	A077887	001	Sep 07, 2007	Jun DISC
		@		6.25MG	A077887	002	Sep 07, 2007	Jun DISC
		@		12.5MG	A077887	003	Sep 07, 2007	Jun DISC
		@		25MG	A077887	004	Sep 07, 2007	Jun DISC
AB			SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Apr CAHN
AB				6.25MG	A076989	002	Sep 05, 2007	Apr CAHN
AB				12.5MG	A076989	003	Sep 05, 2007	Apr CAHN
AB				25MG	A076989	004	Sep 05, 2007	Apr CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION;ORAL							
CEFADROXIL							
	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Apr	CAHN
AB		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Apr	CAHN
AB		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Apr	CAHN

CEFAZOLIN SODIUM

INJECTABLE;INJECTION							
CEFAZOLIN SODIUM							
AP	FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Jan	CAHN
AP +		EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jan	CAHN

CEFIXIME

FOR SUSPENSION;ORAL							
CEFIXIME							
AB	AUROBINDO PHARMA LTD	100MG/5ML	A204835	001	Apr 14, 2015	Apr	NEWA
AB		200MG/5ML	A204835	002	Apr 14, 2015	Apr	NEWA
SUPRAX							
AB	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Apr	CFTG
AB		200MG/5ML	A065355	001	Apr 10, 2007	Apr	CFTG

CEFOTETAN DISODIUM

INJECTABLE;INJECTION							
CEFOTAN							
@	IGI LABS INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	May	CAHN
@		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Mar	CAHN
@		EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	May	CAHN
@		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Mar	CAHN
@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Mar	CAHN
CEFOTAN IN PLASTIC CONTAINER							
@	IGI LABS INC	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Mar	CAHN
@		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Mar	CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL							
CEFPODOXIME PROXETIL							
AB	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Apr	CAHN
AB		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Apr	CAHN
TABLET;ORAL							
CEFPODOXIME PROXETIL							
AB	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Apr	CAHN
AB		EQ 200MG BASE	A065083	002	Aug 20, 2003	Apr	CAHN

CEFTAZIDIME

INJECTABLE;INJECTION							
FORTAZ							
AP +	CONCORDIA PHARMS INC	500MG/VIAL	N050578	001	Jul 19, 1985	Jun	CAHN
AP +		1GM/VIAL	N050578	002	Jul 19, 1985	Jun	CAHN
AP +		2GM/VIAL	N050578	003	Jul 19, 1985	Jun	CAHN
AP +		6GM/VIAL	N050578	004	Jul 19, 1985	Jun	CAHN

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION							
FORTAZ IN PLASTIC CONTAINER							
@	CONCORDIA PHARMS INC	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Jun	CAHN
+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Jun	CAHN
+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Jun	CAHN

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION							
CEFTRIAXONE							
AP	FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Jan	CAHN
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS							
CEFTRIAXONE							
@	FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Jan	CAHN
@		EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Jan	CAHN
>D> AP	FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006	Jul	DISC
>A> @		EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006	Jul	DISC

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL

CEFUROXIME AXETIL

	AB		SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Apr CAHN
	AB			EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Apr CAHN

TABLET;ORAL

CEFUROXIME AXETIL

>A>	AB		ANI PHARMS INC	EQ 250MG BASE	A065190	001	Oct 18, 2004	Jul CAHN
>A>	AB			EQ 500MG BASE	A065190	002	Oct 18, 2004	Jul CAHN
	AB		SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Apr CAHN
	AB			EQ 250MG BASE	A065118	002	Apr 25, 2003	Apr CAHN
	AB			EQ 500MG BASE	A065118	003	Apr 25, 2003	Apr CAHN
>D>	AB		TEVA	EQ 250MG BASE	A065190	001	Oct 18, 2004	Jul CAHN
>D>	AB			EQ 500MG BASE	A065190	002	Oct 18, 2004	Jul CAHN

CEFUROXIME SODIUM

INJECTABLE;INJECTION

CEFUROXIME SODIUM

	AP		FACTA FARMA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Jan CAHN
	AP			EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jan CAHN

ZINACEF

	AP	+	CONCORDIA PHARMS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun CAHN
	AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun CAHN

ZINACEF IN PLASTIC CONTAINER

		@	CONCORDIA PHARMS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun CAHN
		+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jun CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

	AB		FACTA FARMA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Jan CAHN

ZINACEF

	AB	+	CONCORDIA PHARMS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun CAHN

CELECOXIB

CAPSULE;ORAL

CELECOXIB

	AB		APOTEX INC	50MG	A204197	001	Jun 02, 2015	May NEWA
	AB			100MG	A204197	002	Jun 02, 2015	May NEWA
	AB			200MG	A204197	003	Jun 02, 2015	May NEWA
	AB		LUPIN LTD	100MG	A202240	002	Jun 09, 2015	May NEWA
	AB			200MG	A202240	003	Jun 09, 2015	May NEWA
	AB			400MG	A202240	004	Jun 09, 2015	May NEWA
	AB		MYLAN PHARMS INC	100MG	A078857	002	Feb 11, 2015	Jan NEWA
	AB			200MG	A078857	003	Feb 11, 2015	Jan NEWA
	AB			400MG	A078857	004	Feb 11, 2015	Jan NEWA
	AB		WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan NEWA
	AB			100MG	A200562	002	Feb 11, 2015	Jan NEWA
	AB			200MG	A200562	003	Feb 11, 2015	Jan NEWA
	AB			400MG	A200562	004	Feb 11, 2015	Jan NEWA

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

	AB		SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr CAHN
	AB			EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr CAHN

FOR SUSPENSION;ORAL

CEPHALEXIN

		@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Apr CAHN
		@		EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Apr CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

	AP		SAGENT PHARMS	EQ 500MG BASE/VIAL	A202462	001	May 29, 2015	May NEWA

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL

CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

			SPRIASO LLC	8MG;54.3MG	N206323	001	Jun 22, 2015	Jun NEWA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA		TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438	001	Jan 27, 2015	Jan	NEWA

VITUZ

AA	+	CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013	Jan	CFTG

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A> AA		COASTAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015	Jul	NEWA

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

TUZISTRA XR

	+	TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Apr	NEWA
	+	VERNALIS R AND D LTD	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun	CAHN

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

	@	CYCLE PHARMS LTD	30MG/ML	A088157	001	Apr 27, 1983	Jun	CAHN
	@		100MG/ML	A088158	001	Apr 27, 1983	Jun	CAHN

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

	+	EUROHLTH INTL SARL	25MG/ML	A083329	001		Feb	CAHN

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

	@	CYCLE PHARMS LTD	10MG	A085331	001		Jun	CAHN
	@		25MG	A085331	002		Jun	CAHN
	@		50MG	A085331	003		Jun	CAHN
	@		100MG	A085331	004		Jun	CAHN
	@		200MG	A085331	005		Jun	CAHN
	@	SANDOZ	10MG	A080439	001		May	DISC
	@		25MG	A080439	002		May	DISC
	@		50MG	A080439	003		May	DISC
	@		100MG	A080439	004		May	DISC
	@		200MG	A080439	005		May	DISC

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

	@	G AND W LABS INC	50MG	A088651	001	May 30, 1985	Apr	CAHN
AB		MUTUAL PHARM	50MG	A089286	001	Jul 21, 1986	Mar	CMFD
AB	+	MYLAN	50MG	A086831	001		Jun	CTEC

THALITONE

	@	CITRON PHARMA LLC	15MG	N019574	001	Dec 20, 1988	Jun	DISC

CHOLIC ACID

CAPSULE;ORAL

CHOLBAM

		ASKLEPION PHARMS LLC	50MG	N205750	001	Mar 17, 2015	Mar	NEWA
	+		250MG	N205750	002	Mar 17, 2015	Mar	NEWA
		RTRX	50MG	N205750	001	Mar 17, 2015	Apr	CAHN
	+		250MG	N205750	002	Mar 17, 2015	Apr	CAHN

CIDOFOVIR

INJECTABLE;INJECTION

CIDOFOVIR

AP	+	MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May	CRLD

VISTIDE

	@	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May	DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

	@	G AND W LABS INC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994	Apr	CAHN

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN

AP	CLARIS PHARMASERVICE	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Apr CAHN
AP		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Apr CAHN

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	200MG/100ML	A078024	001	Mar 18, 2008	Apr CAHN
AP		400MG/200ML	A078024	002	Mar 18, 2008	Apr CAHN

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 250MG BASE	A075747	001	Jun 09, 2004	Apr CAHN
AB		EQ 500MG BASE	A075747	002	Jun 09, 2004	Apr CAHN
AB		EQ 750MG BASE	A075747	003	Jun 09, 2004	Apr CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP	FRESENIUS KABI USA	EQ 2MG BASE/ML	A203183	001	Feb 26, 2015	Feb NEWA

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP	FRESENIUS KABI USA	EQ 2MG BASE/ML	A203182	001	Feb 26, 2015	Feb NEWA
AP		EQ 10MG BASE/ML	A203182	002	Feb 26, 2015	Feb NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB	G AND W LABS INC	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr CAHN
AB		EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr CAHN
AB		EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr CAHN

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

AB	SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007	Apr CAHN
AB		250MG/5ML	A065382	002	Aug 30, 2007	Apr CAHN

TABLET;ORAL

CLARITHROMYCIN

AB	SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004	Apr CAHN
AB		500MG	A065174	002	Sep 24, 2004	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL

BIAXIN XL

	@ ABBVIE	500MG	N050775	001	Mar 03, 2000	Jan DISC

CLARITHROMYCIN

AB +	TEVA	500MG	A065154	001	May 18, 2005	Jan CRLD

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE;INJECTION

TIMENTIN

	@ GLAXOSMITHKLINE	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986	May DISC
	@	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985	May DISC
	@	EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985	May DISC
	@	EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987	May DISC

TIMENTIN IN PLASTIC CONTAINER

	@ GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989	May DISC

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

>A>	@ ANI PHARMS INC	1.34MG	A073282	001	Jan 31, 1992	Jul CAHN
>D>	@ TEVA	1.34MG	A073282	001	Jan 31, 1992	Jul CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	G AND W LABS INC	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr	CAHN
AB		EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr	CAHN
AB	SUN PHARM INDS LTD	EQ 150MG BASE	A065061	001	Feb 02, 2001	Apr	CAHN
AB		EQ 300MG BASE	A065061	002	Feb 02, 2001	Apr	CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

@	IGI LABS INC	EQ 150MG BASE/ML	A062928	001	Feb 13, 1989	Mar	CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

@	BOCA PHARMA LLC	EQ 1% BASE	A062944	001	Jan 11, 1989	Jan	CAHN
AT	VINTAGE PHARMS	EQ 1% BASE	A203343	001	May 29, 2015	May	NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB	ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564	001	Jun 12, 2015	Jun	NEWA

ZIANA

AB +	MEDICIS	1.2%;0.025%	N050802	001	Nov 07, 2006	Jun	CTEC

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2 +	FOUGERA PHARMS	0.05%	A075430	001	May 26, 1999	May	CRLD

CORMAX

AB1 +	HI TECH PHARMA	0.05%	A074220	001	May 16, 1997	Jun	CRLD

TEMOVATE

@	FOUGERA PHARMS	0.05%	N019322	001	Dec 27, 1985	Jun	DISC

TEMOVATE E

@	FOUGERA PHARMS	0.05%	N020340	001	Jun 17, 1994	May	DISC

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB +	FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	May	CRLD

TEMOVATE

@	FOUGERA PHARMS	0.05%	N020337	001	Apr 29, 1994	May	DISC

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB	G AND W LABS INC	0.05%	A074089	001	Feb 16, 1994	Feb	CAHN

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

AT	G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995	Mar	CMFD

CLOMIPHENE CITRATE

TABLET;ORAL

SEROPHENE

@	EMD SERONO	50MG	N018361	001	Mar 22, 1982	Jun	DISC

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CLONIDINE

AB	ACTAVIS LABS UT INC	0.1MG/24HR	A090873	001	May 06, 2014	Mar	CAHN
AB		0.2MG/24HR	A090873	002	May 06, 2014	Mar	CAHN
AB		0.3MG/24HR	A090873	003	May 06, 2014	Mar	CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

@	DAVA PHARMS INC	0.1MG	A071783	001	Apr 05, 1988	May	DISC
@		0.2MG	A071784	001	Apr 05, 1988	May	DISC
@		0.3MG	A071785	001	Apr 05, 1988	May	DISC

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB2	ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	May	NEWA
AB1		0.1MG	A203320	001	May 15, 2015	May	NEWA
AB2		0.2MG	A202792	002	May 15, 2015	May	NEWA
AB1		0.2MG	A203320	002	May 15, 2015	May	NEWA

TABLET, EXTENDED RELEASE;ORAL
CLONIDINE HYDROCHLORIDE

AB2	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	May CTEC
AB2		0.2MG	A202983	002	Apr 02, 2014	May CTEC

CLONIDINE HYDROCHLORIDE

AB1	ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	May CTEC
AB1		0.2MG	A202984	002	Sep 30, 2013	May CTEC

KAPVAY

AB1	CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010	Jun CRLD
AB1	+	0.1MG	N022331	003	Sep 28, 2010	May CTEC
AB1	+	0.2MG	N022331	004	Sep 28, 2010	Jun CRLD
AB1		0.2MG	N022331	004	Sep 28, 2010	May CTEC

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL
CLORAZEPATE DIPOTASSIUM

AB	SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004	Apr CAHN
AB		7.5MG	A076911	002	Sep 29, 2004	Apr CAHN
AB		15MG	A076911	003	Sep 29, 2004	Apr CAHN

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL
PREZCOBIX

	+ JANSSEN PRODS	150MG;EQ 800MG BASE	N205395	001	Jan 29, 2015	Jan NEWA

CODEINE SULFATE

SOLUTION;ORAL
CODEINE SULFATE

	@ ROXANE	30MG/5ML	N202245	001	Jun 30, 2011	Jan DISC

COLCHICINE

CAPSULE;ORAL
MITIGARE

	HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	Jan CAHN

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION
COLISTIMETHATE SODIUM

AP	XELLIA PHARMS APS	EQ 150MG BASE/VIAL	A205356	001	May 29, 2015	May NEWA

CYANOCOBALAMIN

INJECTABLE;INJECTION
CYANOCOBALAMIN

	@ EUROHLTH INTL SARL	1MG/ML	A080515	002		Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

AB	ORIT LABS LLC	5MG	A078218	002	Jun 19, 2015	Jun NEWA
AB	SUN PHARM INDS LTD	5MG	A078722	001	May 12, 2008	Apr CAHN
AB		7.5MG	A078722	002	May 12, 2008	Apr CAHN
AB		10MG	A078722	003	May 12, 2008	Apr CAHN

DABRAFENIB MESYLATE

CAPSULE;ORAL
TAFINLAR

	NOVARTIS PHARMS CORP	EQ 50MG BASE	N202806	001	May 29, 2013	Mar CAHN
	+	EQ 75MG BASE	N202806	002	May 29, 2013	Mar CAHN

>A> DACLATASVIR DIHYDROCHLORIDE

>A> TABLET;ORAL
>A> DAKLINZA

>A>	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015	Jul NEWA
>A>	+	EQ 60MG BASE	N206843	002	Jul 24, 2015	Jul NEWA

DALTEPARIN SODIUM

INJECTABLE;INJECTION
FRAGMIN

	@ PFIZER INC	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Jun CAHN
	@ PHARMACIA AND UPJOHN	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Apr CAHN

		INJECTABLE;SUBCUTANEOUS						
		FRAGMIN						
		PFIZER INC	2,500IU/0.2ML (12,500IU/ML)	N	020287	001	Dec 22, 1994	Jun CAHN
			5,000IU/0.2ML (25,000IU/ML)	N	020287	003	Mar 18, 1996	Jun CAHN
			7,500IU/0.3ML (25,000IU/ML)	N	020287	005	Apr 04, 2002	Jun CAHN
	@		10,000IU/0.4ML (25,000IU/ML)	N	020287	002	May 01, 2007	Jun CAHN
			10,000IU/ML (10,000IU/ML)	N	020287	004	Jan 30, 1998	Jun CAHN
			12,500IU/0.5ML (25,000IU/ML)	N	020287	009	May 01, 2007	Jun CAHN
			15,000IU/0.6ML (25,000IU/ML)	N	020287	010	May 01, 2007	Jun CAHN
			18,000IU/0.72ML (25,000IU/ML)	N	020287	011	May 01, 2007	Jun CAHN
	+		95,000IU/3.8ML (25,000IU/ML)	N	020287	006	Apr 04, 2002	Jun CAHN
	@		95,000IU/9.5ML (10,000IU/ML)	N	020287	007	Apr 04, 2002	Jun CAHN
		PHARMACIA AND UPJOHN	2,500IU/0.2ML (12,500IU/ML)	N	020287	001	Dec 22, 1994	Apr CAHN
			5,000IU/0.2ML (25,000IU/ML)	N	020287	003	Mar 18, 1996	Apr CAHN
			7,500IU/0.3ML (25,000IU/ML)	N	020287	005	Apr 04, 2002	Apr CAHN
	@		10,000IU/0.4ML (25,000IU/ML)	N	020287	002	May 01, 2007	Apr CAHN
			10,000IU/ML (10,000IU/ML)	N	020287	004	Jan 30, 1998	Apr CAHN
			12,500IU/0.5ML (25,000IU/ML)	N	020287	009	May 01, 2007	Apr CAHN
			15,000IU/0.6ML (25,000IU/ML)	N	020287	010	May 01, 2007	Apr CAHN
			18,000IU/0.72ML (25,000IU/ML)	N	020287	011	May 01, 2007	Apr CAHN
	+		95,000IU/3.8ML (25,000IU/ML)	N	020287	006	Apr 04, 2002	Apr CAHN
	@		95,000IU/9.5ML (10,000IU/ML)	N	020287	007	Apr 04, 2002	Apr CAHN
		DANTROLENE SODIUM						
		CAPSULE;ORAL						
		DANTROLENE SODIUM						
AB		ELITE LABS INC	25MG	A	076686	001	Oct 24, 2005	May CAHN
AB			50MG	A	076686	002	Oct 24, 2005	May CAHN
AB			100MG	A	076686	003	Oct 24, 2005	May CAHN
		DARIFENACIN HYDROBROMIDE						
		TABLET, EXTENDED RELEASE;ORAL						
		DARIFENACIN HYDROBROMIDE						
AB		ANCHEN PHARMS	EQ 7.5MG BASE	A	091190	001	Mar 13, 2015	Mar NEWA
AB			EQ 15MG BASE	A	091190	002	Mar 13, 2015	Mar NEWA
		ENABLEX						
AB		WARNER CHILCOTT LLC	EQ 7.5MG BASE	N	021513	001	Dec 22, 2004	Mar CFTG
AB	+		EQ 15MG BASE	N	021513	002	Dec 22, 2004	Mar CFTG
		DECITABINE						
		INJECTABLE;INTRAVENOUS						
		DACOGEN						
AP	+	OTSUKA PHARM CO LTD	50MG/VIAL	N	021790	001	May 02, 2006	Jan CAHN
		DEFERASIROX						
		TABLET;ORAL						
		JADENU						
		NOVARTIS PHARMS CORP	90MG	N	206910	001	Mar 30, 2015	Mar NEWA
			180MG	N	206910	002	Mar 30, 2015	Mar NEWA
	+		360MG	N	206910	003	Mar 30, 2015	Mar NEWA
		DEOXYCHOLIC ACID						
		SOLUTION;SUBCUTANEOUS						
		KYBELLA						
	+	KYTHERA BIOPHARMS	20MG/2ML (10MG/ML)	N	206333	001	Apr 29, 2015	Apr NEWA
		DESIRUDIN RECOMBINANT						
		INJECTABLE;SUBCUTANEOUS						
		IPRIVASK						
	+	VALEANT PHARMS NORTH	15MG/VIAL	N	021271	001	Apr 04, 2003	May CAHN
		DESLORATADINE						
		SOLUTION;ORAL						
		CLARINEX						
AA	+	MERCK SHARP DOHME	0.5MG/ML	N	021300	001	Sep 01, 2004	Jun CFTG
		DESLORATADINE						
AA		TARO PHARM INDS	0.5MG/ML	A	202592	001	Jun 30, 2015	Jun NEWA

DESMOPRESSIN ACETATE

TABLET;ORAL

DDAVP

AB		FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995	Jan CAHN
AB	+		0.2MG	N019955	002	Sep 06, 1995	Jan CAHN

DESMOPRESSIN ACETATE

AB		GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May NEWA
AB			0.2MG	A201831	002	May 28, 2015	May NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

BEKYREE

>A> AB		LUPIN LTD	0.15MG,N/A;0.02MG,0.01MG	A202226	001	Aug 12, 2015	Jul NEWA

ISIBLOOM

>A> AB		SANDOZ INC	0.15MG;0.03MG	A202789	001	Aug 12, 2015	Jul NEWA

KARIVA

AB	+	BARR	0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002	Apr CTEC

KIMIDESS

AB		VINTAGE PHARMS	0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	Apr NEWA

DESONIDE

CREAM;TOPICAL

DESONIDE

AB		TEVA PHARMS	0.05%	A074027	001	Sep 28, 1992	May CMFD

DESOXIMETASONE

CREAM;TOPICAL

DESOXIMETASONE

AB		VERSAPHARM INC	0.25%	A203234	001	Jun 12, 2015	Jun NEWA

OINTMENT;TOPICAL

DESOXIMETASONE

AB		PERRIGO NEW YORK	0.25%	A077770	001	Apr 20, 2015	Apr NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB		ALEMBIC PHARMS LTD	EQ 50MG BASE	A204003	001	Jun 29, 2015	Jun NEWA
AB			EQ 100MG BASE	A204003	002	Jun 29, 2015	Jun NEWA
AB		LUPIN LTD	EQ 50MG BASE	A204172	001	Jun 29, 2015	Jun NEWA
AB			EQ 100MG BASE	A204172	002	Jun 29, 2015	Jun NEWA
AB		MYLAN PHARMS INC	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun NEWA
AB			EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun NEWA
AB		SANDOZ INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Jun NEWA
AB			EQ 100MG BASE	A204028	002	Jun 29, 2015	Jun NEWA

PRISTIQ

AB	+	WYETH PHARMS INC	EQ 50MG BASE	N021992	001	Feb 29, 2008	Jun CFTG
AB	+		EQ 100MG BASE	N021992	002	Feb 29, 2008	Jun CFTG

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

	@	EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML	A084282	001		Mar CAHN
AP	+		EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Feb CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MAXITROL

AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050065	002		Mar CAHN

SUSPENSION/DROPS;OPHTHALMIC

MAXITROL

AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Mar CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

PRECEDEX

		HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Jan NEWA

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017451	001			Mar DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE;INJECTION

MD-76R

AP	+	LIEBEL-FLARSHEIM	66%;10%	N019292	001	Sep 29, 1989	Feb	CAHN

SOLUTION;ORAL, RECTAL

MD-GASTROVIEW

AA		LIEBEL-FLARSHEIM	66%;10%	A087388	001		Jan	CAHN

DICLOFENAC SODIUM

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AT		IGI LABS INC	1.5%	A202769	001	Jul 08, 2015	Jun	NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

TENUATE

AA	+	ACTAVIS LABS UT INC	25MG	N011722	002		Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL

TENUATE DOSPAN

AB	+	ACTAVIS LABS UT INC	75MG	N012546	001		Mar	CAHN

DIFLORASONE DIACETATE

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

>A> AB		VERSAPHARM INC	0.05%	A206572	001	Jul 24, 2015	Jul	NEWA

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

AB		HERITAGE PHARMA	500MG	A202845	001	Mar 08, 2012	Mar	CAHN

DIGOXIN

INJECTABLE;INJECTION

DIGOXIN

AP		EUROHLTH INTL SARL	0.25MG/ML	A083391	001		Feb	CAHN

TABLET;ORAL

DIGOXIN

AB		MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999	Jan	CTEC
AB			0.25MG	A040282	002	Dec 23, 1999	Jan	CTEC
AB		SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003	Feb	CMFD
AB			0.25MG	A076363	002	Jan 31, 2003	Feb	CMFD

LANOXIN

		CONCORDIA PHARMS INC	0.0625MG	N020405	001	Sep 30, 1997	Apr	CAHN
AB			0.125MG	N020405	002	Sep 30, 1997	Apr	CAHN
			0.1875MG	N020405	003	Sep 30, 1997	Apr	CAHN
AB	+		0.25MG	N020405	004	Sep 30, 1997	Apr	CAHN
	@		0.375MG	N020405	005	Sep 30, 1997	Apr	CAHN
	@		0.5MG	N020405	006	Sep 30, 1997	Apr	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB2	+	MYLAN	240MG	A075124	001	Mar 18, 1998	Feb	CRLD

TIAZAC

AB4		VALEANT PHARMS NORTH	120MG	N020401	001	Sep 11, 1995	Feb	CAHN
AB4			180MG	N020401	002	Sep 11, 1995	Feb	CAHN
AB4			240MG	N020401	003	Sep 11, 1995	Feb	CAHN
AB4			300MG	N020401	004	Sep 11, 1995	Feb	CAHN
AB4			360MG	N020401	005	Sep 11, 1995	Feb	CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998	Feb	CAHN

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP		EUROHLTH INTL SARL	5MG/ML	A078538	001	Dec 17, 2008	Jun	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP	+	EUROHLTH INTL SARL	50MG/ML	A080817	002			Jun CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

AP		EUROHLTH INTL SARL	5MG/ML	A074521	001	Oct 18, 1996		Jun CAHN

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB		MYLAN PHARMS INC	250MG	A203916	001	Mar 04, 2015		Feb NEWA
AB			500MG	A203916	002	Mar 04, 2015		Feb NEWA

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

AB		AMNEAL PHARMS	EQ 250MG VALPROIC ACID	A203730	001	May 29, 2015		May NEWA
AB			EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015		May NEWA
>A>		@ G AND W LABS INC	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009		Jul CAHN
>D>		@ TEVA PHARMS USA	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009		Jul CAHN

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

		@ IGI LABS INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995		Mar CAHN

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB		HETERO LABS LTD V	5MG	A203034	001	Jan 30, 2015		Jan NEWA
AB			10MG	A203034	002	Jan 30, 2015		Jan NEWA
AB		SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010		Apr CAHN
AB			10MG	A076786	002	Nov 26, 2010		Apr CAHN
AB			23MG	A204293	001	Jun 05, 2015		May NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMZARIC

		FOREST LABS LLC	10MG;14MG	N206439	001	Dec 23, 2014		Mar CAHN
	+		10MG;28MG	N206439	002	Dec 23, 2014		Mar CAHN

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

		@ IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985		Mar CAHN
		@	40MG/ML	N018656	001	Jun 28, 1983		Mar CAHN
		@	80MG/ML	A070089	001	Oct 23, 1985		Mar CAHN
		@	80MG/ML	A070090	001	Oct 23, 1985		Mar CAHN
		@	80MG/ML	A070091	001	Oct 23, 1985		Mar CAHN
		@	160MG/ML	A070092	001	Oct 23, 1985		Mar CAHN
		@	160MG/ML	A070093	001	Oct 23, 1985		Mar CAHN
		@	160MG/ML	A070094	001	Oct 23, 1985		Mar CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOPRAM

AP	+	EUROHLTH INTL SARL	20MG/ML	N014879	001			Jun CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	+	MYLAN PHARMS INC	EQ 100MG BASE	A070791	005	May 13, 1986		Jan CRLD
	+	PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987		Jan CRLD

CREAM;TOPICAL

ZONALON

	+	DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994		Mar CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP	AKORN INC	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Apr	NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB	NOVEL LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	May	NEWA
AB		EQ 75MG BASE	A204446	002	May 28, 2015	May	NEWA
AB		EQ 100MG BASE	A204446	003	May 28, 2015	May	NEWA
AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065053	001	Nov 22, 2000	Apr	CAHN
AB		EQ 75MG BASE	A065053	003	Sep 10, 2003	Apr	CAHN
AB		EQ 100MG BASE	A065053	002	Nov 22, 2000	Apr	CAHN

TABLET;ORAL

DOXYCYCLINE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065356	001	May 31, 2006	Apr	CAHN
AB		EQ 75MG BASE	A065356	002	May 31, 2006	Apr	CAHN
AB		EQ 100MG BASE	A065356	003	May 31, 2006	Apr	CAHN

DOXYCYCLINE HYCLATE

INJECTABLE;INJECTION

DOXYCYCLINE

@	EUROHLTH INTL SARL	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jun	CAHN
@		EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jun	CAHN

DROPERIDOL

INJECTABLE;INJECTION

DROPERIDOL

@	IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988	Mar	CAHN
@		2.5MG/ML	A072020	001	Oct 19, 1988	Mar	CAHN
@		2.5MG/ML	A072021	001	Oct 19, 1988	Mar	CAHN

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

AB	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar	CRLD
AB +	PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004	Mar	CRLD

EDOXABAN TOSYLATE

TABLET;ORAL

SAVAYSA

	DAIICHI SANKYO	EQ 15MG BASE	N206316	001	Jan 08, 2015	Jan	NEWA
		EQ 30MG BASE	N206316	002	Jan 08, 2015	Jan	NEWA
+		EQ 60MG BASE	N206316	003	Jan 08, 2015	Jan	NEWA

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON

+	MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985	Mar	CRLD

TENSILON

@	IGI LABS INC	10MG/ML	N007959	001		Apr	CAHN
@	VALEANT PHARMS	10MG/ML	N007959	001		Mar	DISC

TENSILON PRESERVATIVE FREE

@	IGI LABS INC	10MG/ML	N007959	002		Apr	CAHN
@	VALEANT PHARMS	10MG/ML	N007959	002		Mar	DISC

ELTROMBOPAG OLAMINE

TABLET;ORAL

PROMACTA

	NOVARTIS PHARMS CORP	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Mar	CAHN
		EQ 25MG ACID	N022291	001	Nov 20, 2008	Mar	CAHN
		EQ 50MG ACID	N022291	002	Nov 20, 2008	May	CRLD
+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Mar	CAHN
+		EQ 75MG ACID	N022291	003	Sep 08, 2009	May	CRLD
		EQ 75MG ACID	N022291	003	Sep 08, 2009	Mar	CAHN
+		EQ 100MG ACID	N022291	005	Nov 16, 2012	May	CRLD
		EQ 100MG ACID	N022291	005	Nov 16, 2012	Mar	CAHN

ELUXADOLINE

TABLET;ORAL

VIBERZI

>A>		FOREST TOSARA LTD	75MG	N206940	001	May 27, 2015	Jul CAHN
>A>	+		100MG	N206940	002	May 27, 2015	Jul CAHN
>D>		FURIEX PHARMS	75MG	N206940	001	May 27, 2015	Jul CAHN
			75MG	N206940	001	May 27, 2015	May NEWA
>D>	+		100MG	N206940	002	May 27, 2015	Jul CAHN
	+		100MG	N206940	002	May 27, 2015	May NEWA

EMPAGLIFLOZIN; LINAGLIPTIN

TABLET;ORAL

GLYXAMBI

		BOEHRINGER INGELHEIM	10MG;5MG	N206073	001	Jan 30, 2015	Jan NEWA
	+		25MG;5MG	N206073	002	Jan 30, 2015	Jan NEWA

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

AB		SANDOZ INC	2.5MG	A075496	001	Aug 22, 2000	Mar CMFD
AB			5MG	A075496	002	Aug 22, 2000	Mar CMFD
AB			10MG	A075459	001	Aug 22, 2000	Mar CMFD
AB			20MG	A075459	002	Aug 22, 2000	Mar CMFD
	@	SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000	Apr CAHN
	@		5MG	A075556	002	Aug 22, 2000	Apr CAHN
	@		10MG	A075556	003	Aug 22, 2000	Apr CAHN
	@		20MG	A075556	004	Aug 22, 2000	Apr CAHN

VASOTEC

AB		VALEANT PHARMS NORTH	2.5MG	N018998	005	Jul 26, 1988	Apr CAHN
AB			5MG	N018998	001	Dec 24, 1985	Apr CAHN
AB			10MG	N018998	002	Dec 24, 1985	Apr CAHN
AB	+		20MG	N018998	003	Dec 24, 1985	Apr CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB		G AND W LABS INC	5MG;12.5MG	A075727	001	Sep 18, 2001	Apr CAHN
AB			10MG;25MG	A075727	002	Sep 18, 2001	Apr CAHN

ENTACAPONE

TABLET;ORAL

ENTACAPONE

AB		AUROBINDO PHARMA LTD	200MG	A203437	001	Jun 19, 2015	Jun NEWA

>A> EPINEPHRINE

>A> INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

>A> ADRENALIN

>A>	+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jul CAIN

>A> INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

>A> ADRENALIN

>A>	+	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jul CAIN

>D> EPINEPHRINE HYDROCHLORIDE

>D> INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

>D> ADRENALIN

>D>	+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jul CAIN

>D> INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

>D> ADRENALIN

>D>	+	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jul CAIN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEVETEN HCT

	@	ABBVIE	600MG;12.5MG	N021268	001	Nov 01, 2001	Jun DISC
	@		600MG;25MG	N021268	002	Nov 01, 2001	Jun DISC

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

AP		TEVA PHARMS USA	2MG/ML	A090854	001	Jun 12, 2015	Jun NEWA
AP			75MG/100ML	A091555	001	Jun 05, 2015	May NEWA

INTEGRILIN

AP	+	SCHERING	2MG/ML	N020718	001	May 18, 1998	Jun CTEC
AP	+		75MG/100ML	N020718	002	May 18, 1998	May CFTG

ERGOCALCIFEROL

CAPSULE;ORAL

VITAMIN D

AA		BANNER LIFE SCIENCES	50,000 IU	A080704	001		Jan CAHN

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

	@	G AND W LABS INC	EQ 125MG BASE/5ML	A062169	001	Oct 17, 1990	Apr CAHN
	@		EQ 250MG BASE/5ML	A062169	002	Oct 17, 1990	Apr CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

>A>	@	ANI PHARMS INC	EQ 200MG BASE/5ML	A062055	001		Jul CAHN
>D>	@	BARR	EQ 200MG BASE/5ML	A062055	001		Jul CAHN

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA		ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	May NEWA

TABLET;ORAL

ESCITALOPRAM OXALATE

AB		MYLAN PHARMS INC	EQ 5MG BASE	A077550	001	May 14, 2015	Apr NEWA
AB			EQ 10MG BASE	A077550	002	May 14, 2015	Apr NEWA
AB			EQ 20MG BASE	A077550	003	May 14, 2015	Apr NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

>A>	AP		AUROBINDO PHARMA LTD	10MG/ML	A205520	001	Jul 23, 2015	Jul NEWA
	AP		LUITPOLD	10MG/ML	A201126	001	Feb 20, 2015	Feb NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

	AB		IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Jan NEWA
	AB			EQ 40MG BASE	A078003	002	Jan 26, 2015	Jan NEWA
>A>	AB		MYLAN LABS LTD	EQ 20MG BASE	A078936	001	Aug 02, 2015	Jul NEWA
>A>	AB			EQ 40MG BASE	A078936	002	Aug 03, 2015	Jul NEWA

NEXIUM

	AB		ASTRAZENECA PHARMS	EQ 20MG BASE	N021153	001	Feb 20, 2001	Jan CFTG
	AB	+		EQ 40MG BASE	N021153	002	Feb 20, 2001	Jan CFTG

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

ALORA

BX		ACTAVIS LABS UT INC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar CAHN
BX			0.05MG/24HR	N020655	001	Dec 20, 1996	Mar CAHN
BX			0.075MG/24HR	N020655	002	Dec 20, 1996	Mar CAHN
BX			0.1MG/24HR	N020655	003	Dec 20, 1996	Mar CAHN

MINIVELLE

		NOVEN	0.025MG/24HR	N203752	005	Sep 23, 2014	Jan NEWA

TABLET;VAGINAL

ESTRADIOL

	@	AMNEAL PHARMS	10MCG	A205256	001	May 29, 2015	May DISC

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

AB		MACLEODS PHARMS LTD	1MG	A202929	001	Jan 30, 2015	Jan	NEWA
AB			2MG	A202929	002	Jan 30, 2015	Jan	NEWA
AB			3MG	A202929	003	Jan 30, 2015	Jan	NEWA

ETHACRYNATE SODIUM

INJECTABLE;INJECTION

EDECRIN

>D>	+	ATON	EQ 50MG BASE/VIAL	N016093	001		Jul	CFTG
>A> AP	+		EQ 50MG BASE/VIAL	N016093	001		Jul	CFTG

>A> ETHACRYNATE SODIUM

>A> AP		PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Jul	NEWA

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

ETHAMBUTOL HYDROCHLORIDE

AB		VERSAPHARM INC	100MG	A075095	001	Nov 30, 1999	Jan	CMFD
AB			400MG	A075095	002	Nov 30, 1999	Jan	CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

ASHLYNA

AB		GLENMARK GENERICS	0.03MG,0.01MG;0.15MG,N/A	A203163	001	Feb 23, 2015	Feb	NEWA

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB		GLENMARK GENERICS	0.02MG;0.09MG	A202791	001	Apr 09, 2015	Mar	NEWA
AB		GLENMARK PHARMS LTD	0.03MG;0.15MG	A203164	001	Jun 12, 2015	Jun	NEWA
AB	+	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	Mar	CTEC

TABLET;ORAL-28

VIENVA

AB1		SANDOZ INC	0.02MG;0.1MG	A201088	001	May 21, 2015	May	NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ORTHO EVRA

	@	JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR	N021180	001	Nov 20, 2001	Feb	DISC

XULANE

AB	+	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Feb	CRLD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

BREVICON 21-DAY

	@	ACTAVIS LABS UT INC	0.035MG;0.5MG	N017566	001		Mar	CAHN

NORINYL 1+35 21-DAY

AB		ACTAVIS LABS UT INC	0.035MG;1MG	N017565	001		Feb	CAHN

TRI-NORINYL 21-DAY

	@	ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	001	Apr 13, 1984	Feb	CAHN

TABLET;ORAL-28

BREVICON 28-DAY

AB		ACTAVIS LABS UT INC	0.035MG;0.5MG	N017743	001		Mar	CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL

>D> AB		FAMY CARE LTD	0.035MG;0.4MG	A200897	001	May 11, 2015	Jul	CRLD
AB			0.035MG;0.4MG	A200897	001	May 11, 2015	Apr	NEWA
>D> AB	+		0.05MG;1MG	A203006	001	Aug 05, 2013	Jul	CTEC
>A> AB	+	JAI PHARMA LTD	0.035MG;0.4MG	A200897	001	May 11, 2015	Jul	CRLD
>A>	+		0.05MG;1MG	A203006	001	Aug 05, 2013	Jul	CTEC

NORINYL 1+35 28-DAY

AB		ACTAVIS LABS UT INC	0.035MG;1MG	N017565	002		Feb	CAHN

>D> OVCON-35

>D> AB	+	WARNER CHILCOTT LLC	0.035MG;0.4MG	N017716	001		Jul	DISC
>A>	@		0.035MG;0.4MG	N017716	001		Jul	DISC

TRI-NORINYL 28-DAY

AB	+	ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	002	Apr 13, 1984	Feb	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

FEMHRT

AB	WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Mar	CTEC

LARIN 24 FE

AB	NOVAST LABS LTD	0.02MG;1MG	A202994	001	Feb 18, 2015	Feb	NEWA

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB +	BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009	Mar	CTEC
AB	GLENMARK GENERICS	0.0025MG;0.5MG	A203038	001	Apr 02, 2015	Mar	NEWA
AB		0.005MG;1MG	A203038	002	Apr 02, 2015	Mar	NEWA

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB +	AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Jan	CRLD

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	OC PHARMA	0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG	A200383	001	Apr 07, 2015	Mar	NEWA
AB		0.035MG;0.25MG	A200384	001	Apr 07, 2015	Mar	NEWA

TRI-LO-ESTARYLLA

AB	SANDOZ INC	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A091232	001	Jun 29, 2015	Jun	NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

LOW-OGESTREL-28

AB	WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999	Feb	CMFD

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB	BANNER LIFE SCIENCES	250MG	A040430	001	Oct 28, 2002	Jan	CAHN

ETONOGESTREL

IMPLANT;IMPLANTATION

IMPLANON

@	ORGANON USA INC	68MG/IMPLANT	N021529	001	Jul 17, 2006	Jun	DISC

EZETIMIBE

TABLET;ORAL

EZETIMIBE

@	GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015	Jun	DISC
AB		10MG	A078560	001	Jun 26, 2015	Jun	NEWA

ZETIA

+	MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002	Jun	CTEC
AB +		10MG	N021445	001	Oct 25, 2002	Jun	CFTG

FAMOTIDINE

INJECTABLE;INJECTION

FAMOTIDINE

AP +	EUROHLTH INTL SARL	10MG/ML	A075488	001	Apr 16, 2001	Jun	CAHN

FAMOTIDINE PRESERVATIVE FREE

AP +	EUROHLTH INTL SARL	10MG/ML	A075486	001	Apr 16, 2001	Jun	CAHN

TABLET;ORAL

PEPCID

AB	VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Feb	CAHN
AB +		40MG	N019462	002	Oct 15, 1986	Feb	CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

AB	ORCHID HLTHCARE	2.5MG	A203032	001	May 21, 2015	May	NEWA
AB		5MG	A203032	002	May 21, 2015	May	NEWA
AB		10MG	A203032	003	May 21, 2015	May	NEWA
AB	SUN PHARM INDS LTD	2.5MG	A091200	001	Dec 13, 2013	Apr	CAHN
AB		5MG	A091200	002	Dec 13, 2013	Apr	CAHN
AB		10MG	A091200	003	Dec 13, 2013	Apr	CAHN

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE

AB	SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014	Apr	CAHN
AB		130MG	A201748	002	Oct 31, 2014	Apr	CAHN

TABLET;ORAL

FENOFIBRATE

AB	SUN PHARM INDS LTD	54MG	A076635	001	Oct 31, 2005	Apr	CAHN
		107MG	A076635	002	Oct 31, 2005	Apr	CAHN
AB		160MG	A076635	003	Oct 31, 2005	Apr	CAHN

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

	TRIBUTE PHARMS INTL	35MG	N022418	001	Aug 14, 2009	Jun	CAHN
+		105MG	N022418	002	Aug 14, 2009	Jun	CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar	CAHN

FENTANYL-12

AB	MALLINCKRODT INC	12.5MCG/HR	A077154	005	Jun 11, 2015	Jun	NEWA

FENTANYL-25

AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar	CAHN

FENTANYL-50

AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar	CAHN

FENTANYL-75

AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar	CAHN

FENTANYL CITRATE

FILM;BUCCAL

ONSOLIS

@	BIODELIVERY SCI INTL	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Mar	CAHN
@		EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Mar	CAHN
@		EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Mar	CAHN
@		EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Mar	CAHN
@		EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Mar	CAHN

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP +	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb	CAHN

FENTANYL HYDROCHLORIDE

SYSTEM;IONTOPHORESIS, TRANSDERMAL

IONSYS

@	THE MEDICINES CO	10.8MCG	N021338	001	May 22, 2006	Apr	CAHN
+		EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006	Jun	CMFD

FERRIC CITRATE

TABLET;ORAL

AURYXIA

+	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Jan	CTNA

FERRIC PYROPHOSPHATE CITRATE

SOLUTION;IV (INFUSION)

TRIFERIC

+	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015	Jan	NEWA

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

AB	ANI PHARMS INC	50MG	A075882	001	Oct 28, 2002	Apr	CAHN
AB		100MG	A075882	002	Oct 28, 2002	Apr	CAHN
AB		150MG	A075882	003	Oct 28, 2002	Apr	CAHN
AB	AUROBINDO PHARMA LTD	50MG	A202821	001	Jul 08, 2015	Jun	NEWA
AB		100MG	A202821	002	Jul 08, 2015	Jun	NEWA
AB		150MG	A202821	003	Jul 08, 2015	Jun	NEWA
AB	SUN PHARM INDS LTD	50MG	A076421	001	Mar 28, 2003	Apr	CAHN
AB		100MG	A076421	002	Mar 28, 2003	Apr	CAHN
AB		150MG	A076421	003	Mar 28, 2003	Apr	CAHN

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

AB	SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Apr	CAHN
AB		200MG/5ML	A076332	002	Jul 29, 2004	Apr	CAHN

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Apr	CAHN
AP		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Apr	CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Apr	CAHN
AP		400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Apr	CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	CLARIS PHARMASERVICE	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr	NEWA
		100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr	CAHN
AP		200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Apr	CAHN
AP		400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Apr	CAHN

TABLET;ORAL

FLUCONAZOLE

AB	HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	May	CMFD
AB		100MG	A078423	002	Mar 07, 2011	May	CMFD
AB		150MG	A078423	003	Mar 07, 2011	May	CMFD
AB		200MG	A078423	004	Mar 07, 2011	May	CMFD

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	METHODIST HOSP RES	20-300mCi/ML	A203904	001	Apr 23, 2015	Apr	NEWA
	PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar	NEWA
	SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015	Apr	NEWA
>A> AP	UNIV MICHIGAN	20-300mCi/ML	A204531	001	Jul 17, 2015	Jul	NEWA

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

@	CLARIS PHARMASERVICE	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr	CAHN
@		1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr	CAHN
AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jun	CAHN
AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jun	CAHN

FLUOCINOLONE ACETONIDE

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

AT	VERSAPHARM INC	0.01%	A091514	001	Jun 25, 2015	Jun	NEWA

FLUOCINONIDE

GEL;TOPICAL

FLUOCINONIDE

AB	G AND W LABS INC	0.05%	A072537	001	Feb 07, 1989	Apr	CAHN

FLUOROURACIL

CREAM;TOPICAL

CARAC

AB +	VALEANT PHARMS NORTH	0.5%	N020985	001	Oct 27, 2000	Apr	CFTG
+		0.5%	N020985	001	Oct 27, 2000	Feb	CAHN

FLUOROURACIL

AB	SPEAR PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Apr	NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

@	ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Mar	DISC
@		EQ 20MG BASE	A076287	002	May 20, 2008	Mar	DISC
+	MYLAN	EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CRLD
		EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CTEC
@	SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008	Mar	DISC
@		EQ 20MG BASE	A077469	002	Nov 17, 2008	Mar	DISC
AB1	SCIEGEN PHARMS INC	EQ 10MG BASE	A204597	001	Mar 16, 2015	Mar	NEWA
AB1		EQ 20MG BASE	A204597	002	Mar 16, 2015	Mar	NEWA
AB		EQ 40MG BASE	A204597	003	Mar 16, 2015	Mar	NEWA
AB	SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Apr	CAHN

FLURANDRENOLIDE

OINTMENT;TOPICAL

CORDRAN

+	AQUA PHARMS	0.05%	N012806	001			Jun CRLD
		0.05%	N012806	001			May CMFD

TAPE;TOPICAL

CORDRAN

+	ACTAVIS LABS UT INC	0.004MG/SQ CM	N016455	001			Mar CAHN

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER;INHALATION

BREO ELLIPTA

	GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015		Apr NEWA

FLUVOXAMINE MALEATE

TABLET;ORAL

FLUVOXAMINE MALEATE

>A> AB		ANI PHARMS INC	25MG	A075897	001	Jan 25, 2001		Jul CAHN
>A>	@		25MG	A075898	001	Mar 12, 2001		Jul CAHN
>A> AB			50MG	A075897	002	Jan 25, 2001		Jul CAHN
>A>	@		50MG	A075898	002	Mar 12, 2001		Jul CAHN
>A> AB			100MG	A075897	003	Jan 25, 2001		Jul CAHN
>A>	@		100MG	A075898	003	Mar 12, 2001		Jul CAHN
>D> AB		BARR	25MG	A075897	001	Jan 25, 2001		Jul CAHN
>D> AB			50MG	A075897	002	Jan 25, 2001		Jul CAHN
>D> AB			100MG	A075897	003	Jan 25, 2001		Jul CAHN
>D>	@	IVAX SUB TEVA PHARMS	25MG	A075898	001	Mar 12, 2001		Jul CAHN
>D>	@		50MG	A075898	002	Mar 12, 2001		Jul CAHN
>D>	@		100MG	A075898	003	Mar 12, 2001		Jul CAHN

FOLIC ACID

TABLET;ORAL

FOLIC ACID

>A> AA	NUVO PHARM INC	1MG	A204418	001	Jul 28, 2015		Jul NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004		Apr CAHN
AB		20MG;12.5MG	A076739	002	Dec 17, 2004		Apr CAHN

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

@	IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985		Mar CAHN
@		10MG/ML	A070096	001	Sep 09, 1985		Mar CAHN

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB	SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005		Apr CAHN
AB		300MG	A076606	002	Oct 07, 2005		Apr CAHN
AB		400MG	A076606	003	Oct 07, 2005		Apr CAHN

TABLET;ORAL

GABAPENTIN

@	HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011		Jun DISC
@		800MG	A078782	002	Jul 21, 2011		Jun DISC

GADOVERSETAMIDE

INJECTABLE;INJECTION

OPTIMARK

+	LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999		Feb CAHN
+		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999		Feb CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999		Feb CAHN
+		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999		Feb CAHN
+		16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999		Feb CAHN

OPTIMARK IN PLASTIC CONTAINER

+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999		Feb CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999		Feb CAHN
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999		Feb CAHN
+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999		Feb CAHN

>A>	GEFITINIB							
>A>	TABLET;ORAL							
>A>	IRESSA							
>A>	+ ASTRAZENECA PHARMS	250MG	N206995	001	Jul 13, 2015	Jul NEWA		
	GEMIFLOXACIN MESYLATE							
	TABLET;ORAL							
	FACTIVE							
AB	+ LG LIFE SCIENCES	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jun CFTG		
	GEMIFLOXACIN MESYLATE							
AB	ORCHID HLTHCARE	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jun NEWA		
	GLATIRAMER ACETATE							
	INJECTABLE;SUBCUTANEOUS							
	COPAXONE							
AP	+ TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Mar CFTG		
	GLATOPA							
AP	SANDOZ INC	20MG/ML	A090218	001	Apr 16, 2015	Mar NEWA		
	GLIMEPIRIDE							
	TABLET;ORAL							
	GLIMEPIRIDE							
	@ HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Apr DISC		
	@	2MG	A078952	002	Aug 01, 2013	Apr DISC		
	@	4MG	A078952	003	Aug 01, 2013	Apr DISC		
	GLIMEPIRIDE; ROSIGLITAZONE MALEATE							
	TABLET;ORAL							
	AVANDARYL							
	@ SB PHARMCO	1MG;4MG	N021700	001	Nov 23, 2005	Jun DISC		
	@	2MG;4MG	N021700	002	Nov 23, 2005	Jun DISC		
	@	2MG;8MG	N021700	004	Mar 30, 2007	Jun DISC		
	@	4MG;4MG	N021700	003	Nov 23, 2005	Jun DISC		
	@	4MG;8MG	N021700	005	Mar 30, 2007	Jun DISC		
	GLIPIZIDE							
	TABLET, EXTENDED RELEASE;ORAL							
	GLIPIZIDE							
AB	MYLAN PHARMS INC	2.5MG	A202298	001	May 19, 2015	May NEWA		
AB		5MG	A202298	002	May 19, 2015	May NEWA		
AB		10MG	A202298	003	May 19, 2015	May NEWA		
	GLUCAGON HYDROCHLORIDE							
	POWDER;INTRAMUSCULAR, INTRAVENOUS							
	GLUCAGON							
	+ FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015	May NEWA		
	GLYCEROL PHENYLBUTYRATE							
	LIQUID;ORAL							
	RAVICTI							
	+ HORIZON THERAPS INC	1.1GM/ML	N203284	001	Feb 01, 2013	May CAHN		
	GLYCOPYRROLATE							
	INJECTABLE;INJECTION							
	ROBINUL							
AP	+ EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Jun CAHN		
	TABLET;ORAL							
	GLYCOPYRROLATE							
AA	SUN PHARM INDS LTD	1MG	A040844	001	Aug 18, 2009	Apr CAHN		
AA		2MG	A040844	002	Aug 18, 2009	Apr CAHN		
	GRANISETRON HYDROCHLORIDE							
	INJECTABLE;INJECTION							
	GRANISETRON HYDROCHLORIDE							
AP	BANNER LIFE SCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN		
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN		
	@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr CAHN		
	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr CAHN		
AP	EUROHLTH INTL SARL	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jun CAHN		

INJECTABLE;INJECTION
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP		BANNER LIFE SCIENCES	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL
FLOWTUSS

		MIKART INC	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015	May NEWA

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL
HYCOFENIX

	+	MIKART INC	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	May NEWA

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
GUANFACINE HYDROCHLORIDE

AB		MYLAN PHARMS INC	EQ 1MG BASE	A202578	001	Jun 02, 2015	May NEWA
AB			EQ 2MG BASE	A202578	002	Jun 02, 2015	May NEWA
AB			EQ 3MG BASE	A202578	003	Jun 02, 2015	May NEWA
AB			EQ 4MG BASE	A202578	004	Jun 02, 2015	May NEWA
AB		SANDOZ INC	EQ 1MG BASE	A202568	001	Jun 03, 2015	May NEWA
AB			EQ 2MG BASE	A202568	002	Jun 03, 2015	May NEWA
AB			EQ 3MG BASE	A202568	003	Jun 03, 2015	May NEWA
AB			EQ 4MG BASE	A202568	004	Jun 03, 2015	May NEWA
AB		TEVA PHARMS USA	EQ 1MG BASE	A201382	001	Jun 02, 2015	May NEWA
AB			EQ 2MG BASE	A201382	002	Jun 02, 2015	May NEWA
AB			EQ 3MG BASE	A201382	003	Jun 02, 2015	May NEWA
AB			EQ 4MG BASE	A201382	004	Jun 02, 2015	May NEWA
AB		TWI PHARMS INC	EQ 1MG BASE	A201408	001	Jun 02, 2015	May NEWA
AB			EQ 2MG BASE	A201408	002	Jun 02, 2015	May NEWA
AB			EQ 3MG BASE	A201408	003	Jun 02, 2015	May NEWA
AB			EQ 4MG BASE	A201408	004	Jun 02, 2015	May NEWA

HALOPERIDOL

TABLET;ORAL
HALOPERIDOL

	@	CYCLE PHARMS LTD	0.5MG	A071128	001	Feb 17, 1987	May CAHN
	@		1MG	A071129	001	Feb 17, 1987	Jun CAHN
	@		5MG	A071131	001	Feb 17, 1987	Jun CAHN
	@		10MG	A071132	001	May 12, 1987	Jun CAHN
	@		20MG	A071133	001	May 12, 1987	May CAHN
	@	ROXANE	2MG	A071130	001	Feb 17, 1987	Jun CAHN

HALOPERIDOL LACTATE

CONCENTRATE;ORAL
HALOPERIDOL INTENSOL

	@	CYCLE PHARMS LTD	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	May CAHN

INJECTABLE;INJECTION
HALOPERIDOL

	@	CLARIS PHARMASERVICE	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr CAHN
	@		EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	May CAHN

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM

AP	+	EUROHLTH INTL SARL	1,000 UNITS/ML	N017037	001		Jun CAHN
AP	+		5,000 UNITS/ML	N017037	002		Jun CAHN
	@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jun CAHN
AP	+		10,000 UNITS/ML	N017037	003		Jun CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
HYDRALAZINE HYDROCHLORIDE

AP	+	AKORN	20MG/ML	A040730	001	Apr 21, 2009	Feb CRLD
AP		LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb CRLD
AP		X-GEN PHARMS INC	20MG/ML	A203110	001	Jun 29, 2015	Jun NEWA

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

MICROZIDE

AB	+	ACTAVIS LABS UT INC	12.5MG	N020504	001	Dec 27, 1996	Feb	CAHN

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	12.5MG;10MG	A076007	001	Jul 01, 2002	Apr	CAHN
AB			12.5MG;20MG	A076007	002	Jul 01, 2002	Apr	CAHN
AB			25MG;20MG	A076007	003	Jul 01, 2002	Apr	CAHN

ZESTORETIC

AB		ALVOGEN IPCO SARL	12.5MG;10MG	N019888	003	Nov 18, 1993	Feb	CAHN
AB	+		12.5MG;20MG	N019888	001	Sep 20, 1990	Feb	CAHN
AB	+		25MG;20MG	N019888	002	Jul 20, 1989	Feb	CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DUTOPROL

		CONCORDIA PHARMS INC	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jun	CAHN
			12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jun	CAHN
	+		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jun	CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>		@ ANI PHARMS INC	25MG;40MG	A070704	001	Oct 01, 1986	Jul	CAHN
>A>		@	25MG;80MG	A070705	001	Oct 01, 1986	Jul	CAHN
>D>		@ BARR	25MG;40MG	A070704	001	Oct 01, 1986	Jul	CAHN
>D>		@	25MG;80MG	A070705	001	Oct 01, 1986	Jul	CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009	Apr	CAHN
AB			12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009	Apr	CAHN
AB			25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009	Apr	CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

ZOHYDRO ER

	+	FERRIMILL LTD	10MG	N202880	001	Oct 25, 2013	Apr	CAHN
			15MG	N202880	002	Oct 25, 2013	Apr	CAHN
			20MG	N202880	003	Oct 25, 2013	Apr	CAHN
			30MG	N202880	004	Oct 25, 2013	Apr	CAHN
			40MG	N202880	005	Oct 25, 2013	Apr	CAHN
			50MG	N202880	006	Oct 25, 2013	Apr	CAHN
	+	PERNIX IRELAND PAIN	10MG	N202880	001	Oct 25, 2013	Jun	CAHN
			15MG	N202880	002	Oct 25, 2013	Jun	CAHN
			20MG	N202880	003	Oct 25, 2013	Jun	CAHN
			30MG	N202880	004	Oct 25, 2013	Jun	CAHN
			40MG	N202880	005	Oct 25, 2013	Jun	CAHN
			50MG	N202880	006	Oct 25, 2013	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL

HYSINGLA

	+	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Mar	CRLD

HYDROCORTISONE

CREAM;TOPICAL

HYDROCORTISONE

AT		RISING PHARMS INC	2.5%	A040879	001	Aug 20, 2010	Mar	CAHN

POWDER;FOR RX COMPOUNDING

HYDRO-RX

		@ X GEN PHARMS	100%	A085982	001		Apr	DISC

TABLET;ORAL

HYDROCORTISONE

AB		HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015	Feb	NEWA
AB			10MG	A083365	003	Feb 23, 2015	Feb	NEWA
AB			20MG	A083365	001		Feb	CMFD

HYDROCORTISONE ACETATE

POWDER;FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

	@	X GEN PHARMS	100%	A085981	001			Apr DISC

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

	@	G AND W LABS INC	0.2%	A074489	001	Aug 12, 1998	Apr	CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OTIC

CORTISPORIN

AT	+	CITRON PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N060613	001		Jun	CMS2

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB		PADDOCK LLC	8MG	A204278	001	Apr 06, 2015	Mar	NEWA
AB			12MG	A204278	002	Apr 06, 2015	Mar	NEWA
AB			16MG	A204278	003	Apr 06, 2015	Mar	NEWA

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

CYANOKIT

	@	SERB SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Apr	CAHN
	+		5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr	CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

PLAQUENIL

AB	+	CONCORDIA PHARMS INC	200MG	N009768	001		Jun	CAHN

HYDROXYPROGESTERONE CAPROATE

INJECTABLE;INJECTION

HYDROXYPROGESTERONE CAPROATE

	@	ACTAVIS LABS UT INC	125MG/ML	N017439	001		Mar	CAHN
	@		250MG/ML	N017439	002		Mar	CAHN

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB		ELITE LABS INC	10MG	A040600	001	Dec 28, 2004	Jun	CAHN
AB			25MG	A040602	001	Dec 28, 2004	Jun	CAHN
AB			50MG	A040604	001	Dec 28, 2004	Jun	CAHN
AB		HERITAGE PHARMA	10MG	A204279	001	Aug 20, 2014	Mar	CAHN
AB			25MG	A204279	002	Aug 20, 2014	Mar	CAHN
AB			50MG	A204279	003	Aug 20, 2014	Mar	CAHN
AB		MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004	Mar	CMFD
AB			25MG	A040602	001	Dec 28, 2004	Mar	CMFD
AB			50MG	A040604	001	Dec 28, 2004	Mar	CMFD
>D> AB		MUTUAL PHARM	10MG	A089381	001	May 19, 1986	Jul	DISC
>A>	@		10MG	A089381	001	May 19, 1986	Jul	DISC
>D> AB			25MG	A089382	001	May 19, 1986	Jul	DISC
>A>	@		25MG	A089382	001	May 19, 1986	Jul	DISC
>D> AB			50MG	A089383	001	May 19, 1986	Jul	DISC
>A>	@		50MG	A089383	001	May 19, 1986	Jul	DISC
>D> AB		WATSON LABS	10MG	A088348	001	Sep 15, 1983	Jul	DISC
>A>	@		10MG	A088348	001	Sep 15, 1983	Jul	DISC
>D> AB			25MG	A088349	001	Sep 15, 1983	Jul	DISC
>A>	@		25MG	A088349	001	Sep 15, 1983	Jul	DISC
>D> AB			50MG	A088350	001	Sep 15, 1983	Jul	DISC
>A>	@		50MG	A088350	001	Sep 15, 1983	Jul	DISC

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB		HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar	CAHN
AB			EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar	CAHN

IBUPROFEN

TABLET;ORAL

IBUPROFEN

>D>	AB	VINTAGE PHARMS	300MG	A071230	001	Oct 22, 1986	Jul DISC
>A>		@	300MG	A071230	001	Oct 22, 1986	Jul DISC
>D>	AB		400MG	A071231	001	Oct 22, 1986	Jul DISC
>A>		@	400MG	A071231	001	Oct 22, 1986	Jul DISC
>D>	AB		600MG	A071232	001	Oct 22, 1986	Jul DISC
>A>		@	600MG	A071232	001	Oct 22, 1986	Jul DISC
>D>	AB		800MG	A072004	001	Nov 18, 1987	Jul DISC
>A>		@	800MG	A072004	001	Nov 18, 1987	Jul DISC

ILOPERIDONE

TABLET;ORAL

FANAPT

+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Jan CAHN
		2MG	N022192	002	May 06, 2009	Jan CAHN
		4MG	N022192	003	May 06, 2009	Jan CAHN
		6MG	N022192	004	May 06, 2009	Jan CAHN
		8MG	N022192	005	May 06, 2009	Jan CAHN
		10MG	N022192	006	May 06, 2009	Jan CAHN
		12MG	N022192	007	May 06, 2009	Jan CAHN

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

AB	G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Apr CAHN

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

>A>	AB	ANI PHARMS INC	1.25MG	A074299	002	Apr 29, 1996	Jul CAHN
>A>		@	1.25MG	A074498	002	Feb 12, 1998	Jul CAHN
>A>	AB		2.5MG	A074299	001	Jul 27, 1995	Jul CAHN
>A>		@	2.5MG	A074498	001	Oct 31, 1996	Jul CAHN
>D>	AB	IVAX SUB TEVA PHARMS	1.25MG	A074299	002	Apr 29, 1996	Jul CAHN
>D>	AB		2.5MG	A074299	001	Jul 27, 1995	Jul CAHN
>D>		@ TEVA	1.25MG	A074498	002	Feb 12, 1998	Jul CAHN
>D>		@	2.5MG	A074498	001	Oct 31, 1996	Jul CAHN

INGENOL MEBUTATE

GEL;TOPICAL

PICATO

+	LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012	May CRLD

INSULIN GLARGINE RECOMBINANT

SOLUTION;SUBCUTANEOUS

TOUJEO SOLOSTAR

+	SANOFI US SERVICES	300 UNITS/ML (300 UNITS/ML)	N206538	001	Feb 25, 2015	Feb NEWA

INSULIN LISPRO RECOMBINANT

SOLUTION;SUBCUTANEOUS

HUMALOG KWIKPEN

+	ELI LILLY AND CO	200 UNITS/ML	N205747	001	May 26, 2015	May NEWA

INSULIN RECOMBINANT HUMAN

POWDER;INHALATION

AFREZZA

	SANOFI AVENTIS	12 UNITS/INH	N022472	003	Apr 17, 2015	Apr NEWA

IOHEXOL

FOR SOLUTION;ORAL

ORALTAG

	INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015	Mar NEWA

IOPAMIDOL

INJECTABLE;INJECTION

IOPAMIDOL-250

@	FRESENIUS KABI USA	51%	A074679	001	Apr 02, 1997	Jan DISC

IOPAMIDOL-300

@	FRESENIUS KABI USA	61%	A074679	002	Apr 02, 1997	Jan DISC

	INJECTABLE;INJECTION						
	IOPAMIDOL-370						
	@ FRESENIUS KABI USA	76%	A074679	003	Apr 02, 1997		Jan DISC
	ISOVUE-200						
	+ BRACCO	41%	N018735	006	Jul 07, 1987		Feb CTEC
	ISOVUE-250						
	+ BRACCO	51%	N018735	007	Jul 06, 1992		Feb CTEC
	+	51%	N020327	002	Oct 12, 1994		Feb CTEC
	ISOVUE-300						
	+ BRACCO	61%	N020327	003	Oct 12, 1994		Feb CTEC
	ISOVUE-370						
	+ BRACCO	76%	N020327	004	Oct 12, 1994		Feb CTEC
	IOTHALAMATE MEGLUMINE						
	INJECTABLE;INJECTION						
	CONRAY						
	+ LIEBEL-FLARSHEIM	60%	N013295	001			Feb CAHN
	CONRAY 30						
	+ LIEBEL-FLARSHEIM	30%	N016983	001			Feb CAHN
	CONRAY 43						
	+ LIEBEL-FLARSHEIM	43%	N013295	002			Feb CAHN
	SOLUTION;INTRAVESICAL						
	CYSTO-CONRAY II						
	LIEBEL-FLARSHEIM	17.2%	N017057	002			Feb CAHN
	IOVERSOL						
	INJECTABLE;INJECTION						
	OPTIRAY 160						
	@ LIEBEL-FLARSHEIM	34%	N019710	003	Dec 30, 1988		Feb CAHN
	OPTIRAY 240						
	+ LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988		Feb CAHN
	@	51%	N020923	001	May 28, 1998		Feb CAHN
	OPTIRAY 300						
	+ LIEBEL-FLARSHEIM	64%	N019710	004	Jan 22, 1992		Feb CAHN
	+	64%	N020923	004	May 13, 1999		Feb CAHN
	OPTIRAY 320						
	+ LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988		Feb CAHN
	@	68%	N020923	002	May 29, 1998		Feb CAHN
	OPTIRAY 350						
	+ LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992		Feb CAHN
	+	74%	N020923	003	May 28, 1998		Feb CAHN
	IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM						
	INJECTABLE;INJECTION						
	HEXABRIX						
	@ GUERBET	39.3%;19.6%	N018905	002	Jul 26, 1985		May DISC
	IRBESARTAN						
	TABLET;ORAL						
	IRBESARTAN						
AB	JUBILANT GENERICS	75MG	A203534	001	Feb 23, 2015		Feb NEWA
AB		150MG	A203534	002	Feb 23, 2015		Feb NEWA
AB		300MG	A203534	003	Feb 23, 2015		Feb NEWA
	IRON DEXTRAN						
	INJECTABLE;INJECTION						
	INFED						
BP	+ ACTAVIS LABS UT INC	EQ 50MG IRON/ML	N017441	001			Mar CAHN
	ISAVUCONAZONIUM SULFATE						
	CAPSULE;ORAL						
	CRESEMBA						
	+ ASTELLAS	186MG	N207500	001	Mar 06, 2015		Mar NEWA
	POWDER;IV (INFUSION)						
	CRESEMBA						
	+ ASTELLAS	372MG	N207501	001	Mar 06, 2015		Mar NEWA

ISOSORBIDE DINITRATE

TABLET;ORAL

ISORDIL

AB		VALEANT PHARMS NORTH	5MG	N012093	007	Jul 29, 1988	Feb CAHN
	+		40MG	N012093	001	Jul 29, 1988	Feb CAHN

ISOTRETINOIN

CAPSULE;ORAL

ABSORICA

		RANBAXY	25MG	N021951	005	Aug 15, 2014	Feb NEWA
			35MG	N021951	006	Aug 15, 2014	Feb NEWA

SOTRET

AB		SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002	Apr CAHN
AB			20MG	A076041	002	Dec 24, 2002	Apr CAHN
AB			30MG	A076503	001	Jun 20, 2003	Apr CAHN
AB			40MG	A076041	003	Dec 24, 2002	Apr CAHN

ZENATANE

AB		DR REDDYS LABS LTD	30MG	A202099	004	Feb 23, 2015	Feb NEWA

ISRADIPINE

CAPSULE;ORAL

ISRADIPINE

AB		ELITE LABS INC	2.5MG	A077169	001	Apr 24, 2006	Mar CAHN
AB			5MG	A077169	002	Apr 24, 2006	Mar CAHN

IVABRADINE HYDROCHLORIDE

TABLET;ORAL

CORLANOR

		AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Apr NEWA
	+		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Apr NEWA

IVACAFTOR

GRANULE;ORAL

KALYDECO

		VERTEX PHARMS INC	50MG/PACKET	N207925	001	Mar 17, 2015	Mar NEWA
	+		75MG/PACKET	N207925	002	Mar 17, 2015	Mar NEWA

IVACAFTOR; LUMACAFTOR

TABLET;ORAL

ORKAMBI

>A>	+	VERTEX PHARMS INC	125MG;200MG	N206038	001	Jul 02, 2015	Jul NEWA

IXABEPILONE

INJECTABLE;IV (INFUSION)

IXEMPRA KIT

	+	R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007	Jun CAHN
	+		45MG/VIAL	N022065	002	Oct 16, 2007	Jun CAHN

KANAMYCIN SULFATE

INJECTABLE;INJECTION

KANAMYCIN

	@	EUROHLTH INTL SARL	EQ 75MG BASE/2ML	A062324	001		Jun CAHN
	@		EQ 500MG BASE/2ML	A062324	002		Jun CAHN
	@		EQ 1GM BASE/3ML	A062324	003		Jun CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

	@	CLARIS PHARMASERVICE	15MG/ML	A075631	002	Jun 29, 2001	Apr CAHN
	@		30MG/ML	A075631	001	Jun 29, 2001	Apr CAHN
	@	EUROHLTH INTL SARL	15MG/ML	A075772	001	Jul 21, 2004	Jun CAHN
	@		30MG/ML	A075772	002	Jul 21, 2004	Jun CAHN

SPRAY, METERED;NASAL

SPRIX

	+	EGALET US INC	15.75MG/SPRAY	N022382	001	May 14, 2010	Jan CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

		SOLUTION;IRRIGATION						
		OMIDRIA						
	+	OMEROS	EQ 4.24MG BASE/ML;EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	Feb	CPOT

LABETALOL HYDROCHLORIDE

		INJECTABLE;INJECTION						
		LABETALOL HYDROCHLORIDE						
	@	CLARIS PHARMASERVICE	5MG/ML	A076051	001	Jul 05, 2002	Apr	CAHN
		TABLET;ORAL						
		LABETALOL HYDROCHLORIDE						
AB		MUTUAL PHARM	100MG	A075215	001	Jul 29, 1999	Jan	CMFD
AB			200MG	A075215	002	Jul 29, 1999	Jan	CMFD
AB			300MG	A075215	003	Jul 29, 1999	Jan	CMFD

LACTULOSE

		SOLUTION;ORAL, RECTAL						
		LACTULOSE						
AA		BIO-PHARM INC	10GM/15ML	A203762	001	Mar 27, 2015	Mar	NEWA

LAMIVUDINE; RALTEGRAVIR POTASSIUM

		TABLET;ORAL						
		DUTREBIS						
	+	MERCK SHARP DOHME	150MG;EQ 300MG BASE	N206510	001	Feb 06, 2015	Feb	NEWA

LAMIVUDINE; ZIDOVUDINE

		TABLET;ORAL						
		LAMIVUDINE AND ZIDOVUDINE						
AB		STRIDES ARCOLAB LTD	150MG;300MG	A079128	001	May 13, 2015	Apr	NEWA

LAMOTRIGINE

		TABLET;ORAL						
		LAMOTRIGINE						
	@	HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011	May	DISC
	@		100MG	A078134	002	Apr 19, 2011	May	DISC
	@		150MG	A078134	003	Apr 19, 2011	May	DISC
	@		200MG	A078134	004	Apr 19, 2011	May	DISC

LAPATINIB DITOSYLATE

		TABLET;ORAL						
		TYKERB						
	+	NOVARTIS PHARMS CORP	EQ 250MG BASE	N022059	001	Mar 13, 2007	Mar	CAHN

LENVATINIB MESYLATE

		CAPSULE;ORAL						
		LENVIMA						
		EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015	Feb	NEWA
	+		EQ 10MG BASE	N206947	002	Feb 13, 2015	Feb	NEWA

LEVETIRACETAM

		INJECTABLE;IV (INFUSION)						
		LEVETIRACETAM						
>A>	AP	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090876	001	Aug 13, 2015	Jul	NEWA
		SOLUTION;ORAL						
		LEVETIRACETAM						
	AA	PHARM ASSOC	100MG/ML	A201157	001	Jun 04, 2015	May	NEWA
		TABLET;ORAL						
		SPRITAM						
>A>		APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Jul	NEWA
>A>			500MG	N207958	002	Jul 31, 2015	Jul	NEWA
>A>			750MG	N207958	003	Jul 31, 2015	Jul	NEWA
>A>			1GM	N207958	004	Jul 31, 2015	Jul	NEWA
		TABLET, EXTENDED RELEASE;ORAL						
		ELEPSIA XR						
		SPARC	1GM	N204417	001	Mar 02, 2015	Mar	NEWA
			1.5GM	N204417	002	Mar 02, 2015	Mar	NEWA
		LEVETIRACETAM						
		APOTEX INC	1GM	A202958	001	Feb 25, 2015	Feb	NEWA
	AB	PRINSTON INC	500MG	A203468	001	May 21, 2015	May	NEWA
	AB		750MG	A203468	002	May 21, 2015	May	NEWA

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

		@	TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	Apr DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	AB		APOTEX INC	5MG	A203027	001	Feb 13, 2015	Feb NEWA
	AB		SUN PHARM INDS LTD	5MG	A201653	001	Jun 26, 2015	Jun NEWA

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

	AP		CLARIS PHARMASERVICE	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr CAHN
>A>	AP		HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)	A078577	001	Aug 12, 2015	Jul NEWA
>A>	AP			EQ 750MG/30ML (EQ 25MG/ML)	A078577	002	Aug 12, 2015	Jul NEWA

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

	AP		CLARIS PHARMASERVICE	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Apr CAHN
	AP			EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Apr CAHN
	AP			EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Apr CAHN

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

>D>	AT		NEXUS PHARMS	0.5%	A077700	001	Dec 20, 2010	Jul CRLD
>A>	AT	+		0.5%	A077700	001	Dec 20, 2010	Jul CRLD

>D>

QUIXIN

>D>	AT	+	SANTEN	0.5%	N021199	001	Aug 18, 2000	Jul DISC
>A>		@		0.5%	N021199	001	Aug 18, 2000	Jul DISC

TABLET;ORAL

LEVOFLOXACIN

	AB		JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015	Jun NEWA
	AB			500MG	A203613	002	Jun 19, 2015	Jun NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION;IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

			SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Feb NEWA
			SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Feb NEWA
		+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Mar CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE

LILETTA

			MEDICINES360	52MG	N206229	001	Feb 26, 2015	Feb NEWA

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

		+	SENTYNL THERAPS INC	2MG	A074278	001	Mar 31, 2000	Apr CAHN

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

>A>	AT		AMNEAL PHARMS	5%	A206297	001	Aug 07, 2015	Jul NEWA

PATCH;TOPICAL

LIDOCAINE

	AB		ACTAVIS LABS UT INC	5%	A200675	001	Aug 23, 2012	Mar CAHN
>A>	AB		MYLAN TECHNOLOGIES	5%	A202346	001	Aug 07, 2015	Jul NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

			@ EUROHLTH INTL SARL	1%	A080407	001		Mar CAHN
			@	2%	A080407	002		Mar CAHN

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

			@ EUROHLTH INTL SARL	1%	A084625	001		Feb CAHN
			@	2%	A084625	002		Feb CAHN

		JELLY;TOPICAL						
		ANESTACON						
		@ BANNER LIFE SCIENCES	2%	A080429	001			Jan CAHN
		LIDOCAINE HYDROCHLORIDE						
		@ G AND W LABS INC	2%	A081318	001	Apr 29, 1993		Apr CAHN
		LIDOCAINE; PRILOCAINE						
		CREAM;TOPICAL						
		EMLA						
	AB	+ ACTAVIS LABS UT INC	2.5%;2.5%	N019941	001	Dec 30, 1992		Feb CAHN
		LINACLOTIDE						
		CAPSULE;ORAL						
		LINZESS						
		FOREST LABS LLC	145MCG	N202811	001	Aug 30, 2012		Mar CAHN
		+	290MCG	N202811	002	Aug 30, 2012		Mar CAHN
		LINCOMYCIN HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		LINCOCIN						
	AP	+ PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N050317	001			May CFTG
		LINCOMYCIN						
	AP	X-GEN PHARMS INC	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015		May NEWA
		LINEZOLID						
		FOR SUSPENSION;ORAL						
		LINEZOLID						
	AB	ROXANE	100MG/5ML	A200068	001	Jun 03, 2015		May NEWA
		ZYVOX						
	AB	+ PHARMACIA AND UPJOHN	100MG/5ML	N021132	001	Apr 18, 2000		May CFTG
		SOLUTION;IV (INFUSION)						
		LINEZOLID						
	AP	HOSPIRA INC	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015		Jun NEWA
>A>	AP	SANDOZ INC	200MG/100ML (2MG/ML)	A200904	001	Jul 16, 2015		Jul NEWA
>A>	AP		600MG/300ML (2MG/ML)	A200904	002	Jul 16, 2015		Jul NEWA
	AP	TEVA PHARMS	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012		May CDFR
		LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
		+ HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015		Jun NEWA
		ZYVOX						
>D>		PHARMACIA AND UPJOHN	200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000		Jul CTEC
>A>	AP		200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000		Jul CTEC
			200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000		May CDFR
			400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000		May NEWA
	AP	+	600MG/300ML (2MG/ML)	N021131	003	Apr 18, 2000		May NEWA
		TABLET;ORAL						
		LINEZOLID						
	AB	TEVA PHARMS USA	600MG	A078061	001	May 18, 2015		May NEWA
		ZYVOX						
	AB	+ PHARMACIA AND UPJOHN	600MG	N021130	002	Apr 18, 2000		May CFTG
		LISINOPRIL						
		TABLET;ORAL						
		LISINOPRIL						
	AB	SUN PHARM INDS LTD	2.5MG	A075944	001	Jul 01, 2002		Apr CAHN
	AB		5MG	A075944	002	Jul 01, 2002		Apr CAHN
	AB		10MG	A075944	003	Jul 01, 2002		Apr CAHN
	AB		20MG	A075944	004	Jul 01, 2002		Apr CAHN
	AB		30MG	A075944	006	Feb 11, 2003		Apr CAHN
	AB		40MG	A075944	005	Jul 01, 2002		Apr CAHN
		ZESTRIL						
	AB	ALVOGEN IPCO SARL	2.5MG	N019777	005	Apr 29, 1993		Feb CAHN
	AB		5MG	N019777	001	May 19, 1988		Feb CAHN
	AB		10MG	N019777	002	May 19, 1988		Feb CAHN
	AB		20MG	N019777	003	May 19, 1988		Feb CAHN
	AB		30MG	N019777	006	Jan 20, 1999		Feb CAHN
	AB	+	40MG	N019777	004	May 19, 1988		Feb CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

	AB		ALEMBIC PHARMS LTD	300MG	A204445	001	Jun 10, 2015	May NEWA
		@	HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003	Feb DISC
>A>	AB		UNIQUE PHARM LABS	300MG	A204779	001	Jul 27, 2015	Jul NEWA

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

			AEGERION	EQ 30MG BASE	N203858	004	Apr 23, 2015	Apr NEWA
				EQ 40MG BASE	N203858	005	Apr 23, 2015	Apr NEWA
				EQ 60MG BASE	N203858	006	Apr 23, 2015	Apr NEWA

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

			CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014	Jan NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

IMODIUM

>A>		@	J AND J CONSUMER INC	2MG	N017690	001		Jul CAHN
>A>	AB	+		2MG	N017694	001		Jul CAHN
>D>	AB	+	MCNEIL CONS	2MG	N017694	001		Jul CAHN
>D>		@	MCNEIL PED	2MG	N017690	001		Jul CAHN

LOPINAVIR; RITONAVIR

CAPSULE;ORAL

KALETRA

		@	ABBVIE	133.3MG;33.3MG	N021226	001	Sep 15, 2000	Jun DISC

LORAZEPAM

INJECTABLE;INJECTION

ATIVAN

	AP	+	EUROHLTH INTL SARL	2MG/ML	N018140	001		Jun CAHN
	AP	+		4MG/ML	N018140	002		Jun CAHN

TABLET;ORAL

LORAZEPAM

	AB		SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001	Apr CAHN
	AB			1MG	A076045	002	Aug 29, 2001	Apr CAHN
	AB			2MG	A076045	003	Aug 29, 2001	Apr CAHN

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

>A>	AB		HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Jul NEWA
>A>	AB			50MG	A203835	002	Aug 12, 2015	Jul NEWA
>A>	AB			100MG	A203835	003	Aug 12, 2015	Jul NEWA
	AB		WATSON LABS	25MG	A091129	001	Oct 06, 2010	Feb CMFD
	AB			50MG	A091129	002	Oct 06, 2010	Feb CMFD
	AB			100MG	A091129	003	Oct 06, 2010	Feb CMFD

LOVASTATIN

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

		@	COVIS PHARMA SARL	10MG	N021316	001	Jun 26, 2002	May CAHN
				20MG	N021316	002	Jun 26, 2002	May CAHN
				40MG	N021316	003	Jun 26, 2002	May CAHN
		+		60MG	N021316	004	Jun 26, 2002	May CAHN

LOXAPINE HYDROCHLORIDE

CONCENTRATE;ORAL

LOXITANE C

		@	ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658	001		Mar CAHN

INJECTABLE;INJECTION

LOXITANE IM

		@	ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001		Mar CAHN

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

AB	ELITE LABS INC	EQ 5MG BASE	A076868	001	Aug 04, 2005	May	CAHN
AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May	CAHN
AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May	CAHN
AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May	CAHN

LOXITANE

@	ACTAVIS LABS UT INC	EQ 5MG BASE	N017525	001		Mar	CAHN
@		EQ 10MG BASE	N017525	002		Mar	CAHN
@		EQ 25MG BASE	N017525	003		Mar	CAHN
@		EQ 50MG BASE	N017525	004		Mar	CAHN

TABLET;ORAL

LOXITANE

@	ACTAVIS LABS UT INC	EQ 10MG BASE	N017525	006		Mar	CAHN
@		EQ 25MG BASE	N017525	007		Mar	CAHN
@		EQ 50MG BASE	N017525	008		Mar	CAHN

LUCINACTANT

SUSPENSION;INTRATRACHEAL

SURFAXIN

@	DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	May	DISC

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984	Mar	DISC

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP	EXELA PHARMA SCS LLC	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014	Apr	CDFR
AP +	FRESENIUS KABI USA	5GM/10ML (500MG/ML)	N019316	001	Sep 08, 1986	Apr	CPOT
AP +	HOSPIRA	5GM/10ML (500MG/ML)	A075151	001	Apr 25, 2000	Apr	CDFR
	HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Apr	NEWA

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	Apr	NEWA

MANNITOL

INJECTABLE;INJECTION

MANNITOL 25%

@	IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987	Mar	CAHN
@		12.5GM/50ML	A089240	001	May 06, 1987	Mar	CAHN

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

@	VINTAGE PHARMS	12.5MG	A040179	001	Jan 30, 1997	Jun	DISC
@		25MG	A040179	002	Jan 30, 1997	Jun	DISC

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMENDA XR

	FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Mar	CAHN
		14MG	N022525	002	Jun 21, 2010	Mar	CAHN
		21MG	N022525	003	Jun 21, 2010	Mar	CAHN
+		28MG	N022525	004	Jun 21, 2010	Mar	CAHN

SOLUTION;ORAL

NAMENDA

+	FOREST LABS LLC	2MG/ML	N021627	001	Apr 18, 2005	Mar	CAHN

TABLET;ORAL

MEMANTINE

AB	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Mar	CMFD
AB		10MG	A090058	002	May 05, 2010	Mar	CMFD

MEMANTINE HYDROCHLORIDE

AB	AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	Mar	NEWA
AB		10MG	A090041	002	Apr 10, 2015	Mar	NEWA
AB	DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Jun	CMFD

TABLET;ORAL
MEMANTINE HYDROCHLORIDE

AB		10MG	A090048	002	Apr 14, 2010	Jun	CMFD
AB	LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar	NEWA
AB		10MG	A090051	002	Apr 10, 2015	Mar	NEWA
AB	MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Jun	CMFD
@		5MG	A079225	001	Jan 30, 2015	Mar	DISC
AB		5MG	A079225	001	Jan 30, 2015	Jan	NEWA
AB		10MG	A079225	002	Jan 30, 2015	Jun	CMFD
@		10MG	A079225	002	Jan 30, 2015	Mar	DISC
AB		10MG	A079225	002	Jan 30, 2015	Jan	NEWA
AB	TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	May	CMFD
AB		10MG	A090052	002	Oct 25, 2011	May	CMFD
>A> AB	UPSHER SMITH	5MG	A090043	001	Jul 31, 2015	Jul	NEWA
>A> AB		10MG	A090043	002	Jul 31, 2015	Jul	NEWA

NAMENDA

AB	FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar	CAHN
AB +		10MG	N021487	002	Oct 16, 2003	Mar	CAHN

MENOTROPINS (FSH;LH)
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
REPRONEX

@	FERRING	75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999	May	DISC

MEPERIDINE HYDROCHLORIDE
INJECTABLE;INJECTION
MEPERIDINE HYDROCHLORIDE

AP	EUROHLTH INTL SARL	25MG/ML	A080445	001		Feb	CAHN
AP		50MG/ML	A080445	002		Feb	CAHN
AP		75MG/ML	A080445	003		Feb	CAHN
AP		100MG/ML	A080445	004		Feb	CAHN
@	IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989	May	CAHN
@		50MG/ML	A089782	001	Mar 31, 1989	Mar	CAHN
@		50MG/ML	A089783	001	Mar 31, 1989	Mar	CAHN
@		50MG/ML	A089784	001	Mar 31, 1989	Mar	CAHN
@		75MG/ML	A089785	001	Mar 31, 1989	Mar	CAHN
@		100MG/ML	A089786	001	Mar 31, 1989	Mar	CAHN
@		100MG/ML	A089787	001	Mar 31, 1989	Mar	CAHN
@		100MG/ML	A089788	001	Mar 31, 1989	Mar	CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
INJECTABLE;INJECTION
MEPERGAN

@	EUROHLTH INTL SARL	25MG/ML;25MG/ML	N011730	001		Jun	CAHN

MEROPENEM
POWDER;IV (INFUSION)
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

	B BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015	Apr	NEWA
		1GM/VIAL	N202106	002	Apr 30, 2015	Apr	NEWA

MESALAMINE
CAPSULE, EXTENDED RELEASE;ORAL
APRISO

>D> +	SALIX PHARMS	375MG	N022301	001	Oct 31, 2008	Jul	CAHN
>A> +	VALEANT PHARMS INTL	375MG	N022301	001	Oct 31, 2008	Jul	CAHN

MESTRANOL; NORETHINDRONE
TABLET;ORAL-20
NORINYL

@	ACTAVIS LABS UT INC	0.1MG;2MG	N013625	004		Mar	CAHN

TABLET;ORAL-21
NORINYL 1+50 21-DAY

@	ACTAVIS LABS UT INC	0.05MG;1MG	N013625	002		Mar	CAHN

TABLET;ORAL-28
NORINYL 1+50 28-DAY

+	ACTAVIS LABS UT INC	0.05MG;1MG	N016659	001		Mar	CAHN

METAPROTERENOL SULFATE

SOLUTION;INHALATION

METAPROTERENOL SULFATE

	@ MYLAN SPECLT	0.4%	A071786	001	Aug 05, 1988	Apr	DISC
	@	0.6%	A070804	001	Aug 17, 1987	Apr	DISC
	@ WOCKHARDT	0.4%	A075586	001	May 30, 2002	Apr	DISC
	@	0.6%	A075586	002	May 30, 2002	Apr	DISC

SYRUP;ORAL

METAPROTERENOL SULFATE

	@ G AND W LABS INC	10MG/5ML	A072761	001	Feb 27, 1992	Apr	CAHN
	@	10MG/5ML	A073034	001	Aug 30, 1991	Apr	CAHN

METAXALONE

TABLET;ORAL

METAXALONE

	COREPHARMA	400MG	A040486	001	Feb 27, 2015	Feb	NEWA
		640MG	N022503	001	Jun 01, 2015	Jun	NEWA

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

RIOMET

+	SUN PHARM INDS LTD	500MG/5ML	N021591	001	Sep 11, 2003	Apr	CAHN

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

PRANDIMET

AB	NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008	Jun	CFTG
AB +		500MG;2MG	N022386	002	Jun 23, 2008	Jun	CFTG

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

AB	LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015	Jun	NEWA
AB		500MG;2MG	A200624	002	Jul 15, 2015	Jun	NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDAMET

	@ SB PHARMCO	500MG;EQ 2MG BASE	N021410	002	Oct 10, 2002	May	DISC
	@	500MG;EQ 4MG BASE	N021410	003	Oct 10, 2002	May	DISC
	@	1GM;EQ 2MG BASE	N021410	004	Aug 25, 2003	May	DISC
	@	1GM;EQ 4MG BASE	N021410	005	Aug 25, 2003	May	DISC

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

	TEVA	500MG;EQ 2MG BASE	A077337	001	May 07, 2014	May	CTEC
		500MG;EQ 4MG BASE	A077337	002	May 07, 2014	May	CTEC
+		1GM;EQ 4MG BASE	A077337	004	May 07, 2014	May	CRLD
		1GM;EQ 2MG BASE	A077337	003	May 07, 2014	May	CTEC

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB	HERITAGE PHARMA	5MG	A040734	001	Dec 14, 2007	Mar	CAHN
AB		10MG	A040734	002	Dec 14, 2007	Mar	CAHN

METHOCARBAMOL

SOLUTION;IM-IV

ROBAXIN

AP +	EUROHLTH INTL SARL	1GM/10ML (100MG/ML)	N011790	001		Jun	CAHN

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999	May	CMFD

TABLET;ORAL

METHOTREXATE SODIUM

AB	ORION CORP ORION	EQ 2.5MG BASE	A201749	001	May 21, 2015	May	NEWA

METHOXSALEN

CAPSULE;ORAL

METHOXSALEN

AB	ACTAVIS INC	10MG	A202603	001	Jun 09, 2015	May	NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

APTENSIO XR

	RHODES PHARMS	10MG	N205831	001	Apr 17, 2015	Apr	NEWA
		15MG	N205831	002	Apr 17, 2015	Apr	NEWA
		20MG	N205831	003	Apr 17, 2015	Apr	NEWA
		30MG	N205831	004	Apr 17, 2015	Apr	NEWA
		40MG	N205831	005	Apr 17, 2015	Apr	NEWA
		50MG	N205831	006	Apr 17, 2015	Apr	NEWA
+		60MG	N205831	007	Apr 17, 2015	Apr	NEWA

RITALIN LA

AB1	NOVARTIS	40MG	N021284	003	Jun 05, 2002	Feb	CRLD
+		60MG	N021284	005	Oct 27, 2014	Feb	CRLD

TABLET, CHEWABLE;ORAL

METHYLIN

AB	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Feb	CFTG
AB		5MG	N021475	002	Apr 15, 2003	Feb	CFTG
AB +		10MG	N021475	003	Apr 15, 2003	Feb	CFTG

METHYLPHENIDATE HYDROCHLORIDE

AB	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Feb	NEWA
AB		5MG	A204115	002	Feb 25, 2015	Feb	NEWA
AB		10MG	A204115	003	Feb 25, 2015	Feb	NEWA

TABLET, EXTENDED RELEASE;ORAL

METHYLIN ER

AB	MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	May	CTEC

METHYLPHENIDATE HYDROCHLORIDE

AB	ABHAI	10MG	A207488	001	Jun 09, 2015	May	NEWA
AB		20MG	A207488	002	Jun 09, 2015	May	NEWA

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP	CLARIS PHARMASERVICE	1MG/ML	A078950	001	Apr 29, 2013	Apr	CAHN

TABLET;ORAL

METOPROLOL TARTRATE

	MYLAN	37.5MG	A076704	004	Mar 18, 2015	Mar	NEWA
		75MG	A076704	005	Mar 18, 2015	Mar	NEWA

METRONIDAZOLE

CREAM;TOPICAL

NORITATE

+	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997	Feb	CAHN

GEL;VAGINAL

METRONIDAZOLE

+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb	CAHN

NUVESSA

+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb	CTNA

INJECTABLE;INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	500MG/100ML	A078084	001	Mar 31, 2008	Apr	CAHN

TABLET;ORAL

METRONIDAZOLE

AB	AUROBINDO PHARMA LTD	250MG	A203974	001	May 29, 2015	May	NEWA
AB		500MG	A203974	002	May 29, 2015	May	NEWA

MICONAZOLE

TABLET;BUCCAL

ORAVIG

+	DARA BIOSCIENCES	50MG	N022404	001	Apr 16, 2010	Apr	CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

@	CLARIS PHARMASERVICE	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr	CAHN
@		EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr	CAHN
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jun	CAHN
AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jun	CAHN
@	IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000	Apr	CAHN
@	WOCKHARDT	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Mar	DISC
@		EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Mar	DISC

INJECTABLE;INJECTION
MIDAZOLAM HYDROCHLORIDE

@		EQ 5MG BASE/ML	A078141	002	May 30, 2008	Mar	DISC
@		EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Mar	DISC

SYRUP;ORAL
MIDAZOLAM HYDROCHLORIDE

AA	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002	Apr	CAHN

MIGLITOL
TABLET;ORAL
GLYSET

AB	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Mar	CTEC
AA		25MG	N020682	001	Dec 18, 1996	Feb	CFTG
AB		50MG	N020682	002	Dec 18, 1996	Mar	CTEC
AA		50MG	N020682	002	Dec 18, 1996	Feb	CFTG
AB +		100MG	N020682	003	Dec 18, 1996	Mar	CTEC
AA +		100MG	N020682	003	Dec 18, 1996	Feb	CFTG

MIGLITOL

AB	ORIENT PHARMA CO LTD	25MG	A203965	001	Feb 24, 2015	Mar	CTEC
AA		25MG	A203965	001	Feb 24, 2015	Feb	NEWA
AB		50MG	A203965	002	Feb 24, 2015	Mar	CTEC
AA		50MG	A203965	002	Feb 24, 2015	Feb	NEWA
AB		100MG	A203965	003	Feb 24, 2015	Mar	CTEC
AA		100MG	A203965	003	Feb 24, 2015	Feb	NEWA

MILRINONE LACTATE
INJECTABLE;INJECTION
MILRINONE LACTATE

AP	BEDFORD	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan	CRLD
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jun	CAHN
AP +	HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A077966	001	Dec 03, 2010	Jan	CRLD

MINOCYCLINE HYDROCHLORIDE
CAPSULE;ORAL
MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065062	001	Nov 30, 2000	Apr	CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Apr	CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Apr	CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A065062	001	Nov 30, 2000	Jun	CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Jun	CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Jun	CAHN

CAPSULE, EXTENDED RELEASE;ORAL
XIMINO

@	SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr	CAHN
@		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Apr	CAHN
@		EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr	CAHN
@		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Apr	CAHN
@		EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr	CAHN

TABLET;ORAL
MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065156	001	Jan 06, 2004	Apr	CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Apr	CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Apr	CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A065156	001	Jan 06, 2004	Jun	CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Jun	CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Apr	CAHN
AB		EQ 80MG BASE	A091118	004	Sep 25, 2014	Apr	CAHN
AB		EQ 90MG BASE	A091118	005	Sep 25, 2014	Apr	CAHN
AB		EQ 105MG BASE	A091118	006	Sep 25, 2014	Apr	CAHN
AB		EQ 135MG BASE	A091118	008	Sep 25, 2014	Apr	CAHN

MIVACURIUM CHLORIDE
SOLUTION;INTRAVENOUS
MIVACRON

	ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992	Jan	NEWA
+		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992	Jan	NEWA

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOLINDONE HYDROCHLORIDE

			COREPHARMA	5MG	A090453	001	Mar 20, 2015	Mar NEWA
				10MG	A090453	002	Mar 20, 2015	Mar NEWA
		+		25MG	A090453	003	Mar 20, 2015	Mar NEWA

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

>A>	AB		AJANTA PHARMA LTD	EQ 4MG BASE/PACKET	A203438	001	Jul 31, 2015	Jul NEWA

TABLET;ORAL

MONTELUKAST SODIUM

>A>	AB		AJANTA PHARMA LTD	EQ 10MG BASE	A203432	001	Jul 31, 2015	Jul NEWA
	AB		KREMERS URBAN PHARMS	EQ 10MG BASE	A201522	001	Aug 03, 2012	Mar CAHN

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

>A>	AB		AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015	Jul NEWA
>A>	AB			EQ 5MG BASE	A203328	002	Jul 31, 2015	Jul NEWA
	AB		HETERO LABS LTD V	EQ 4MG BASE	A204093	001	May 22, 2015	May NEWA
	AB			EQ 5MG BASE	A204093	002	May 22, 2015	May NEWA
	AB		JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Feb NEWA
	AB			EQ 5MG BASE	A203795	002	Feb 27, 2015	Feb NEWA
	AB		KREMERS URBAN PHARMS	EQ 4MG BASE	A200405	001	Aug 03, 2012	Mar CAHN
	AB			EQ 5MG BASE	A200405	002	Aug 03, 2012	Mar CAHN
	AB		MACLEODS PHARMS LTD	EQ 4MG BASE	A203582	001	Mar 12, 2015	Feb NEWA
	AB			EQ 5MG BASE	A203582	002	Mar 12, 2015	Feb NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

KADIAN

	AB1	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Mar CAHN
	AB1			20MG	N020616	001	Jul 03, 1996	Mar CAHN
	AB1			30MG	N020616	004	Mar 09, 2001	Mar CAHN
	AB1			40MG	N020616	009	Jul 09, 2012	May CTEC
				40MG	N020616	009	Jul 09, 2012	Mar CAHN
	AB1			50MG	N020616	002	Jul 03, 1996	Mar CAHN
	AB1			60MG	N020616	005	Mar 09, 2001	Mar CAHN
	AB1			70MG	N020616	010	Jul 09, 2012	May CTEC
				70MG	N020616	010	Jul 09, 2012	Mar CAHN
	AB1			80MG	N020616	006	Oct 27, 2006	Mar CAHN
	AB1	+		100MG	N020616	003	Jul 03, 1996	Mar CAHN
				130MG	N020616	011	Jul 09, 2012	Mar CAHN
				150MG	N020616	012	Jul 09, 2012	Mar CAHN
	AB1	+		200MG	N020616	007	Feb 27, 2007	Mar CAHN

MORPHINE SULFATE

	AB1		TEVA PHARMS USA	40MG	A202718	007	Jun 03, 2015	May NEWA
	AB1			70MG	A202718	008	Jun 03, 2015	May NEWA

INJECTABLE;INJECTION

DURAMORPH PF

	AP	+	EUROHLTH INTL SARL	0.5MG/ML	N018565	001	Sep 18, 1984	Jun CAHN
	AP	+		1MG/ML	N018565	002	Sep 18, 1984	Jun CAHN

INFUMORPH

		+	EUROHLTH INTL SARL	10MG/ML	N018565	003	Jul 19, 1991	Jun CAHN
		+		25MG/ML	N018565	004	Jul 19, 1991	Jun CAHN

MORPHINE SULFATE

	AP		EUROHLTH INTL SARL	4MG/ML	A205758	001	May 21, 2015	May NEWA
	AP			8MG/ML	A205758	002	May 21, 2015	May NEWA
	AP			10MG/ML	A205758	003	May 21, 2015	May NEWA
	AP	+	HOSPIRA INC	4MG/ML	N202515	002	Nov 14, 2011	May CFTG
	AP	+		8MG/ML	N202515	003	Nov 14, 2011	May CFTG
	AP	+		10MG/ML	N202515	004	Nov 14, 2011	May CFTG

SOLUTION;ORAL

MORPHINE SULFATE

	AA		TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	May NEWA
	AA			100MG/5ML	A203518	002	May 12, 2015	May NEWA

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

	AB		ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Mar NEWA
	AB			30MG	A203849	002	Apr 06, 2015	Mar NEWA
	AB			60MG	A203849	003	Apr 06, 2015	Mar NEWA

	TABLET, EXTENDED RELEASE;ORAL						
	MORPHINE SULFATE						
AB		100MG	A203849	004	Apr 06, 2015	Mar	NEWA
AB		200MG	A203849	005	Apr 06, 2015	Mar	NEWA
AB	SUN PHARM INDS LTD	15MG	A078761	001	May 11, 2012	Apr	CAHN
AB		30MG	A078761	002	May 11, 2012	Apr	CAHN
AB		60MG	A078761	003	May 11, 2012	Apr	CAHN
AB		100MG	A078761	004	May 11, 2012	Apr	CAHN
AB		200MG	A078761	005	May 11, 2012	Apr	CAHN
	MOXIFLOXACIN HYDROCHLORIDE						
	SOLUTION;IV (INFUSION)						
	MOXIFLOXACIN HYDROCHLORIDE						
+	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Apr	NEWA
	SOLUTION/DROPS;OPHTHALMIC						
	MOXEZA						
AT2 +	ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May	CFTG
	MOXIFLOXACIN HYDROCHLORIDE						
AT1	LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	May	CTEC
AT2		EQ 0.5% BASE	A204079	001	May 28, 2015	May	NEWA
AT1	WATSON LABS INC	EQ 0.5% BASE	A202525	001	Mar 06, 2015	May	CTEC
AT		EQ 0.5% BASE	A202525	001	Mar 06, 2015	Feb	NEWA
	VIGAMOX						
AT1 +	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	May	CTEC
	NALBUPHINE HYDROCHLORIDE						
	INJECTABLE;INJECTION						
	NALBUPHINE HYDROCHLORIDE						
	@ IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989	Mar	CAHN
	@	10MG/ML	A072071	001	Apr 10, 1989	Mar	CAHN
	@	10MG/ML	A072072	001	Apr 10, 1989	Mar	CAHN
	@	20MG/ML	A072073	001	Apr 10, 1989	Mar	CAHN
	@	20MG/ML	A072074	001	Apr 10, 1989	Mar	CAHN
	@	20MG/ML	A072075	001	Apr 10, 1989	Mar	CAHN
	NALMEFENE HYDROCHLORIDE						
	INJECTABLE;INJECTION						
	REVEX						
	@ EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Jun	CAHN
	@	EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Jun	CAHN
	NALOXONE HYDROCHLORIDE						
	INJECTABLE;INJECTION						
	NALOXONE						
	@ EUROHLTH INTL SARL	0.4MG/ML	A070299	001	Sep 24, 1986	Mar	CAHN
	NALOXONE HYDROCHLORIDE						
	@ IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989	Mar	CAHN
	@	0.02MG/ML	A072083	001	Apr 11, 1989	Mar	CAHN
	@	0.02MG/ML	A072084	001	Apr 11, 1989	Mar	CAHN
	@	0.02MG/ML	A072085	001	Apr 11, 1989	Mar	CAHN
	@	0.4MG/ML	A072086	001	Apr 11, 1989	Mar	CAHN
	@	0.4MG/ML	A072087	001	Apr 11, 1989	Mar	CAHN
	@	0.4MG/ML	A072088	001	Apr 11, 1989	Mar	CAHN
	@	0.4MG/ML	A072089	001	Apr 11, 1989	Mar	CAHN
	@	0.4MG/ML	A072090	001	Apr 11, 1989	Mar	CAHN
	@	1MG/ML	A072091	001	Apr 11, 1989	Mar	CAHN
	@	1MG/ML	A072092	001	Apr 11, 1989	Mar	CAHN
	@	1MG/ML	A072093	001	Apr 11, 1989	Mar	CAHN
	NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE						
	TABLET;ORAL						
	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE						
AB	SUN PHARM INDS LTD	EQ 0.5MG BASE;EQ 50MG BASE	A075523	001	Mar 17, 2000	Apr	CAHN
	NAPROXEN						
	SUSPENSION;ORAL						
	NAPROSYN						
AB +	PEDIAPHARM INC	25MG/ML	N018965	001	Mar 23, 1987	Apr	CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

TREXIMET

	PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Jun	NEWA

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

	@ ALKEM LABS LTD	EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun	DISC
		EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun	NEWA
	@	EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun	DISC
		EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun	NEWA
	@	EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun	DISC
		EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun	NEWA
	@	EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun	DISC
		EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun	NEWA
	@ AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Apr	DISC
AB		EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Mar	NEWA
	@	EQ 5MG BASE	A203659	002	Apr 16, 2015	Apr	DISC
AB		EQ 5MG BASE	A203659	002	Apr 16, 2015	Mar	NEWA
	@	EQ 10MG BASE	A203659	003	Apr 16, 2015	Apr	DISC
AB		EQ 10MG BASE	A203659	003	Apr 16, 2015	Mar	NEWA
	@	EQ 20MG BASE	A203659	004	Apr 16, 2015	Apr	DISC
AB		EQ 20MG BASE	A203659	004	Apr 16, 2015	Mar	NEWA
>A>	@ INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul	DISC
>A>		EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul	NEWA
>A>	@	EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul	DISC
>A>		EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul	NEWA
>A>	@	EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul	DISC
>A>		EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul	NEWA
>A>	@	EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul	DISC
>A>		EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul	NEWA

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

	@ IDT AUSTRALIA LTD	50MG	A076072	001	Sep 16, 2003	Apr	CAHN
	@	100MG	A076072	002	Sep 16, 2003	Apr	CAHN
	@	150MG	A076072	003	Sep 16, 2003	Apr	CAHN
	@	200MG	A076072	004	Sep 16, 2003	Apr	CAHN
	@	250MG	A076072	005	Sep 16, 2003	Apr	CAHN
AB	SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Apr	CAHN
AB		100MG	A076409	002	Sep 16, 2003	Apr	CAHN
AB		150MG	A076409	003	Sep 16, 2003	Apr	CAHN
AB		200MG	A076409	004	Sep 16, 2003	Apr	CAHN
AB		250MG	A076409	005	Sep 16, 2003	Apr	CAHN

NELARABINE

INJECTABLE;IV (INFUSION)

ARRANON

+	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Mar	CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

	FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Jan	NEWA
		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Jan	NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

AB	ALVOGEN PINE BROOK	400MG	A204621	001	Jul 10, 2015	Jun	NEWA

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

>A> AB	AMNEAL PHARMS	500MG	A203578	001	Jul 24, 2015	Jul	NEWA
>A> AB		1GM	A203578	002	Jul 24, 2015	Jul	NEWA

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB		HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar CAHN
AB			20MG	A202644	002	Apr 25, 2013	Mar CAHN

NILUTAMIDE

TABLET;ORAL

NILANDRON

	@	CONCORDIA PHARMS INC	50MG	N020169	001	Sep 19, 1996	Apr CAHN
	+		150MG	N020169	002	Apr 30, 1999	Apr CAHN

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

AB	+	BANNER LIFE SCIENCES	30MG	A076740	001	Jan 17, 2008	Jan CAHN
>A> AB		SOFGEN PHARMS	30MG	A201832	001	Jul 24, 2015	Jul NEWA

NINTEDANIB ESYLATE

CAPSULE;ORAL

OFEV

		BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014	Mar CAIN
	+		EQ 150MG BASE	N205832	002	Oct 15, 2014	Mar CAIN

NITRIC OXIDE

GAS;INHALATION

INOMAX

	@	INO	100PPM	N020845	002	Dec 23, 1999	Jun DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACRODANTIN

AB		ALVOGEN INC	25MG	N016620	003		Jun CTEC

NITROFURANTOIN

AB		ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015	Jun NEWA
AB			50MG	A091095	002	Jun 18, 2015	Jun NEWA
AB			100MG	A091095	003	Jun 18, 2015	Jun NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		WATSON LABS INC	75MG;25MG	A202250	001	Jul 08, 2015	Jun NEWA

NORETHINDRONE

TABLET;ORAL-28

NOR-QD

AB1	+	ACTAVIS LABS UT INC	0.35MG	N017060	001		Mar CAHN

NORGESTREL

TABLET;ORAL

OVRETTE

	@	LABORATOIRE HRA	0.075MG	N017031	001		Jun CAHN

NYSTATIN

CREAM;TOPICAL

NYSTATIN

AT		G AND W LABS INC	100,000 UNITS/GM	A061966	001		Jun CMFD

SUSPENSION;ORAL

NYSTATIN

AA		G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982	Apr CAHN
	@		100,000 UNITS/ML	A062776	001	Dec 17, 1987	Apr CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYKACET

AT		G AND W LABS INC	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Mar CMFD

OINTMENT;TOPICAL

MYKACET

AT		G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987	Mar CMFD

OFLOXACIN

TABLET;ORAL

OFLOXACIN

>D>		@ LARKEN LABS	400MG	A076093	003	Sep 02, 2003	Jul	CMFD
>A>	AB		400MG	A076093	003	Sep 02, 2003	Jul	CMFD

OLANZAPINE

TABLET;ORAL

OLANZAPINE

	AB	IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015	Apr	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

	AB	MACLEODS PHARMS LTD	5MG	A203044	001	Feb 20, 2015	Feb	NEWA
	AB		10MG	A203044	002	Feb 20, 2015	Feb	NEWA
	AB		15MG	A203044	003	Feb 20, 2015	Feb	NEWA
	AB		20MG	A203044	004	Feb 20, 2015	Feb	NEWA
	AB	ORCHID HLTHCARE	5MG	A202937	001	Mar 02, 2015	Feb	NEWA
	AB		10MG	A202937	002	Mar 02, 2015	Feb	NEWA
	AB		15MG	A202937	003	Mar 02, 2015	Feb	NEWA
	AB		20MG	A202937	004	Mar 02, 2015	Feb	NEWA

OLAPARIB

CAPSULE;ORAL

LYNPARZA

		ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Jan	CTNA

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED;INHALATION

STIOLTO RESPIMAT

	+	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015	May	NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

	AT	BARR LABS INC	EQ 0.2% BASE	A090848	001	Jul 13, 2015	Jun	NEWA

PATADAY

	AT	+ ALCON PHARMS LTD	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Jun	CFTG

PAZEO

		+ ALCON RES LTD	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Jan	NEWA

>A> OMBITASVIR; PARITAPREVIR; RITONAVIR

>A> TABLET;ORAL

>A> TECHNIVIE

>A>		+ ABBVIE INC	12.5MG;75MG;50MG	N207931	001	Jul 25, 2015	Jul	NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

	AB	SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Apr	CAHN
	AB		8MG	A078602	002	Feb 24, 2011	Apr	CAHN

ZOFRAN ODT

	AB	NOVARTIS PHARMS CORP	4MG	N020781	001	Jan 27, 1999	Mar	CAHN
	AB	+	8MG	N020781	002	Jan 27, 1999	Mar	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

	AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206846	001	Jul 13, 2015	Jun	NEWA
	AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Apr	CAHN
	AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077365	001	Dec 26, 2006	Jun	CAHN

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

	AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Apr	CAHN
	AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jun	CAHN
		@ TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008	Jan	DISC

ZOFRAN

	AP	+ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar	CAHN

ZOFRAN PRESERVATIVE FREE

	AP	+ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar	CAHN

		SOLUTION;ORAL						
		ZOFRAN						
AA	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Mar CAHN
		TABLET;ORAL						
		ZOFRAN						
AB		NOVARTIS PHARMS CORP	EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar CAHN
AB			EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar CAHN
AB	+		EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar CAHN
		ORPHENADRINE CITRATE						
		INJECTABLE;INJECTION						
		NORFLEX						
		@ IGI LABS INC	30MG/ML	N013055	001		Apr CAHN
		@ MEDICIS	30MG/ML	N013055	001		Mar DISC
		ORPHENADRINE CITRATE						
AP	+	AKORN	30MG/ML	A040484	001	May 24, 2006	Mar CRLD
		OXCARBAZEPINE						
		SUSPENSION;ORAL						
		OXCARBAZEPINE						
AB		SUN PHARM INDS LTD	300MG/5ML	A078734	001	Jun 26, 2009	Apr CAHN
		OXYBUTYNIN						
		FILM, EXTENDED RELEASE;TRANSDERMAL						
		OXYTROL						
AB	+	ACTAVIS LABS UT INC	3.9MG/24HR	N021351	002	Feb 26, 2003	Mar CAHN
		GEL, METERED;TRANSDERMAL						
		GELNIQUE 3%						
	+	ACTAVIS LABS UT INC	3%	N202513	001	Dec 07, 2011	Mar CAHN
		OXYBUTYNIN CHLORIDE						
		GEL;TRANSDERMAL						
		GELNIQUE						
	+	ACTAVIS LABS UT INC	10%(100MG/PACKET)	N022204	001	Jan 27, 2009	Mar CAHN
		OXYCODONE HYDROCHLORIDE						
		SOLUTION;ORAL						
		OXYCODONE HYDROCHLORIDE						
AA		ANI PHARMS INC	5MG/5ML	A204979	001	Jun 01, 2015	May NEWA
AA		NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015	Apr NEWA
AA		WOCKHARDT BIO AG	5MG/5ML	A206456	001	Jun 16, 2015	Jun NEWA
		TABLET;ORAL						
		OXAYDO						
		ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	Mar CTNA
			7.5MG	N202080	002	Jun 17, 2011	Mar CTNA
>D>		EGALET LTD	5MG	N202080	001	Jun 17, 2011	Jul CAHN
			5MG	N202080	001	Jun 17, 2011	May CAHN
>D>			7.5MG	N202080	002	Jun 17, 2011	Jul CAHN
			7.5MG	N202080	002	Jun 17, 2011	May CAHN
>A>		EGALET US INC	5MG	N202080	001	Jun 17, 2011	Jul CAHN
>A>			7.5MG	N202080	002	Jun 17, 2011	Jul CAHN
		OXYCODONE HYDROCHLORIDE						
AB		ACTAVIS ELIZABETH	5MG	A076636	003	Apr 07, 2015	Mar NEWA
AB		VINTAGE PHARMS	10MG	A077712	004	Apr 13, 2015	Mar NEWA
AB			20MG	A077712	005	Apr 13, 2015	Mar NEWA
		OXYMORPHONE HYDROCHLORIDE						
		TABLET, EXTENDED RELEASE;ORAL						
		OXYMORPHONE HYDROCHLORIDE						
AB		SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015	Apr NEWA
AB			7.5MG	A203506	002	Apr 24, 2015	Apr NEWA
AB			10MG	A203506	003	Apr 24, 2015	Apr NEWA
AB			15MG	A203506	004	Apr 24, 2015	Apr NEWA
AB			20MG	A203506	005	Apr 24, 2015	Apr NEWA
AB			30MG	A203506	006	Apr 24, 2015	Apr NEWA
AB			40MG	A203506	007	Apr 24, 2015	Apr NEWA

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

AP	+	EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001			Feb CAHN
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007		Feb CAHN

PALBOCICLIB

CAPSULE;ORAL

IBRANCE

		PFIZER INC	75MG	N207103	001	Feb 03, 2015		Feb NEWA
			100MG	N207103	002	Feb 03, 2015		Feb NEWA
	+		125MG	N207103	003	Feb 03, 2015		Feb NEWA

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

INVEGA

>D>		JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008		Jul CFTG
>A>	AB		1.5MG	N021999	006	Aug 26, 2008		Jul CFTG
>D>			3MG	N021999	001	Dec 19, 2006		Jul CFTG
>A>	AB		3MG	N021999	001	Dec 19, 2006		Jul CFTG
>D>		+	6MG	N021999	002	Dec 19, 2006		Jul CFTG
>A>	AB	+	6MG	N021999	002	Dec 19, 2006		Jul CFTG
>D>			9MG	N021999	003	Dec 19, 2006		Jul CFTG
>A>	AB		9MG	N021999	003	Dec 19, 2006		Jul CFTG

PALIPERIDONE

>A>	AB	ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015		Jul NEWA
>A>	AB		3MG	A202645	002	Aug 03, 2015		Jul NEWA
>A>	AB		6MG	A202645	003	Aug 03, 2015		Jul NEWA
>A>	AB		9MG	A202645	004	Aug 03, 2015		Jul NEWA

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA TRINZA

		JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015		May NEWA
			410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015		May NEWA
			546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015		May NEWA
	+		819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015		May NEWA

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

PANCURONIUM BROMIDE

	@	IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988		Mar CAHN
	@		2MG/ML	A072211	001	Mar 31, 1988		Mar CAHN
	@		2MG/ML	A072212	001	Mar 31, 1988		Mar CAHN
	@		2MG/ML	A072213	001	Mar 31, 1988		Mar CAHN

PANOBINOSTAT

CAPSULE;ORAL

FARYDAK

		NOVARTIS PHARMS CORP	10MG	N205353	001	Feb 23, 2015		Feb NEWA
			15MG	N205353	002	Feb 23, 2015		Feb NEWA
	+		20MG	N205353	003	Feb 23, 2015		Feb NEWA

PANOBINOSTAT LACTATE

CAPSULE;ORAL

FARYDAK

		NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015		Mar CAIN
			EQ 10MG BASE	N205353	001	Feb 23, 2015		Mar CPOT
			EQ 15MG BASE	N205353	002	Feb 23, 2015		Mar CAIN
			EQ 15MG BASE	N205353	002	Feb 23, 2015		Mar CPOT
	+		EQ 20MG BASE	N205353	003	Feb 23, 2015		Mar CAIN
	+		EQ 20MG BASE	N205353	003	Feb 23, 2015		Mar CPOT

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)

PANTOPRAZOLE SODIUM

AP		SANDOZ INC	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015		Jun NEWA

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB		KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011		Mar CAHN
AB			EQ 40MG BASE	A078281	002	Jan 20, 2011		Mar CAHN

TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

AB	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr	CAHN
AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr	CAHN

PARICALCITOL

CAPSULE;ORAL
PARICALCITOL

AB	BANNER LIFE SCIENCES	1MCG	A202539	001	Mar 27, 2014	Jan	CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan	CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan	CAHN

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL
VOTRIENT

+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar	CAHN
		EQ 400MG BASE	N022465	002	Oct 19, 2009	Mar	CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

AB	VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998	Feb	CAHN

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL
BONTRIL

@	VALEANT	105MG	A088021	001	Sep 21, 1982	Jan	DISC

PHENDIMETRAZINE TARTRATE

+	SANDOZ	105MG	N018074	001		Jan	CTEC

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL
DIBENZYLINE

AB +	CONCORDIA PHARMS INC	10MG	N008708	001		Jun	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL
PHENTERMINE HYDROCHLORIDE

AA	MIKAH PHARMA LLC	37.5MG	A040228	001	Jun 19, 1997	Jun	CMFD

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE

	AKORN INC	2.5%	N207926	001	Jan 15, 2015	Jan	NEWA
		10%	N207926	002	Jan 15, 2015	Jan	NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETH VC PLAIN

>D> AA	+	ACTAVIS MID ATLANTIC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jul	CAHN
>A> AA	+	G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jul	CAHN

PHENYTOIN SODIUM

CAPSULE;ORAL
EXTENDED PHENYTOIN SODIUM

@	WOCKHARDT	30MG EXTENDED	A040759	001	Dec 18, 2007	Jun	DISC
@	WOCKHARDT USA	100MG EXTENDED	A040732	001	Jan 30, 2008	Jun	DISC

PHENYTOIN SODIUM

AB	AUROBINDO PHARMA LTD	100MG EXTENDED	A204309	001	Jun 10, 2015	May	NEWA

INJECTABLE;INJECTION
PHENYTOIN SODIUM

AP +	EUROHLTH INTL SARL	50MG/ML	A084307	001		Feb	CAHN

PHYTONADIONE

INJECTABLE;INJECTION
AQUAMEPHYTON

@	IGI LABS INC	1MG/0.5ML	N012223	002		Apr	CAHN
@		10MG/ML	N012223	001		Apr	CAHN

PILOCARPINE HYDROCHLORIDE

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB	ELAN PHARMA INTL LTD	5MG	A076746	001	Nov 16, 2004	Mar	CAHN

PINDOLOL

TABLET;ORAL

PINDOLOL

@	G AND W LABS INC	5MG	A073661	001	Oct 31, 1993	Apr	CAHN
@		5MG	A073687	001	Feb 26, 1993	Apr	CAHN
@		5MG	A074123	001	Apr 17, 1997	Apr	CAHN
@		10MG	A073661	002	Oct 31, 1993	Apr	CAHN
@		10MG	A073687	002	Feb 26, 1993	Apr	CAHN
@		10MG	A074123	002	Apr 17, 1997	Apr	CAHN

PIRBUTEROL ACETATE

AEROSOL, METERED;INHALATION

MAXAIR

@	MEDICIS	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992	Jan	DISC

PIRFENIDONE

CAPSULE;ORAL

ESBRIET

+	GENENTECH INC	267MG	N022535	001	Oct 15, 2014	Feb	CAHN

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB	MYLAN PHARMS INC	10MG	A074116	001	Jun 15, 1993	May	CAHN
AB		20MG	A074118	001	Jun 15, 1993	May	CAHN

PODOFILOX

GEL;TOPICAL

CONDYLOX

+	ACTAVIS LABS UT INC	0.5%	N020529	001	Mar 13, 1997	Feb	CAHN

SOLUTION;TOPICAL

CONDYLOX

AT +	ACTAVIS LABS UT INC	0.5%	N019795	001	Dec 13, 1990	Jan	CAHN

PODOFILOX

AT	BAUSCH AND LOMB INC	0.5%	A090184	001	Jul 21, 2010	May	CAHN

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	ALCON RES LTD	10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Jan	CAHN

PONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

	ARIAD	EQ 30MG BASE	N203469	003	Apr 23, 2015	Apr	NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

KLOR-CON

AB	UPSHER SMITH	8MEQ	A203106	001	Jul 10, 2015	Jun	NEWA
AB		10MEQ	A203106	002	Jul 10, 2015	Jun	NEWA

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

>A> AB1	ADARE PHARMS INC	20MEQ	A076368	001	Aug 18, 2004	Jul	CAHN
>D> AB1	EURAND	20MEQ	A076368	001	Aug 18, 2004	Jul	CAHN
AB2	MYLAN PHARMS INC	8MEQ	A204662	001	Aug 21, 2014	Feb	CPOT
AB2		10MEQ	A204662	002	Aug 21, 2014	Feb	CPOT

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

>A> AB	DR REDDYS LABS LTD	0.375MG	A203354	001	Aug 07, 2015	Jul	NEWA
>A> AB		0.75MG	A203354	002	Aug 07, 2015	Jul	NEWA
>A> AB		1.5MG	A203354	003	Aug 07, 2015	Jul	NEWA
>A> AB		3MG	A203354	004	Aug 07, 2015	Jul	NEWA
>A> AB		4.5MG	A203354	005	Aug 07, 2015	Jul	NEWA

PREDNICARBATE
OINTMENT;TOPICAL
DERMATOP

AB	+	VALEANT PHARMS NORTH	0.1%	N019568	001	Sep 23, 1991	Apr	CAHN

PREGABALIN
CAPSULE;ORAL
LYRICA

		PF PRISM CV	25MG	N021446	001	Dec 30, 2004	Apr	CTEC
			50MG	N021446	002	Dec 30, 2004	Apr	CTEC
			75MG	N021446	003	Dec 30, 2004	Apr	CTEC
			100MG	N021446	004	Dec 30, 2004	Apr	CTEC
			150MG	N021446	005	Dec 30, 2004	Apr	CTEC
			200MG	N021446	006	Dec 30, 2004	Apr	CTEC
			225MG	N021446	007	Dec 30, 2004	Apr	CTEC
	+		300MG	N021446	008	Dec 30, 2004	Apr	CTEC

PROCAINAMIDE HYDROCHLORIDE
CAPSULE;ORAL
PROCAINAMIDE HYDROCHLORIDE

	@	IDT AUSTRALIA LTD	250MG	A089219	001	Jul 01, 1986	Jun	CAHN
	@		500MG	A089221	001	Jul 01, 1986	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL
PROCAINAMIDE HYDROCHLORIDE

	@	IDT AUSTRALIA LTD	250MG	A089369	001	Aug 14, 1987	Jun	CAHN
	@		500MG	A089370	001	Jan 09, 1987	Jun	CAHN
	@		750MG	A089371	001	Aug 14, 1987	Jun	CAHN

PROCHLORPERAZINE EDISYLATE
INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

AP	+	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Feb	CAHN

PROGESTERONE
CAPSULE;ORAL
PROGESTERONE

AB		BANNER LIFE SCIENCES	100MG	A200900	001	Aug 16, 2013	Jan	CAHN
AB			200MG	A200900	002	Aug 16, 2013	Jan	CAHN

GEL;VAGINAL
CRINONE

		ACTAVIS LABS UT INC	4%	N020701	001	Jul 31, 1997	Feb	CAHN
	+		8%	N020701	002	Jul 31, 1997	Feb	CAHN

INJECTABLE;INJECTION
PROGESTERONE

AO	+	ACTAVIS LABS UT INC	50MG/ML	N017362	002		Mar	CAHN

PROMETHAZINE HYDROCHLORIDE
INJECTABLE;INJECTION
PROMETHAZINE HYDROCHLORIDE

AP	+	EUROHLTH INTL SARL	25MG/ML	A083312	001		Jun	CAHN
AP	+		50MG/ML	A083312	002		Jun	CAHN

SUPPOSITORY;RECTAL
PHENERGAN

	@	DELCOR ASSET CORP	12.5MG	N010926	002		Apr	CAHN
	@		25MG	N010926	001		Apr	CAHN

TABLET;ORAL
PROMETHAZINE HYDROCHLORIDE

AB		HERITAGE PHARMA	12.5MG	A040673	001	Mar 05, 2008	Mar	CAHN
AB			25MG	A040673	002	Mar 05, 2008	Mar	CAHN
AB			50MG	A040673	003	Mar 05, 2008	Mar	CAHN

PYRIDOSTIGMINE BROMIDE
TABLET;ORAL
PYRIDOSTIGMINE BROMIDE

AB		ZYDUS PHARMS USA INC	60MG	A205650	001	Jun 22, 2015	Jun	NEWA

TABLET, EXTENDED RELEASE;ORAL
MESTINON

AB	+	VALEANT PHARMS LLC	180MG	N011665	001		Jun	CFTG

PYRIDOSTIGMINE BROMIDE

AB		ALVOGEN INC	180MG	A204737	001	Jun 26, 2015	Jun	NEWA

QUAZEPAM

TABLET;ORAL

DORAL

	@	SCIECURE PHARMA INC	15MG	N018708	001	Dec 27, 1985	Jun DISC	

QUETIAPINE FUMARATE

TABLET;ORAL

SEROQUEL

AB	+	ASTRAZENECA PHARMS	EQ 25MG BASE	N020639	001	Sep 26, 1997	May CAHN	
AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	May CAHN	
AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	May CAHN	
	@		EQ 150MG BASE	N020639	004	Dec 20, 1998	May CAHN	
AB			EQ 200MG BASE	N020639	003	Sep 26, 1997	May CAHN	
AB	+		EQ 300MG BASE	N020639	005	Jul 26, 2000	May CAHN	
AB			EQ 400MG BASE	N020639	006	Oct 04, 2005	May CAHN	

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr CAHN	
AB			EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr CAHN	
AB			EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr CAHN	
AB			EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr CAHN	

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

	@	CYCLE PHARMS LTD	324MG	A088431	001	Jan 06, 1984	Jun CAHN	

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

	@	CYCLE PHARMS LTD	200MG	A083640	001		Jun CAHN	
	@		300MG	A085632	001		Jun CAHN	

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE SULFATE

	+	G AND W LABS INC	300MG	A040045	001	Jun 30, 1994	Apr CAHN	

QUININE SULFATE

CAPSULE;ORAL

QUININE SULFATE

AB		AMNEAL PHARMS	324MG	A203729	001	Jul 15, 2015	Jun NEWA	
AB		LUPIN LTD	324MG	A203112	001	Apr 24, 2015	Apr NEWA	
>A> AB		RICONPHARMA LLC	324MG	A204372	001	Jul 22, 2015	Jul NEWA	

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

RABEPRAZOLE SODIUM

>A> AB		AMNEAL PHARMS	20MG	A204179	001	Jul 31, 2015	Jul NEWA	

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

RALOXIFENE HYDROCHLORIDE

AB		WATSON LABS INC	60MG	A200825	001	Jan 21, 2015	Jan NEWA	

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

ZANTAC

AP	+	CONCORDIA PHARMS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jun CAHN	

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	@	SUN PHARM INDS LTD	EQ 150MG BASE	A075439	001	Apr 19, 2000	Apr CAHN	
	@		EQ 300MG BASE	A075439	002	Apr 19, 2000	Apr CAHN	

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB		STANDARD CHEM PHARM	0.5MG	A091517	001	Apr 24, 2015	Apr NEWA	
AB			1MG	A091517	002	Apr 24, 2015	Apr NEWA	
AB			2MG	A091517	003	Apr 24, 2015	Apr NEWA	

RIBAVIRIN

CAPSULE;ORAL

REBETOL

	@	MERCK SHARP DOHME	200MG	N020903	001	Jun 03, 1998	Jun DISC

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE;ORAL

ATELVIA

AB	+	WARNER CHILCOTT LLC	35MG	N022560	001	Oct 08, 2010	May CFTG

RISEDRONATE SODIUM

AB		TEVA PHARMS USA	35MG	A203217	001	May 18, 2015	May NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

AB		SUN PHARM INDS LTD	0.5MG	A077542	001	Aug 06, 2010	Apr CAHN
AB			1MG	A077542	002	Aug 06, 2010	Apr CAHN
AB			2MG	A077542	003	Aug 06, 2010	Apr CAHN
AB			3MG	A078474	001	Aug 06, 2010	Apr CAHN
AB			4MG	A078474	002	Aug 06, 2010	Apr CAHN

RIVAROXABAN

TABLET;ORAL

XARELTO

		JANSSEN PHARMS	10MG	N022406	001	Jul 01, 2011	Apr CRLD

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB		ORCHID HLTHCARE	EQ 1.5MG BASE	A090879	001	Jun 10, 2015	May NEWA
AB			EQ 3MG BASE	A090879	002	Jun 10, 2015	May NEWA
AB			EQ 4.5MG BASE	A090879	003	Jun 10, 2015	May NEWA
AB			EQ 6MG BASE	A090879	004	Jun 10, 2015	May NEWA

ROFLUMILAST

TABLET;ORAL

DALIRESP

	+	ASTRAZENECA PHARMS	500MCG	N022522	001	Feb 28, 2011	Mar CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB		G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Apr CAHN
AB			EQ 0.5MG BASE	A077460	002	May 05, 2008	Apr CAHN
AB			EQ 1MG BASE	A077460	003	May 05, 2008	Apr CAHN
AB			EQ 2MG BASE	A077460	004	May 05, 2008	Apr CAHN
AB			EQ 3MG BASE	A077460	005	May 05, 2008	Apr CAHN
AB			EQ 4MG BASE	A077460	006	May 05, 2008	Apr CAHN
AB			EQ 5MG BASE	A077460	007	May 19, 2008	Apr CAHN

>A> SACUBITRIL; VALSARTAN

>A> TABLET;ORAL

>A> ENTRESTO

>A>		NOVARTIS PHARMS CORP	24MG;26MG	N207620	001	Jul 07, 2015	Jul NEWA
>A>			49MG;51MG	N207620	002	Jul 07, 2015	Jul NEWA
>A>	+		97MG;103MG	N207620	003	Jul 07, 2015	Jul NEWA

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

SCOPOLAMINE

AB		PERRIGO PHARMS CO	1MG/72HR	A078830	001	Jan 30, 2015	Mar CAHN
AB		PERRIGO R AND D	1MG/72HR	A078830	001	Jan 30, 2015	Jan NEWA

TRANSDERM SCOP

AB	+	NOVARTIS	1MG/72HR	N017874	001		Jan CFTG

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

	@	G AND W LABS INC	5MG	A074537	001	Aug 02, 1996	Apr CAHN
	@		5MG	A074744	001	Jan 27, 1997	Apr CAHN
	@		5MG	A074756	001	Nov 25, 1998	Apr CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

	@	HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009	May	DISC
	@		EQ 50MG BASE	A077864	002	Aug 10, 2009	May	DISC
	@		EQ 100MG BASE	A077864	003	Aug 10, 2009	May	DISC
AB		SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007	Apr	CAHN
AB			EQ 50MG BASE	A077977	002	Feb 06, 2007	Apr	CAHN
AB			EQ 100MG BASE	A077977	003	Feb 06, 2007	Apr	CAHN
			EQ 150MG BASE	A077977	004	Feb 06, 2007	Apr	CAHN
			EQ 200MG BASE	A077977	005	Feb 06, 2007	Apr	CAHN

SILDENAFIL CITRATE

SOLUTION;INTRAVENOUS

REVATIO

AP	+	PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Mar	CFTG

SILDENAFIL CITRATE

AP		AUROBINDO PHARMA LTD	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	A203988	001	Apr 01, 2015	Mar	NEWA

SILODOSIN

CAPSULE;ORAL

RAPAFLO

	+	ACTAVIS LABS UT INC	4MG	N022206	001	Oct 08, 2008	Mar	CAHN
			8MG	N022206	002	Oct 08, 2008	Mar	CAHN

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

AB		SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Apr	CAHN
AB			10MG	A076285	002	Dec 20, 2006	Apr	CAHN
AB			20MG	A076285	003	Dec 20, 2006	Apr	CAHN
AB			40MG	A076285	004	Dec 20, 2006	Apr	CAHN
AB			80MG	A076285	005	Jun 23, 2006	Apr	CAHN

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9%

AP		EUROHLTH INTL SARL	9MG/ML	A201850	001	Jan 20, 2012	Feb	CAHN

SODIUM CHLORIDE 0.9%

		EUROHLTH INTL SARL	9MG/ML	A201833	001	Sep 24, 2013	Feb	CAHN

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+	LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb	CAHN
			112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb	CAHN
	+		405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb	CPOT
			1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb	CPOT

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE;INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		EUROHLTH INTL SARL	62.5MG/5ML	A078215	001	Mar 31, 2011	Jun	CAHN

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

>A> AP		CARDINAL HEALTH 414	10-200mCi/ML	A203780	001	Jul 30, 2015	Jul	NEWA
>A> AP		HOT SHOTS NM LLC	10-200mCi/ML	A204530	001	Jul 29, 2015	Jul	NEWA
>A> AP		MIPS CRF	10-200mCi/ML	A204517	001	Jul 21, 2015	Jul	NEWA
AP		PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb 27, 2015	Feb	NEWA
AP		SPECTRON MRC LLC	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr	NEWA
AP		UNIV UTAH CYCLOTRON	10-200mCi/ML	A204497	001	Apr 20, 2015	Apr	NEWA

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

AA	+	CARDINAL HEALTH 418	100uCi	N018671	001	May 27, 1982	Apr	CAHN
AA	+		200uCi	N018671	002	May 27, 1982	Apr	CAHN
	@		400uCi	N018671	003	May 27, 1982	Apr	CAHN

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

KALEXATE

		KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015	Mar	NEWA

KAYEXALATE

AA	+	CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001		Apr	CAHN

SODIUM TETRADECYL SULFATE

INJECTABLE;INJECTION

SOTRADECOL

>D>		MYLAN INSTITUTIONAL	20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004	Jul	CRLD
>A>	+		20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004	Jul	CRLD

SOMATROPIN RECOMBINANT

INJECTABLE;INJECTION

NORDITROPIN FLEXPRO

		NOVO NORDISK INC	30MG/3ML	N021148	011	Jan 23, 2015	Jan	NEWA

NORDITROPIN NORDIFLEX

>D>		NOVO NORDISK INC	30MG/3ML	N021148	007	Mar 10, 2009	Jul	DISC
>A>	@		30MG/3ML	N021148	007	Mar 10, 2009	Jul	DISC
			30MG/3ML	N021148	007	Mar 10, 2009	Mar	CMFD
	@		30MG/3ML	N021148	007	Mar 10, 2009	Jan	DISC

NUTROPIN

	@	GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993	Jun	DISC
	@		10MG/VIAL	N020168	002	Nov 17, 1993	Jun	DISC
BX	+		10MG/VIAL	N020168	002	Nov 17, 1993	Mar	CTEC

NUTROPIN AQ

	@	GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Jun	DISC

NUTROPIN AQ NUSPIN

	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Jun	CTNA
	+		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008	Jun	NEWA
	+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Jun	CTNA

NUTROPIN AQ PEN

	+	GENENTECH	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Jun	NEWA

ZOMACTON

BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Mar	CTNA
BX			10MG/VIAL	N019774	003	Mar 07, 2012	Apr	CRLD
BX	+		10MG/VIAL	N019774	003	Mar 07, 2012	Mar	NEWA

>A> SONIDEGIB PHOSPHATE

>A> CAPSULE;ORAL

>A> ODOMZO

>A>	+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N205266	001	Jul 24, 2015	Jul	NEWA

SOTALOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

SOTALOL HYDROCHLORIDE

	+	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009	Apr	CAHN

TABLET;ORAL

BETAPACE

AB1		COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992	Mar	CAHN
AB1			120MG	N019865	005	Apr 20, 1994	Mar	CAHN
AB1	+		160MG	N019865	002	Oct 30, 1992	Mar	CAHN
AB1			240MG	N019865	003	Oct 30, 1992	Mar	CAHN
	@		320MG	N019865	004	Oct 30, 1992	Mar	CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

QUELICIN PRESERVATIVE FREE

	@	HOSPIRA	100MG/ML	N008845	004		Jun	DISC

SUCRALFATE

TABLET;ORAL

SUCRALFATE

AB		MYLAN PHARMS INC	1GM	A074415	001	Jun 08, 1998	May	CAHN

SUFENTANIL CITRATE

INJECTABLE;INJECTION

SUFENTANIL CITRATE

AP	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Jun	CAHN

SULFACETAMIDE SODIUM

LOTION;TOPICAL

KLARON

AB +	VALEANT PHARMS NORTH	10%	N019931	001	Dec 23, 1996	Mar	CAHN

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM

AT	AKORN	10%	A040215	001	May 25, 1999	Mar	CMFD

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>A>	@ ANI PHARMS INC	200MG/5ML;40MG/5ML	A070028	001	Jun 02, 1987	Jul	CAHN
>D>	@ TEVA	200MG/5ML;40MG/5ML	A070028	001	Jun 02, 1987	Jul	CAHN

SULFANILAMIDE

CREAM;VAGINAL

SULFANILAMIDE

	@ G AND W LABS INC	15%	A088718	001	Sep 19, 1985	Apr	CAHN

SUMATRIPTAN SUCCINATE

TABLET;ORAL

SUMATRIPTAN SUCCINATE

AB	SUN PHARM INDS LTD	EQ 25MG BASE	A076554	001	Aug 10, 2009	Apr	CAHN
AB		EQ 50MG BASE	A076554	002	Aug 10, 2009	Apr	CAHN
AB		EQ 100MG BASE	A076572	001	Feb 09, 2009	Apr	CAHN

TACROLIMUS

>A> TABLET, EXTENDED RELEASE;ORAL

>A> ENVARSUS XR

>A>	VELOXIS PHARMS INC	EQ 0.75MG BASE	N206406	001	Jul 10, 2015	Jul	NEWA
>A>		EQ 1MG BASE	N206406	002	Jul 10, 2015	Jul	NEWA
>A> +		EQ 4MG BASE	N206406	003	Jul 10, 2015	Jul	NEWA

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL

NUCYNTA

+	DEPOMED INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	May	CAHN

TABLET;ORAL

NUCYNTA

	DEPOMED INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	May	CAHN
		EQ 75MG BASE	N022304	002	Nov 20, 2008	May	CAHN
+		EQ 100MG BASE	N022304	003	Nov 20, 2008	May	CAHN

TABLET, EXTENDED RELEASE;ORAL

NUCYNTA ER

	DEPOMED INC	EQ 50MG BASE	N200533	001	Aug 25, 2011	May	CAHN
		EQ 100MG BASE	N200533	002	Aug 25, 2011	May	CAHN
		EQ 150MG BASE	N200533	003	Aug 25, 2011	May	CAHN
		EQ 200MG BASE	N200533	004	Aug 25, 2011	May	CAHN
+		EQ 250MG BASE	N200533	005	Aug 25, 2011	May	CAHN

TELAPREVIR

TABLET;ORAL

INCIVEK

	@ VERTEX PHARMS	375MG	N201917	001	May 23, 2011	Jan	DISC

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

AB	VINTAGE PHARMS	7.5MG	A201781	001	Jun 04, 2015	May	NEWA
AB		15MG	A201781	002	Jun 04, 2015	May	NEWA
AB		22.5MG	A201781	003	Jun 04, 2015	May	NEWA
AB		30MG	A201781	004	Jun 04, 2015	May	NEWA

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB		AMNEAL PHARMS	5MG	A203691	001	May 08, 2015	Apr	NEWA
AB			20MG	A203691	002	May 08, 2015	Apr	NEWA
AB			100MG	A203691	003	May 08, 2015	Apr	NEWA
AB			140MG	A203691	004	May 08, 2015	Apr	NEWA
AB			180MG	A203691	005	May 08, 2015	Apr	NEWA
AB			250MG	A203691	006	May 08, 2015	Apr	NEWA

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB		TEVA PHARMS USA	300MG	A091612	001	Mar 18, 2015	Mar	NEWA

VIREAD

AB	+	GILEAD SCIENCES INC	300MG	N021356	001	Oct 26, 2001	Mar	CFTG

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

	@	WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007	Feb	DISC

TESTOSTERONE

GEL;TRANSDERMAL

ANDROGEL

AB1		ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan	CTEC
AB1	+		50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan	CTEC

TESTIM

AB2	+	AUXILIUM PHARMS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Jan	CTEC

TESTOSTERONE

>D>	@	ACTAVIS LABS UT INC	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Jul	CMFD
	@		1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Mar	CAHN
>D>	@		1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Jul	CMFD
	@		1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Mar	CAHN
>A>	AB1		25MG/2.5GM PACKET	A076737	001	Jan 27, 2006	Jul	CMFD
>A>	AB1		50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jul	CMFD
	BX	ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	May	CAHN
	BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	May	CAHN
	AB1	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan	CTEC
	AB1		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan	CTEC

VOGELXO

AB2		UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jan	CTEC

GEL, METERED;TRANSDERMAL

ANDROGEL

>D>	+	ABBVIE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Jul	CFTG
>A>	AB +		1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Jul	CFTG

FORTESTA

>D>	+	ENDO PHARMS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jul	CFTG
>A>	AB +		10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jul	CFTG

>A>

TESTOSTERONE

>A>	AB	ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jul	NEWA
>A>	AB	PERRIGO ISRAEL	1.62% (20.25MG/1.25GM ACTUATION)	A204268	001	Aug 04, 2015	Jul	NEWA

TETRABENAZINE

TABLET;ORAL

XENAZINE

		VALEANT PHARMS NORTH	12.5MG	N021894	001	Aug 15, 2008	Feb	CAHN
	+		25MG	N021894	002	Aug 15, 2008	Feb	CAHN

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

ACHROMYCIN V

AB	+	HERITAGE PHARMS INC	500MG	N050278	001		Apr	CRLD

TETRACYCLINE HYDROCHLORIDE

	@	IVAX SUB TEVA PHARMS	250MG	A060704	001		Apr	DISC
	@		500MG	A060704	002		Apr	DISC

THEOPHYLLINE
TABLET;ORAL
THEOLAIR

		@ MEDICIS	125MG	A086399	001			Mar DISC
		@	250MG	A086399	002			Mar DISC

TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

AB		MYLAN PHARMS INC	400MG	A040595	001	Apr 21, 2006		May CAHN
AB	+		600MG	A040560	002	Apr 21, 2006		May CAHN

THIOTEPA
INJECTABLE;INJECTION
THIOTEPA

	+	EUROHLTH INTL SARL	15MG/VIAL	A075547	001	Apr 02, 2001		May CRLD

TIGECYCLINE
INJECTABLE;IV (INFUSION)
TIGECYCLINE

AP		SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015		May NEWA

TYGACIL

AP	+	PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005		May CFTG

TIMOLOL MALEATE
SOLUTION/DROPS;OPHTHALMIC
ISTALOL

AT2	+	BAUSCH AND LOMB	EQ 0.5% BASE	N021516	001	Jun 04, 2004		Apr CFTG

TIMOLOL MALEATE

AT1		AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997		Apr CTEC
AT1			EQ 0.5% BASE	A074516	001	Mar 25, 1997		Apr CTEC
AT1		ALCON RES LTD	EQ 0.5% BASE	A074262	001	Apr 28, 1995		Apr CTEC
AT2		APOTEX INC	EQ 0.5% BASE	A204936	001	Apr 17, 2015		Apr NEWA
AT1		BAUSCH AND LOMB	EQ 0.5% BASE	A074776	001	Mar 25, 1997		Apr CTEC
AT1		FDC LTD	EQ 0.5% BASE	A077259	002	Apr 30, 2008		Apr CTEC
AT1		HI TECH PHARMA	EQ 0.5% BASE	A075163	001	Sep 10, 2002		Apr CTEC
AT1		PACIFIC PHARMA	EQ 0.5% BASE	A074747	001	Mar 25, 1997		Apr CTEC
AT1		WOCKHARDT	EQ 0.5% BASE	A078771	002	Sep 28, 2009		Apr CTEC

TIMOPTIC

AT1	+	ATON	EQ 0.5% BASE	N018086	002			Apr CTEC

TINIDAZOLE
TABLET;ORAL
TINIDAZOLE

>A> AB		EDENBRIDGE PHARMS	250MG	A203808	001	Aug 04, 2015		Jul NEWA
>A> AB			500MG	A203808	002	Aug 04, 2015		Jul NEWA

TOBRAMYCIN
SOLUTION;INHALATION
KITABIS PAK

AN		PULMOFLOW INC	300MG/5ML	N205433	001	Dec 02, 2014		Feb CTEC

TOBRAMYCIN

AN		AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015		Jun NEWA

SOLUTION/DROPS;OPHTHALMIC
TOBREX

AT	+	ALCON LABS INC	0.3%	N050541	001			Mar CAHN

TOBRAMYCIN SULFATE
INJECTABLE;INJECTION
TOBRAMYCIN SULFATE

>D> AP	+	HOSPIRA	EQ 40MG BASE/ML	A063116	001	May 18, 1992		Jul CTNA
	@	IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994		Mar CAHN
	@		EQ 40MG BASE/ML	A063120	001	Oct 31, 1994		Mar CAHN
	@		EQ 40MG BASE/ML	A063121	001	Oct 31, 1994		Mar CAHN
	@		EQ 40MG BASE/ML	A063122	001	Oct 31, 1994		Mar CAHN

TOBRAMYCIN SULFATE (PHARMACY BULK)

>D> AP		FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002		Jul CRLD
>A>	+		EQ 40MG BASE/ML	A065120	001	Nov 29, 2002		Jul CTEC
>A> AP	+		EQ 40MG BASE/ML	A065120	001	Nov 29, 2002		Jul CRLD
>A>	@	HOSPIRA	EQ 40MG BASE/ML	A063116	001	May 18, 1992		Jul DISC
>A> AP			EQ 40MG BASE/ML	A063116	001	May 18, 1992		Jul CTNA

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

@	G AND W LABS INC	100MG	N018894	001	Nov 02, 1984	Apr	CAHN
@		250MG	N018894	002	Nov 02, 1984	Apr	CAHN
@		500MG	N018894	003	Nov 02, 1984	Apr	CAHN

TOLCAPONE

TABLET;ORAL

TASMAR

AB	+ VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar	CFTG

TOLCAPONE

AB	PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar	NEWA

TOLMETIN SODIUM

TABLET;ORAL

TOLMETIN SODIUM

@	G AND W LABS INC	EQ 600MG BASE	A074399	001	Mar 28, 1996	May	CAHN
@		EQ 600MG BASE	A074729	001	Feb 27, 1997	Apr	CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

TOLTERODINE TARTRATE

>A> AB	TORRENT PHARMS LTD	2MG	A203016	001	Aug 11, 2015	Jul	NEWA
>A> AB		4MG	A203016	002	Aug 11, 2015	Jul	NEWA

TABLET;ORAL

TOLTERODINE TARTRATE

AB	IVAX SUB TEVA PHARMS	1MG	A077006	001	Feb 23, 2015	Feb	NEWA
AB		2MG	A077006	002	Feb 23, 2015	Feb	NEWA

TOPIRAMATE

TABLET;ORAL

TOPIRAMATE

AB	SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Apr	CAHN
AB		100MG	A076327	002	Mar 27, 2009	Apr	CAHN
AB		200MG	A076327	003	Mar 27, 2009	Apr	CAHN
@	WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010	Apr	DISC
@		50MG	A090353	002	Sep 01, 2010	Apr	DISC
@		100MG	A090353	003	Sep 01, 2010	Apr	DISC
@		200MG	A090353	004	Sep 01, 2010	Apr	DISC

TOPIRAMATE

@	HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013	May	DISC
@		50MG	A091185	002	Nov 25, 2013	May	DISC
@		100MG	A091185	003	Nov 25, 2013	May	DISC
@		200MG	A091185	004	Nov 25, 2013	May	DISC

TOPOTECAN HYDROCHLORIDE

CAPSULE;ORAL

HYCAMTIN

	NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Mar	CAHN
+		EQ 1MG BASE	N020981	002	Oct 11, 2007	Mar	CAHN

INJECTABLE;INJECTION

HYCAMTIN

AP	+ NOVARTIS PHARMS CORP	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar	CAHN

TOPOTECAN HYDROCHLORIDE

AP	CHEM WERTH INC	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	May	CAHN

TORSEMIDE

INJECTABLE;INJECTION

TORSEMIDE

@	EUROHLTH INTL SARL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Jan	DISC
@		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Jan	DISC
@	LUITPOLD	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Jan	DISC
@		50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Jan	DISC

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

MEKINIST

		NOVARTIS PHARMS CORP	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	Mar	CAHN
			EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	Mar	CAHN
	+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	Mar	CAHN

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

AP		FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Apr	CMFD

TRANYLCYPROMINE SULFATE

TABLET;ORAL

PARNATE

AB	+	CONCORDIA PHARMS INC	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jun	CAHN

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

IZBA

>D>	+	ALCON LABS INC	0.003%	N204822	001	May 15, 2014	Jul	DISC
>A>	@		0.003%	N204822	001	May 15, 2014	Jul	DISC

TRAVATAN Z

AT	+	ALCON PHARMS LTD	0.004%	N021994	001	Sep 21, 2006	Jun	CTEC

TRAVOPROST

AT		APOTEX INC	0.004%	A203431	001	Jul 10, 2015	Jun	NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

DESYREL

	@	PRAGMA PHARMS LLC	50MG	N018207	001		May	CAHN
	@		100MG	N018207	002		May	CAHN
	@		150MG	N018207	003	Mar 25, 1985	May	CAHN
	@		300MG	N018207	004	Nov 07, 1988	May	CAHN

TABLET, EXTENDED RELEASE;ORAL

OLEPTRO

	@	ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010	Mar	DISC
	@		300MG	N022411	002	Feb 02, 2010	Mar	DISC

TRETINOIN

CREAM;TOPICAL

RENOVA

	+	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000	Apr	CAHN
AB2	+		0.05%	N019963	001	Dec 29, 1995	Apr	CAHN

RETIN-A

AB	+	VALEANT PHARMS NORTH	0.1%	N017340	001		Apr	CAHN

GEL;TOPICAL

ATRALIN

>D>	+	DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Jul	CTEC
>A> AB	+		0.05%	N022070	001	Jul 26, 2007	Jul	CTEC

TRETINOIN

>A> AB		SPEAR PHARMS INC	0.05%	A207955	001	Aug 13, 2015	Jul	NEWA

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		G AND W LABS	0.025%	A089797	001	May 31, 1991	Apr	CMFD
AT			0.1%	A089798	001	May 31, 1991	Apr	CMFD

TRIDERM

AT		CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar	NEWA
AT			0.5%	A088042	003	Mar 25, 2015	Mar	NEWA

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Mar	CMFD

OINTMENT;TOPICAL

KENALOG

AT		DELCOR ASSET CORP	0.025%	N011600	003		Mar	CMFD
AT			0.1%	N011600	001		Mar	CMFD

SPRAY;TOPICAL
KENALOG
AT + RANBAXY 0.147MG/GM N012104 001 Mar CFTG
TRIAMCINOLONE ACETONIDE
AT PERRIGO UK FINCO 0.147MG/GM A205782 001 Apr 13, 2015 Mar NEWA

TRIAMTERENE
CAPSULE;ORAL
DYRENIUM
CONCORDIA PHARMS INC 50MG N013174 001 Apr CAHN
+ 100MG N013174 002 Apr CAHN

TRIMIPRAMINE MALEATE
CAPSULE;ORAL
SURMONTIL
AB + ODYSSEY PHARMS EQ 50MG BASE N016792 002 Jun CRLD
AB EQ 100MG BASE N016792 003 Sep 15, 1982 Jun CRLD

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)
CREAM;VAGINAL
VAGILIA
>A> @ G AND W LABS INC 3.7%;2.86%;3.42% A088821 001 Nov 09, 1987 Jul CAHN
>D> @ TEVA 3.7%;2.86%;3.42% A088821 001 Nov 09, 1987 Jul CAHN

TRIPTORELIN PAMOATE
INJECTABLE;INTRAMUSCULAR
TRELSTAR
+ ACTAVIS LABS UT INC EQ 3.75MG BASE/VIAL N020715 001 Jun 15, 2000 Jan CAHN
+ EQ 11.25MG BASE/VIAL N021288 001 Jun 29, 2001 Jan CAHN
+ EQ 22.5MG BASE/VIAL N022437 001 Mar 10, 2010 Jan CAHN

TROSPIUM CHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
SANCTURA XR
@ ALLERGAN 60MG N022103 001 Aug 03, 2007 May DISC
TROSPIUM CHLORIDE
AB ACTAVIS LABS FL INC 60MG A091289 001 Oct 12, 2012 Jun CRLD
AB + 60MG A091289 001 Oct 12, 2012 May CRLD
AB SANDOZ INC 60MG A091635 001 Apr 29, 2015 Apr NEWA
TABLET;ORAL
SANCTURA
@ ALLERGAN 20MG N021595 001 May 28, 2004 May DISC
TROSPIUM CHLORIDE
AB GLENMARK GENERICS 20MG A091575 001 Aug 13, 2010 Jun CRLD
AB + 20MG A091575 001 Aug 13, 2010 May CRLD

UNOPROSTONE ISOPROPYL
SOLUTION/DROPS;OPHTHALMIC
RESCULA
+ R-TECH UENO LTD 0.15% N021214 001 Aug 03, 2000 May CAHN
+ SUCAMPO PHARMA LLC 0.15% N021214 001 Aug 03, 2000 Jan CAHN

URSODIOL
CAPSULE;ORAL
ACTIGALL
@ ACTAVIS LABS UT INC 150MG N019594 001 Dec 31, 1987 Mar CAHN
AB + 300MG N019594 002 Dec 31, 1987 Mar CAHN

VALACYCLOVIR HYDROCHLORIDE
TABLET;ORAL
VALACYCLOVIR HYDROCHLORIDE
AB HETERO LABS LTD V EQ 500MG BASE A203047 001 Apr 08, 2015 Mar NEWA
AB EQ 1GM BASE A203047 002 Apr 08, 2015 Mar NEWA
AB SUN PHARM INDS LTD EQ 500MG BASE A076588 001 Jan 31, 2007 Apr CAHN
AB EQ 1GM BASE A076588 002 Jan 31, 2007 Apr CAHN

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

AB		BANNER LIFE SCIENCES	250MG	A073484	001	Jun 29, 1993	Jan CAHN

CAPSULE, DELAYED RELEASE;ORAL

STAVZOR

	@	BANNER LIFE SCIENCES	125MG	N022152	001	Jul 29, 2008	Jan CAHN
	@		250MG	N022152	002	Jul 29, 2008	Jan CAHN
	@		500MG	N022152	003	Jul 29, 2008	Jan CAHN

VALSARTAN

TABLET;ORAL

VALSARTAN

AB		PRINSTON INC	40MG	A204821	001	Jun 09, 2015	May NEWA
AB			80MG	A204821	002	Jun 09, 2015	May NEWA
AB			160MG	A204821	003	Jun 09, 2015	May NEWA
AB			320MG	A204821	004	Jun 09, 2015	May NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

AB		LUPIN LTD	EQ 125MG BASE	A090439	001	Jan 28, 2015	Jan NEWA
AB			EQ 250MG BASE	A090439	002	Jan 28, 2015	Jan NEWA

INJECTABLE;INJECTION

VANCOLED

	@	EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Jun CAHN
	@		EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Jun CAHN
	@		EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Jun CAHN
	@		EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Jun CAHN
	@		EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Jun CAHN

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

STAXYN

AB	+	BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Apr CFTG

VARDENAFIL HYDROCHLORIDE

AB		WATSON LABS INC	10MG	A203689	001	Apr 22, 2015	Apr NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Feb CAHN
AB			EQ 75MG BASE	A090071	002	Apr 15, 2011	Feb CAHN
AB			EQ 150MG BASE	A090071	003	Apr 15, 2011	Feb CAHN

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		YAOPHARMA CO LTD	EQ 25MG BASE	A202036	001	May 28, 2015	May NEWA
AB			EQ 37.5MG BASE	A202036	002	May 28, 2015	May NEWA
AB			EQ 50MG BASE	A202036	003	May 28, 2015	May NEWA
AB			EQ 75MG BASE	A202036	004	May 28, 2015	May NEWA
AB			EQ 100MG BASE	A202036	005	May 28, 2015	May NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

AB		RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990	Apr CAHN
AB			180MG	N019614	003	Jan 09, 1992	Apr CAHN
AB			240MG	N019614	002	May 29, 1990	Apr CAHN
	+		360MG	N019614	004	May 10, 1996	Apr CAHN

VERELAN PM

AB		RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Apr CAHN
AB			200MG	N020943	002	Nov 25, 1998	Apr CAHN
AB	+		300MG	N020943	003	Nov 25, 1998	Apr CAHN

INJECTABLE;INJECTION

ISOPTIN

	@	MT ADAMS	2.5MG/ML	N018485	001		Apr CAHN

TABLET;ORAL

ISOPTIN

	@	MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr CAHN
	@		80MG	N018593	001	Mar 08, 1982	Apr CAHN
	@		120MG	N018593	002	Mar 08, 1982	Apr CAHN

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

	+	VALEANT LUXEMBOURG	15MG/VIAL	N	021119	001	Apr 12, 2000	Mar CAHN

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

	+	FOREST LABS LLC	10MG	N	022567	001	Jan 21, 2011	Mar CAHN
			20MG	N	022567	002	Jan 21, 2011	Mar CAHN
			40MG	N	022567	003	Jan 21, 2011	Mar CAHN

ZAFIRLUKAST

TABLET;ORAL

ACCOLATE

AB		PAR PHARM INC	10MG	N	020547	003	Sep 17, 1999	Feb CAHN
AB	+		20MG	N	020547	001	Sep 26, 1996	Feb CAHN

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

>D> AP		AGILA SPECLTS	EQ 4MG BASE/5ML	A	202650	001	Mar 04, 2013	Jul CAHN
AP		FRESENIUS KABI USA	EQ 4MG BASE/5ML	A	091516	001	Apr 23, 2015	Apr NEWA
AP		HOSPIRA INC	EQ 4MG BASE/5ML	A	090621	001	Mar 19, 2015	Mar NEWA
>A> AP		MYLAN LABS LTD	EQ 4MG BASE/5ML	A	202650	001	Mar 04, 2013	Jul CAHN
AP		USV NORTH AMERICA	EQ 4MG BASE/5ML	A	202923	001	Sep 04, 2014	Mar CPOT

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

	@	HIKMA	5MG	A	078129	001	Apr 30, 2008	Mar DISC
	@		10MG	A	078129	002	Apr 30, 2008	Mar DISC
AB		SUN PHARM INDS LTD	5MG	A	078055	001	Apr 23, 2007	Apr CAHN
AB			10MG	A	078055	002	Apr 23, 2007	Apr CAHN

TABLET;SUBLINGUAL

INTERMEZZO

AB		PURDUE PHARMA	1.75MG	N	022328	001	Nov 23, 2011	May CFTG
AB	+		3.5MG	N	022328	002	Nov 23, 2011	May CFTG

ZOLPIDEM TARTRATE

AB		NOVEL LABS INC	1.75MG	A	204299	001	Jun 03, 2015	May NEWA
AB			3.5MG	A	204299	002	Jun 03, 2015	May NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

AB		BANNER LIFE SCIENCES	25MG	A	077813	001	Aug 16, 2006	Jan CAHN
AB			50MG	A	077813	002	Aug 16, 2006	Jan CAHN
AB			100MG	A	077813	003	Aug 16, 2006	Jan CAHN

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

	SUN PHARM INDS LTD	650MG	A078569	001	Dec 14, 2011	Apr CAHN
@		650MG	A090205	001	Nov 18, 2009	Apr CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL

SHADE UVAGUARD

+	BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045	001	Dec 07, 1992	Mar CAHN

BUDESONIDE

SPRAY, METERED;NASAL

RHINOCORT ALLERGY

+	ASTRAZENECA PHARMS	0.032MG/SPRAY	N020746	003	Mar 23, 2015	Mar NEWA

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

LOTRIMIN ULTRA

+	BAYER HEALTHCARE LLC	1%	N021307	001	Dec 07, 2001	Mar CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	BANNER LIFE SCIENCES	5MG	N022429	001	Jul 23, 2009	Jan CAHN
+		10MG	N022429	004	Jul 23, 2009	Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	BANNER LIFE SCIENCES	5MG	N022429	003	Jul 23, 2009	Jan CAHN
+		10MG	N022429	002	Jul 23, 2009	Jan CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	AUROBINDO PHARMA LTD	5MG	A090760	001	Aug 05, 2015	Jul NEWA
>A>		10MG	A090760	003	Aug 05, 2015	Jul NEWA
	SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007	Apr CAHN
		10MG	A077498	002	Dec 27, 2007	Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES

	SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007	Apr CAHN
		10MG	A077498	004	Dec 27, 2007	Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>A>	AUROBINDO PHARMA LTD	5MG	A090760	002	Aug 05, 2015	Jul NEWA
>A>		10MG	A090760	004	Aug 05, 2015	Jul NEWA

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	JUBILANT GENERICS	5MG	A091116	001	Feb 19, 2015	Feb NEWA
		10MG	A091116	002	Feb 19, 2015	Feb NEWA
	SANDOZ	5MG	A078692	001	Feb 14, 2008	Feb CTNA
+		10MG	A078692	002	Feb 14, 2008	Feb CTNA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	JUBILANT GENERICS	5MG	A091116	003	Feb 19, 2015	Feb NEWA
		10MG	A091116	004	Feb 19, 2015	Feb NEWA

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

@	BAYER HEALTHCARE LLC	8MG	N007638	001		Mar CAHN
+		12MG	N007638	002		Mar CAHN

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

+	BAYER HEALTHCARE LLC	8MG;120MG	N018397	001		Mar CAHN

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

>A>	@ ANI PHARMS INC	1.34MG	A073282	002	Dec 03, 1992	Jul CAHN
>D>	@ TEVA	1.34MG	A073282	002	Dec 03, 1992	Jul CAHN

CLOTRIMAZOLE

CREAM;VAGINAL

GYNE-LOTRIMIN

+	BAYER HEALTHCARE LLC	1%	N018052	002	Nov 30, 1990	Mar	CAHN

GYNE-LOTRIMIN 3

+	BAYER HEALTHCARE LLC	2%	N020574	001	Nov 24, 1998	Mar	CAHN

CREAM, TABLET;TOPICAL, VAGINAL

GYNE-LOTRIMIN COMBINATION PACK

+	BAYER HEALTHCARE LLC	1%,100MG	N020289	002	Apr 26, 1993	Mar	CAHN

TABLET;VAGINAL

GYNE-LOTRIMIN

+	BAYER HEALTHCARE LLC	100MG	N017717	002	Nov 30, 1990	Mar	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

	BANNER LIFE SCIENCES	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010	Jan	CAHN

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

	SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009	Apr	CAHN
		20MG	A090283	002	Nov 17, 2009	Apr	CAHN

PEPCID AC

>A>		J AND J CONSUMER INC	10MG	N020325	001	Apr 28, 1995	Jul	CAHN
>A>	+		20MG	N020325	002	Sep 23, 2003	Jul	CAHN
>D>		MCNEIL CONS	10MG	N020325	001	Apr 28, 1995	Jul	CAHN
>D>	+		20MG	N020325	002	Sep 23, 2003	Jul	CAHN

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	SUN PHARMA GLOBAL	60MG;120MG	A090818	001	Jan 29, 2015	Jan	NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

	ACTAVIS LABS FL INC	600MG;60MG	A091071	001	May 27, 2015	May	NEWA
		1.2GM;120MG	A091071	002	May 27, 2015	May	NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

	BANNER LIFE SCIENCES	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan	CAHN

MIDOL LIQUID GELS

+	BANNER LIFE SCIENCES	200MG	N021472	001	Oct 18, 2002	Jan	CAHN

IBUPROFEN SODIUM

TABLET;ORAL

IBUPROFEN SODIUM

>A>		PERRIGO R AND D	EQ 200MG BASE	A206581	001	Aug 03, 2015	Jul	NEWA

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

	BAUSCH AND LOMB	EQ 0.035% BASE	N021996	002	Feb 11, 2015	Feb	NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

	LOTUS PHARM CO LTD	1.5MG	A202246	001	Jun 05, 2015	May	NEWA
	OC PHARMA	1.5MG	A202380	001	May 29, 2015	May	NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

	BANNER LIFE SCIENCES	1MG	N021855	001	Aug 04, 2005	Jan	CAHN
+		2MG	N021855	002	Aug 04, 2005	Jan	CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

	SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006	Apr	CAHN

LORATADINE

CAPSULE;ORAL

CLARITIN

+	BAYER HEALTHCARE LLC	10MG	N021952	001	Jun 16, 2008	Mar	CAHN

SYRUP;ORAL

CLARITIN

+	BAYER HEALTHCARE LLC	1MG/ML	N020641	002	Nov 27, 2002	Mar	CAHN

CLARITIN HIVES RELIEF

@	BAYER HEALTHCARE LLC	1MG/ML	N020641	003	Nov 19, 2003	Mar	CAHN

LORATADINE

>A>	TARO	1MG/ML	A201865	001	Jul 31, 2015	Jul	NEWA

TABLET;ORAL

LORATADINE

	SUN PHARM INDS LTD	10MG	A076134	001	Aug 18, 2003	Apr	CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+	BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006	Mar	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

CLARITIN REDITABS

+	BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006	Mar	CAHN

LORATADINE REDIDOSE

	SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007	Apr	CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARITIN-D

+	BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002	Mar	CAHN

CLARITIN-D 24 HOUR

+	BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002	Mar	CAHN

LORATADINE AND PSEUDOEPHEDRINE SULFATE

	SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004	Apr	CAHN

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+	BANNER LIFE SCIENCES	EQ 200MG BASE	N021920	001	Feb 17, 2006	Jan	CAHN
	CATALENT	EQ 200MG BASE	A202807	001	Feb 13, 2015	Feb	NEWA
	OHM LABS INC	EQ 200MG BASE	A202807	001	Feb 13, 2015	Jun	CAHN

TABLET;ORAL

NAPROXEN SODIUM

	SUN PHARM INDS LTD	EQ 200MG BASE	A091183	001	May 20, 2011	Apr	CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

@	IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009	Mar	DISC
@		EQ 4MG BASE	A077850	001	Feb 18, 2009	Mar	DISC

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

>A>	PERRIGO R AND D	EQ 20MG BASE	A204152	001	Jul 30, 2015	Jul	NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

ZEGERID OTC

+	BAYER HEALTHCARE LLC	20MG;1.1GM	N022281	001	Dec 01, 2009	Mar	CAHN

FOR SUSPENSION;ORAL
ZEGERID OTC
\+ BAYER HEALTHCARE LLC 20MG/PACKET;1.68GM/PACKET N022283 001 Jun 17, 2013 Mar CAHN

OXYMETAZOLINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
OCUCLEAR
BAYER HEALTHCARE LLC 0.025% N018471 001 May 30, 1986 Mar CAHN

POLYETHYLENE GLYCOL 3350
FOR SOLUTION;ORAL
MIRALAX
\+ BAYER HEALTHCARE LLC 17GM/SCOOPFUL N022015 001 Oct 06, 2006 Mar CAHN
POLYETHYLENE GLYCOL 3350
RARITAN PHARMS INC 17GM/SCOOPFUL A202071 001 Dec 28, 2012 Jan CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
PSEUDOEPHEDRINE HYDROCHLORIDE
SUN PHARM INDS LTD 120MG A077442 001 Sep 28, 2005 Apr CAHN

RANITIDINE HYDROCHLORIDE
TABLET;ORAL
RANITIDINE HYDROCHLORIDE
@ SUN PHARM INDS LTD EQ 75MG BASE A075132 001 Jan 14, 2000 Apr CAHN
@ WOCKHARDT EQ 75MG BASE A078884 001 Jul 31, 2008 Jan DISC

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 7 JULY 2015

NO JULY 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JULY 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE - ZIAGEN							
N 020977 001						D-147	Mar 23, 2018
ABACAVIR SULFATE - ZIAGEN							
N 020978 001						D-147	Mar 23, 2018
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ							
N 205551 001		6417191	Mar 28, 2016	DP U-1572			
		6417191*PED	Sep 28, 2016				
ABACAVIR SULFATE; LAMIVUDINE - EPZICOM							
N 021652 001		6417191	Mar 28, 2016	DP U-257			
		6417191*PED	Sep 28, 2016				
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR							
N 204031 001		8980319	Dec 21, 2030	DP			
		8992975	May 16, 2032	DP			
		9050335	May 16, 2032	DP			
ACLIDINIUM BROMIDE - TUDORZA PRESSAIR							
N 202450 001		9056100	Jul 07, 2020	DP U-1263			
ACYCLOVIR; HYDROCORTISONE - XERESE							
N 022436 001		7223387	Jul 24, 2021	DP U-1006			
		7223387	Jul 24, 2021	DP U-1484			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO							
N 022320 001		8936800	Dec 23, 2022	DP U-1078			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE							
N 207917 001	>A>	8445543	Jul 12, 2027	U-1078		>A> NP	Jul 15, 2018
	>A>	8703820	Mar 12, 2023	U-1078			
	>A>	8729127	Mar 12, 2023	U-1078			
	>A>	8785420	Dec 23, 2022	U-1078			
	>A>	8909305	Dec 23, 2022	U-1078			
	>A>	8936800	Dec 23, 2022	DP U-1078			
ALBUTEROL SULFATE - PROAIR RESPICLICK							
N 205636 001		6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
		6701917	Jun 23, 2021	DP			
		6718972	Jun 23, 2021	DP			
		6748947	Jun 23, 2021	DP			
		6871646	Jun 23, 2021	DP			
		7540282	May 06, 2023	DP			
		8006690	Jun 23, 2021	DP			
		8651103	Mar 26, 2028	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 001	>A>	8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 002	>A>	8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 003	>A>	8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 004	>A>	8637079	Jun 04, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	005 >A>	8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	006 >A>	8637079	Jun 04, 2029	DP			
ALVIMOPAN - ENTEREG							
N 021775	001	8946262	Feb 12, 2030	U-1655			
AMOXICILLIN - MOXATAG							
N 050813	001	8778924	Dec 08, 2026	DS DP U-897			
APREMILAST - OTEZLA							
N 205437	001	9018243	Mar 19, 2023	U-1505			
		9018243	Mar 19, 2023	U-1595			
APREMILAST - OTEZLA							
N 205437	002	9018243	Mar 19, 2023	U-1505			
		9018243	Mar 19, 2023	U-1595			
APREMILAST - OTEZLA							
N 205437	003	9018243	Mar 19, 2023	U-1505			
		9018243	Mar 19, 2023	U-1595			
ARIPIPRAZOLE - ABILIFY							
N 021436	001					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021436	002					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021436	003					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021436	004					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021436	005					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021436	006					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021713	001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
		5006528	Oct 20, 2014	DS DP U-761			
		5006528*PED	Apr 20, 2015				
		6977257	Apr 24, 2022	DP			
		6977257*PED	Oct 24, 2022				
ARIPIPRAZOLE - ABILIFY							
N 021729	002					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021729	003					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021729	004					ODE	Dec 12, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021729 005					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY						
N 021866 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-763			
	5006528*PED	Apr 20, 2015				
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 001	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 002	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 003	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 004	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 004	8993761	Sep 25, 2022	DS			
ASENAPINE MALEATE - SAPHRIS						
N 022117 001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS						
N 022117 002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
ATAZANAVIR SULFATE - REYATAZ						
N 021567 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ						
N 021567 002	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ						
N 021567 003	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ						
N 021567 004	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	5849911*PED	Dec 20, 2017			PED	Dec 02, 2017
	6087383	Dec 21, 2018	DS DP			
ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ						
N 206353 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
	8148374	Sep 03, 2029	DS DP U-1279			
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ						
N 206494 001	7112592	Feb 24, 2022	DS DP U-282			
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP U-282			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZELAIC ACID - FINACEA							
N 207071 001						>A> NP	Jul 29, 2018
AZELASTINE HYDROCHLORIDE - ASTEPRO							
N 022203 001						NPP	Feb 20, 2018
						NPP	Feb 20, 2018
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA							
N 202236 001		8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
		8163723	Aug 29, 2023	U-81			
		8163723	Aug 29, 2023	U-644			
		8163723	Aug 29, 2023	U-707			
		8163723	Aug 29, 2023	U-1667			
AZILSARTAN KAMEDOXOMIL - EDARBI							
N 200796 001	>A>	9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL - EDARBI							
N 200796 002	>A>	9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR							
N 202331 001	>A>	9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR							
N 202331 002	>A>	9066936	Mar 26, 2028	DP			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA							
N 050819 001		8895070	Jun 03, 2029	U-124			
BESIFLOXACIN HYDROCHLORIDE - BESIVANCE							
N 022308 001		8937062	Nov 13, 2029	U-80			
BIMATOPROST - LUMIGAN							
N 022184 001		8933120	Mar 16, 2025	DP			
		8933127	Mar 16, 2025	DP			
BIMATOPROST - LATISSE							
N 022369 001		7351404	May 25, 2024	U-939	Y		
		7388029	Jan 21, 2022	U-938	Y		
		8541466	Jan 31, 2021	U-1217			
		8986715	Jan 15, 2023	U-1217			
BREXPIPRAZOLE - REXULTI							
N 205422 001	>A>	7888362	Feb 23, 2027	DS		>A> NCE	Jul 10, 2020
	>A>	8349840	Apr 12, 2026	DP U-1529			
	>A>	8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI							
N 205422 002	>A>	7888362	Feb 23, 2027	DS		>A> NCE	Jul 10, 2020
	>A>	8349840	Apr 12, 2026	DP U-1529			
	>A>	8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI							
N 205422 003	>A>	7888362	Feb 23, 2027	DS		>A> NCE	Jul 10, 2020
	>A>	8349840	Apr 12, 2026	DP U-1529			
	>A>	8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI							
N 205422 004	>A>	7888362	Feb 23, 2027	DS		>A> NCE	Jul 10, 2020
	>A>	8349840	Apr 12, 2026	DP U-1529			
	>A>	8618109	Apr 12, 2026	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BREXPIPRAZOLE - REXULTI							
N 205422	005	>A> 7888362	Feb 23, 2027	DS		>A> NCE	Jul 10, 2020
		>A> 8349840	Apr 12, 2026	DP U-1529			
		>A> 8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI							
N 205422	006	>A> 7888362	Feb 23, 2027	DS		>A> NCE	Jul 10, 2020
		>A> 8349840	Apr 12, 2026	DP U-1529			
		>A> 8618109	Apr 12, 2026	U-543			
BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA							
N 204251	001	9044484	Oct 30, 2030	DP			
BROMOCRIPTINE MESYLATE - CYCLOSET							
N 020866	001	8877708	Jun 07, 2030	DP U-1706			
BUDESONIDE - UCERIS							
N 205613	001	5914122	Dec 19, 2015	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	001	8470361	May 22, 2030	DP U-1425			
		8940330	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	002	8470361	May 22, 2030	DP U-1425			
		8940330	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	003	8470361	May 22, 2030	DP U-1425			
		8940330	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	004	8470361	May 22, 2030	DP U-1425			
		8940330	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	005	8454996	Sep 24, 2019	U-1421			
		8470361	May 22, 2030	DP U-1425			
		8658198	Dec 03, 2027	DP U-1494			
		8940330	Sep 18, 2032	DP			
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE							
N 200063	001	8916195	Feb 02, 2030	U-1639			
CALCIUM ACETATE - PHOSLO GELCAPS							
N 021160	003	6875445	Jul 30, 2021	DP			
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER							
N 207026	001					>A> ODE	Jan 13, 2022
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER							
N 207026	002					>A> ODE	Jan 13, 2022
CANGRELOR - KENGREAL							
N 204958	001	>A> 6114313	Dec 11, 2017	DP U-1715		NCE	Jun 22, 2020
		>A> 6130208	Jun 29, 2018	DP U-1715			
		>A> 8680052	Mar 09, 2033	U-1715			
		>A> 8759316	May 13, 2029	U-1715			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1720			
	>A> 9089608	Dec 26, 2028	DP			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1720			
	>A> 9089608	Dec 26, 2028	DP			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1720			
	>A> 9089608	Dec 26, 2028	DP			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1720			
	>A> 9089608	Dec 26, 2028	DP			
CARBIDOPA; LEVODOPA - DUOPA						
N 203952 001					NP	Jan 09, 2018
					ODE	Jan 09, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARFILZOMIB - KYPROLIS							
N 202714	001					>A> I-712	Jul 24, 2018
CEFTAROLINE FOSAMIL - TEFLARO							
N 200327	001	6417175	Apr 11, 2022	DS DP U-1676			
CEFTAROLINE FOSAMIL - TEFLARO							
N 200327	002	6417175	Apr 11, 2022	DS DP U-1676			
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA							
N 206829	001	8968753	Mar 14, 2034	U-1672			
		8968753	Mar 14, 2034	U-1673			
CELECOXIB - CELECOXIB							
A 076898	002					PC	Jun 02, 2015
CELECOXIB - CELECOXIB							
A 076898	003					PC	Jun 02, 2015
CELECOXIB - CELECOXIB							
A 076898	004					PC	Jun 02, 2015
CELECOXIB - CELECOXIB							
A 078857	002					PC	Jun 02, 2015
CELECOXIB - CELECOXIB							
A 078857	003					PC	Jun 02, 2015
CELECOXIB - CELECOXIB							
A 078857	004					PC	Jun 02, 2015
CELECOXIB - CELECOXIB							
A 200562	002					PC	Jun 02, 2015
CELECOXIB - CELECOXIB							
A 200562	003					PC	Jun 02, 2015
CELECOXIB - CELECOXIB							
A 200562	004					PC	Jun 02, 2015
CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE							
N 206323	001	>A> 6248363	Nov 23, 2019	DP U-1716			
		>A> 6383471	Apr 06, 2019	DP U-1716			
		>A> 9066942	Jan 03, 2032	U-1716			
CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR							
N 207768	001	8062667	Mar 29, 2029	DP			
		8790700	Mar 15, 2027	DP			
CHOLIC ACID - CHOLBAM							
N 205750	001					ODE	Mar 17, 2022
CHOLIC ACID - CHOLBAM							
N 205750	002					ODE	Mar 17, 2022
CICLESONIDE - ALVESCO							
N 021658	002	8371292	Feb 01, 2028	U-1355			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CICLESONIDE - ALVESCO						
N 021658 003	8371292	Feb 01, 2028	U-1355			
CICLESONIDE - OMNARIS						
N 022004 001	8371292	Feb 01, 2028	U-1356			
CICLESONIDE - ZETONNA						
N 202129 001	8371292	Feb 01, 2028	U-1357			
CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE						
A 090898 001					PC	Jul 01, 2015
CLOBETASOL PROPIONATE - OLUX E						
N 022013 001	8962000	Aug 31, 2025	DP U-1410			
COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX						
N 205395 001	5843946	Dec 01, 2015	DP U-1660			
	5843946*PED	Jun 01, 2016				
	7470506	Jun 23, 2019	U-1660			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1660			
	RE43802*PED	Apr 19, 2017				
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD						
N 203100 001	8981103	Oct 26, 2026	DS DP		I-704	Dec 17, 2017
COLCHICINE - MITIGARE						
N 204820 001	8927607	Aug 22, 2033	U-1020			
CRIZOTINIB - XALKORI						
N 202570 001	7230098	Aug 26, 2025	DS			
CRIZOTINIB - XALKORI						
N 202570 002	7230098	Aug 26, 2025	DS			
CROFELEMER - FULYZAQ						
N 202292 001	8962680	Oct 31, 2031	U-1319			
CYANOCOBALAMIN - NASCOBAL						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 001	8703781	Oct 15, 2030	DS DP U-1713			
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 002	8703781	Oct 15, 2030	DS DP U-1713			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 001					>A> NCE	Jul 24, 2020
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 002					>A> NCE	Jul 24, 2020
DANTROLENE SODIUM - RYANODEX						
N 205579 001					ODE	Jul 22, 2021
DAPAGLIFLOZIN PROPANEDIOL - FARXIGA						
N 202293 001					M-157	Mar 11, 2018
DAPAGLIFLOZIN PROPANEDIOL - FARXIGA						
N 202293 002					M-157	Mar 11, 2018
DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)						
N 206619 001	6037157	Jun 26, 2016		U-1635		
	6703403	Jun 26, 2016		U-1635		
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP	U-1636		
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032		U-1637		
	8492386	Sep 04, 2032		U-1637		
	8501238	Sep 17, 2028	DS DP	U-1636		
	8642538	Sep 10, 2029	DS DP	U-1638		
	8680106	Sep 04, 2032		U-1637		
	8685984	Sep 04, 2032		U-1637		
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030		U-1687		
	9044480	Apr 10, 2031		U-1638		
DEFERASIROX - EXJADE						
N 021882 001					ODE	Jan 23, 2020
DEFERASIROX - EXJADE						
N 021882 002					ODE	Jan 23, 2020
DEFERASIROX - EXJADE						
N 021882 003					ODE	Jan 23, 2020
DEFERASIROX - JADENU						
N 206910 001	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS	U-735		
DEFERASIROX - JADENU						
N 206910 002	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS	U-735		
DEFERASIROX - JADENU						
N 206910 003	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS	U-735		
DEOXYCHOLIC ACID - KYBELLA						
N 206333 001	7622130	Dec 10, 2027		U-1690		
	7754230	Dec 10, 2027		U-1690		
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025		U-1690		
	8367649	Mar 02, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEOXYCHOLIC ACID - KYBELLA						
N 206333 001	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP		U-1690	
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025			U-1690	
	8883770	Feb 21, 2028	DP			
DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE						
A 200653 001					PC	May 16, 2015
DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE						
A 200653 002					PC	May 16, 2015
DESONIDE - VERDESO						
N 021978 001	8962000	Aug 31, 2025	DP		U-1412	
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 003	6673838	Mar 01, 2022	DS		U-860	
	6673838	Mar 01, 2022	DS		U-1364	
	8269040	Jul 05, 2027	DS			
DEXAMETHASONE - OZURDEX						
N 022315 001	8043628	Oct 20, 2020			U-1205	
	8088407	Oct 20, 2020			U-1205	
	9012437	Oct 20, 2020			U-1205	
DEXLANSOPRAZOLE - DEXILANT						
N 022287 001	9011926	Feb 24, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 002	8784885	Oct 15, 2023	DP		U-1552	
	8784885	Oct 15, 2023	DP		U-1553	
	8784885	Oct 15, 2023	DP		U-1554	
	8784885*PED	Apr 15, 2024				
	9011926	Feb 24, 2026	DP			
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 004	6716867	Mar 31, 2019			U-1472	
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032			U-421	
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE						
A 078908 002					PC	Aug 01, 2015
DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE						
A 078908 003					PC	Dec 19, 2015
DICLOFENAC - ZORVOLEX						
N 204592 001	8999387	Apr 23, 2030			U-55	
	9017721	Apr 23, 2030	DP			
DICLOFENAC - ZORVOLEX						
N 204592 002	8999387	Apr 23, 2030			U-55	
	9017721	Apr 23, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DICLOFENAC POTASSIUM - CAMBIA							
N 022165 001		8927604	Jun 16, 2026	U-436			
DICLOFENAC SODIUM - DYLOJECT							
N 022396 001		6407079	Jun 18, 2019	DP			
		8946292	Mar 22, 2027	U-1659			
DICLOFENAC SODIUM - PENNSAID							
N 204623 001		9066913	Oct 17, 2027	DP U-1488			
	>A>	9101591	Oct 17, 2027	DP U-1488			
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439 001		5061703	Apr 11, 2015	U-1641			
		5061703*PED	Oct 11, 2015				
		8058291	Dec 05, 2029	U-1641			
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025	U-1641			
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025	U-1641			
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439 002		5061703	Apr 11, 2015	U-1641			
		5061703*PED	Oct 11, 2015				
		8039009	Mar 24, 2029	U-1641			
		8039009*PED	Sep 24, 2029				
		8058291	Dec 05, 2029	U-1641			
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025	U-1641			
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025	U-1641			
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8338485	Nov 22, 2025	DP			
		8338486	Nov 22, 2025	U-1641			
		8362085	Nov 22, 2025	U-1641			
		8362085*PED	May 22, 2026				
		8580858	Nov 22, 2025	U-1641			
		8598233	Nov 22, 2025	DP			
		8598233*PED	May 22, 2026				
DOXYCYCLINE HYCLATE - DOXTERIC							
N 050795 006		6958161	Dec 15, 2022	DP U-918			
		8715724	Feb 03, 2028	DP			
DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE							
A 090694 003						>A> PC	Jan 11, 2016
EDOXABAN TOSYLATE - SAVAYSA							
N 206316 001		7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
EDOXABAN TOSYLATE - SAVAYSA							
N 206316 002		7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
EDOXABAN TOSYLATE - SAVAYSA							
N 206316 003		7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA							
N 021937 001		9018192	Jun 13, 2026	U-750			
		9018192	Jun 13, 2026	U-1170			
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291 001	>A>	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	>A>	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	>A>	6280959	Oct 30, 2018	DS DP U-1575			
	>A>	6280959	Oct 30, 2018	DS DP U-1714			
		7160870	Nov 20, 2022	DS DP U-930			
		7160870	Nov 20, 2022	DS DP U-1306			
		7160870	Nov 20, 2022	DS DP U-1575			
		7160870	Nov 20, 2022	DS DP U-1714			
	>A>	7332481	May 24, 2021	U-930			
	>A>	7332481	May 24, 2021	U-1306			
	>A>	7332481	May 24, 2021	U-1575			
	>A>	7332481	May 24, 2021	U-1714			
		7473686	May 24, 2021	DS DP U-930			
		7473686	May 24, 2021	DS DP U-1306			
		7473686	May 24, 2021	DS DP U-1575			
		7473686	May 24, 2021	DS DP U-1714			
		7547719	Jul 13, 2025	DS DP U-930			
		7547719	Jul 13, 2025	DS DP U-1306			
		7547719	Jul 13, 2025	DS DP U-1575			
		7547719	Jul 13, 2025	DS DP U-1714			
		7790704	May 24, 2021	U-930			
		7790704	May 24, 2021	U-1306			
		7790704	May 24, 2021	U-1575			
		7790704	May 24, 2021	U-1714			
		7795293	May 21, 2023	U-930			
		7795293	May 21, 2023	U-1306			
		7795293	May 21, 2023	U-1575			
		7795293	May 21, 2023	U-1714			
		8052993	Aug 01, 2027	DP U-930			
		8052993	Aug 01, 2027	DP U-1306			
		8052993	Aug 01, 2027	DP U-1575			
		8052993	Aug 01, 2027	DP U-1714			
		8052994	Aug 01, 2027	DP U-1714			
		8062665	Aug 01, 2027	DP U-1714			
		8071129	Aug 01, 2027	DP U-1714			
		8828430	Aug 01, 2027	DP U-1306			
		8828430	Aug 01, 2027	DP U-1619			
		8828430	Aug 01, 2027	DP U-1714			
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291 002	>A>	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	>A>	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	>A>	6280959	Oct 30, 2018	DS DP U-1575			
	>A>	6280959	Oct 30, 2018	DS DP U-1714			
		7160870	Nov 20, 2022	DS DP U-930			
		7160870	Nov 20, 2022	DS DP U-1306			
		7160870	Nov 20, 2022	DS DP U-1575			
		7160870	Nov 20, 2022	DS DP U-1714			
	>A>	7332481	May 24, 2021	U-930			
	>A>	7332481	May 24, 2021	U-1306			
	>A>	7332481	May 24, 2021	U-1575			
	>A>	7332481	May 24, 2021	U-1714			
		7473686	May 24, 2021	DS DP U-930			
		7473686	May 24, 2021	DS DP U-1306			
		7473686	May 24, 2021	DS DP U-1575			
		7473686	May 24, 2021	DS DP U-1714			
		7547719	Jul 13, 2025	DS DP U-930			
		7547719	Jul 13, 2025	DS DP U-1306			
		7547719	Jul 13, 2025	DS DP U-1575			
		7547719	Jul 13, 2025	DS DP U-1714			
		7790704	May 24, 2021	U-930			
		7790704	May 24, 2021	U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291 002		7790704	May 24, 2021	U-1575			
		7790704	May 24, 2021	U-1714			
		7795293	May 21, 2023	U-930			
		7795293	May 21, 2023	U-1306			
		7795293	May 21, 2023	U-1575			
		7795293	May 21, 2023	U-1714			
		8052993	Aug 01, 2027	DP U-1714			
		8052994	Aug 01, 2027	DP U-930			
		8052994	Aug 01, 2027	DP U-1306			
		8052994	Aug 01, 2027	DP U-1575			
		8052994	Aug 01, 2027	DP U-1714			
		8062665	Aug 01, 2027	DP U-1714			
		8071129	Aug 01, 2027	DP U-1714			
		8828430	Aug 01, 2027	DP U-1306			
		8828430	Aug 01, 2027	DP U-1619			
		8828430	Aug 01, 2027	DP U-1714			
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291 003	>A>	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	>A>	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	>A>	6280959	Oct 30, 2018	DS DP U-1575			
	>A>	6280959	Oct 30, 2018	DS DP U-1714			
		7160870	Nov 20, 2022	DS DP U-930			
		7160870	Nov 20, 2022	DS DP U-1306			
		7160870	Nov 20, 2022	DS DP U-1575			
		7160870	Nov 20, 2022	DS DP U-1714			
	>A>	7332481	May 24, 2021	U-930			
	>A>	7332481	May 24, 2021	U-1306			
	>A>	7332481	May 24, 2021	U-1575			
	>A>	7332481	May 24, 2021	U-1714			
		7473686	May 24, 2021	DS DP U-930			
		7473686	May 24, 2021	DS DP U-1306			
		7473686	May 24, 2021	DS DP U-1575			
		7473686	May 24, 2021	DS DP U-1714			
		7547719	Jul 13, 2025	DS DP U-930			
		7547719	Jul 13, 2025	DS DP U-1306			
		7547719	Jul 13, 2025	DS DP U-1575			
		7547719	Jul 13, 2025	DS DP U-1714			
		7790704	May 24, 2021	U-930			
		7790704	May 24, 2021	U-1306			
		7790704	May 24, 2021	U-1575			
		7790704	May 24, 2021	U-1714			
		7795293	May 21, 2023	U-930			
		7795293	May 21, 2023	U-1306			
		7795293	May 21, 2023	U-1575			
		7795293	May 21, 2023	U-1714			
		8052993	Aug 01, 2027	DP U-1714			
		8052994	Aug 01, 2027	DP U-1714			
		8062665	Aug 01, 2027	DP U-714			
		8062665	Aug 01, 2027	DP U-930			
		8062665	Aug 01, 2027	DP U-1306			
		8062665	Aug 01, 2027	DP U-1575			
		8071129	Aug 01, 2027	DP U-1714			
		8828430	Aug 01, 2027	DP U-1306			
		8828430	Aug 01, 2027	DP U-1619			
		8828430	Aug 01, 2027	DP U-1714			
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291 004	>A>	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	>A>	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	>A>	6280959	Oct 30, 2018	DS DP U-1575			
	>A>	6280959	Oct 30, 2018	DS DP U-1714			
		7160870	Nov 20, 2022	DS DP U-930			
		7160870	Nov 20, 2022	DS DP U-1306			
		7160870	Nov 20, 2022	DS DP U-1575			
		7160870	Nov 20, 2022	DS DP U-1714			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291 004	>A>	7332481	May 24, 2021	U-930			
	>A>	7332481	May 24, 2021	U-1306			
	>A>	7332481	May 24, 2021	U-1575			
	>A>	7332481	May 24, 2021	U-1714			
		7473686	May 24, 2021	DS DP U-930			
		7473686	May 24, 2021	DS DP U-1306			
		7473686	May 24, 2021	DS DP U-1575			
		7473686	May 24, 2021	DS DP U-1714			
		7547719	Jul 13, 2025	DS DP U-930			
		7547719	Jul 13, 2025	DS DP U-1306			
		7547719	Jul 13, 2025	DS DP U-1575			
		7547719	Jul 13, 2025	DS DP U-1714			
		7790704	May 24, 2021	U-930			
		7790704	May 24, 2021	U-1306			
		7790704	May 24, 2021	U-1575			
		7790704	May 24, 2021	U-1714			
		7795293	May 21, 2023	U-930			
		7795293	May 21, 2023	U-1306			
		7795293	May 21, 2023	U-1575			
		7795293	May 21, 2023	U-1714			
		8052993	Aug 01, 2027	DP U-1714			
		8052994	Aug 01, 2027	DP U-1714			
		8062665	Aug 01, 2027	DP U-1714			
		8071129	Aug 01, 2027	DP U-930			
		8071129	Aug 01, 2027	DP U-1306			
		8071129	Aug 01, 2027	DP U-1575			
		8071129	Aug 01, 2027	DP U-1714			
		8828430	Aug 01, 2027	DP U-1306			
		8828430	Aug 01, 2027	DP U-1619			
		8828430	Aug 01, 2027	DP U-1714			
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291 005						D-149	Jun 11, 2018
						I-711	Jun 11, 2018
ELUXADOLINE - VIBERZI							
N 206940 001		7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
		7786158	Mar 14, 2025	DS			
		8344011	Mar 14, 2025	U-1709			
		8609709	Mar 14, 2025	DS			
		8691860	Jul 07, 2028	DS U-1709			
ELUXADOLINE - VIBERZI							
N 206940 002		7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
		7786158	Mar 14, 2025	DS			
		8344011	Mar 14, 2025	U-1709			
		8609709	Mar 14, 2025	DS			
		8691860	Jul 07, 2028	DS U-1709			
ELVITEGRAVIR - VITEKTA							
N 203093 001		8981103	Oct 26, 2026	DS DP			
ELVITEGRAVIR - VITEKTA							
N 203093 002		8981103	Oct 26, 2026	DS DP			
EMPAGLIFLOZIN - JARDIANCE							
N 204629 001						M-160	Jun 26, 2018
						M-161	Jun 26, 2018
EMPAGLIFLOZIN - JARDIANCE							
N 204629 002						M-160	Jun 26, 2018
						M-161	Jun 26, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 001	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 002	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2024	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
EPINEPHRINE - AUVI-Q						
N 201739 001	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
>A>	9056170	Nov 23, 2024	DP			
EPINEPHRINE - AUVI-Q						
N 201739 002	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
>A>	9056170	Nov 23, 2024	DP			
ERIBULIN MESYLATE - HALAVEN						
N 201532 001	6214865	Jul 20, 2023	DS			
ERLOTINIB HYDROCHLORIDE - TARCEVA						
N 021743 001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
ERLOTINIB HYDROCHLORIDE - TARCEVA						
N 021743 002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ERLOTINIB HYDROCHLORIDE - TARCEVA						
N 021743 002	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
ERLOTINIB HYDROCHLORIDE - TARCEVA						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR						
N 204655 001	5690960	Nov 25, 2014	DP U-1509			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1509			
	5714504*PED	Aug 03, 2015				
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1509			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1509			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810*PED	May 03, 2020				
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO						
N 022511 001	8945621	Oct 17, 2031	U-1661			
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO						
N 022511 002	8945621	Oct 17, 2031	U-1661			
ESTRADIOL - MINIVELLE						
N 203752 005	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
EVEROLIMUS - AFINITOR						
N 022334 001	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR						
N 022334 002	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EVEROLIMUS - AFINITOR							
N 022334 003		8410131	Nov 01, 2025	DS DP U-1368			
		8410131*PED	May 01, 2026				
		9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR							
N 022334 004		8410131	Nov 01, 2025	DS DP U-1368			
		8410131*PED	May 01, 2026				
		9006224	Jul 01, 2028	U-1681			
FENTANYL CITRATE - LAZANDA							
N 022569 001	>A>	9078814	Jan 08, 2024	DP			
FENTANYL CITRATE - LAZANDA							
N 022569 002	>A>	9078814	Jan 08, 2024	DP			
FENTANYL HYDROCHLORIDE - IONSYS							
N 021338 001		6169920	Jan 02, 2018	DP U-736			
		6181963	Nov 02, 2019	DP			
		8301238	Sep 30, 2031	DP			
		8428708	May 21, 2032	U-736			
		8428709	Jun 11, 2032	DP U-736			
		8781571	Mar 31, 2032	DP U-736			
	>A>	9095706	Jan 17, 2033	DP			
FERRIC CITRATE - AURYXIA							
N 205874 001		8901349	Feb 18, 2024	U-1577			
		9050316	Feb 18, 2024	U-1577			
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC							
N 206317 001		6689275	Dec 31, 2016	U-1656			
		6779468	Dec 31, 2016	U-1656			
		7816404	Apr 17, 2029	DP U-1656			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY							
N 201373 001		8933097	Aug 16, 2032	DP			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES							
N 201373 002		8933097	Aug 16, 2032	DP			
FINAFLOXACIN - XTORO							
N 206307 001		6133260	Apr 12, 2017	DS DP			
		6432948	Apr 12, 2017	DS DP			
		8536167	Aug 08, 2031	U-1679			
FLUTEMETAMOL F-18 - VIZAMYL							
N 203137 001		8916131	Sep 16, 2028	DP			
FLUTEMETAMOL F-18 - VIZAMYL							
N 203137 002		8916131	Sep 16, 2028	DP			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA							
N 204275 001		6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
		6537983	Aug 03, 2021	DP U-1691			
		6759398	Aug 03, 2021	DP U-1401			
		6759398	Aug 03, 2021	DP U-1691			
		7101866	Aug 03, 2021	DS DP U-1401			
		7101866	Aug 03, 2021	DS DP U-1691			
		7439393	Sep 11, 2022	DS DP U-1401			
		7439393	Sep 11, 2022	DS DP U-1691			
		8511304	Jun 14, 2027	DP U-1424			
		8511304	Jun 14, 2027	DP U-1691			
		RE44874	Mar 23, 2023	DS DP U-1548			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA							
N 204275 001		RE44874	Mar 23, 2023	DS DP U-1691			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA							
N 204275 002		5873360	Feb 23, 2016	DP		NP	Apr 30, 2018
		6537983	Aug 03, 2021	DP U-1691			
		6759398	Aug 03, 2021	DP U-1691			
		7101866	Aug 03, 2021	DS DP U-1691			
		7439393	Sep 11, 2022	DS DP U-1691			
		7629335	Aug 03, 2021	DP			
		7776895	Sep 11, 2022	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8511304	Jun 14, 2027	DP U-1691			
		8534281	Aug 10, 2029	DP			
		8746242	Oct 11, 2030	DP			
		RE44874	Mar 23, 2023	DS DP U-1691			
FLUTICASONE PROPIONATE - CUTIVATE							
N 021152 001						NPP	Jan 16, 2018
GADOXETATE DISODIUM - EOVIST							
N 022090 001						M-155	Mar 27, 2018
GADOXETATE DISODIUM - EOVIST							
N 022090 002						M-155	Mar 27, 2018
GEFITINIB - IRESSA							
N 206995 001	>A>	5770599	May 05, 2017	DS DP U-1403	>A>	NP	Jul 13, 2018
GLATIRAMER ACETATE - COPAXONE							
N 020622 003		8969302	Aug 19, 2030	U-441			
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE							
A 200881 001						PC	May 30, 2015
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE							
A 200881 002						PC	May 30, 2015
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE							
A 200881 003						PC	May 30, 2015
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE							
A 200881 004						PC	May 30, 2015
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037 001						M-154	Mar 18, 2018
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037 002						M-154	Mar 18, 2018
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037 003						M-154	Mar 18, 2018
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037 004						M-154	Mar 18, 2018
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627 001		9023401	Oct 30, 2021	DP			
		9056052	Oct 30, 2021	DP			
	>A>	9060940	Oct 30, 2021	U-1556			
	>A>	9084816	Aug 24, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627 001	>A>	9095614	Aug 24, 2027	U-1556			
	>A>	9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627 002		9023401	Oct 30, 2021	DP			
		9056052	Oct 30, 2021	DP			
	>A>	9060940	Oct 30, 2021	U-1556			
	>A>	9084816	Aug 24, 2027	DP			
	>A>	9095614	Aug 24, 2027	U-1556			
	>A>	9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627 003		9023401	Oct 30, 2021	DP			
		9056052	Oct 30, 2021	DP			
	>A>	9060940	Oct 30, 2021	U-1556			
	>A>	9084816	Aug 24, 2027	DP			
	>A>	9095614	Aug 24, 2027	U-1556			
	>A>	9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627 004		9023401	Oct 30, 2021	DP			
		9056052	Oct 30, 2021	DP			
	>A>	9060940	Oct 30, 2021	U-1556			
	>A>	9084816	Aug 24, 2027	DP			
	>A>	9095614	Aug 24, 2027	U-1556			
	>A>	9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627 005		9056052	Oct 30, 2021	DP			
	>A>	9060940	Oct 30, 2021	U-1556			
	>A>	9084816	Aug 24, 2027	DP			
	>A>	9095614	Aug 24, 2027	U-1556			
	>A>	9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627 006		9056052	Oct 30, 2021	DP			
	>A>	9060940	Oct 30, 2021	U-1556			
	>A>	9084816	Aug 24, 2027	DP			
	>A>	9095614	Aug 24, 2027	U-1556			
	>A>	9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627 007		9056052	Oct 30, 2021	DP			
	>A>	9060940	Oct 30, 2021	U-1556			
	>A>	9084816	Aug 24, 2027	DP			
	>A>	9095614	Aug 24, 2027	U-1556			
	>A>	9095615	Aug 24, 2027	DP			
IBRUTINIB - IMBRUVICA							
N 205552 001		8497277	Dec 28, 2026	U-1456		I-702	Jan 29, 2018
		8497277	Dec 28, 2026	U-1491		ODE	Jan 29, 2022
		8497277	Dec 28, 2026	U-1650			
		8957079	Dec 28, 2026	DS DP			
		8999999	Jun 03, 2031	U-1683			
		8999999	Jun 03, 2031	U-1684			
IBUPROFEN - CALDOLOR							
N 022348 002		8871810	Sep 30, 2029	U-1599			
		9012508	Sep 14, 2030	U-981			
ICATIBANT ACETATE - FIRAZYR							
N 022150 001		5648333	Jul 15, 2019	DS DP U-1187			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IDELALISIB - ZYDELIG							
N 205858 001		8138195	Apr 24, 2021	DS DP U-1549			
		8865730	Mar 05, 2033	DS DP U-1615			
		8980901	May 12, 2025	U-1678			
		RE44599	Jul 21, 2025	U-1558			
		RE44599	Jul 21, 2025	U-1615			
IDELALISIB - ZYDELIG							
N 205858 002		8138195	Apr 24, 2021	DS DP U-1549			
		8865730	Mar 05, 2033	DS DP U-1615			
		8980901	May 12, 2025	U-1678			
		RE44599	Jul 21, 2025	U-1558			
		RE44599	Jul 21, 2025	U-1615			
ILOPERIDONE - FANAPT							
N 022192 001		8652776	Aug 31, 2030	U-1685			
		8999638	Oct 28, 2030	U-1674			
	>A>	9072742	Jan 16, 2031	U-1674			
	>A>	9074254	Dec 28, 2031	U-1674			
	>A>	9074255	Dec 17, 2030	U-1674			
	>A>	9074256	Feb 10, 2031	U-1674			
ILOPERIDONE - FANAPT							
N 022192 002		8652776	Aug 31, 2030	U-1685			
		8999638	Oct 28, 2030	U-1674			
	>A>	9072742	Jan 16, 2031	U-1674			
	>A>	9074254	Dec 28, 2031	U-1674			
	>A>	9074255	Dec 17, 2030	U-1674			
	>A>	9074256	Feb 10, 2031	U-1674			
ILOPERIDONE - FANAPT							
N 022192 003		8652776	Aug 31, 2030	U-1685			
		8999638	Oct 28, 2030	U-1674			
	>A>	9072742	Jan 16, 2031	U-1674			
	>A>	9074254	Dec 28, 2031	U-1674			
	>A>	9074255	Dec 17, 2030	U-1674			
	>A>	9074256	Feb 10, 2031	U-1674			
ILOPERIDONE - FANAPT							
N 022192 004		8652776	Aug 31, 2030	U-1685			
		8999638	Oct 28, 2030	U-1674			
	>A>	9072742	Jan 16, 2031	U-1674			
	>A>	9074254	Dec 28, 2031	U-1674			
	>A>	9074255	Dec 17, 2030	U-1674			
	>A>	9074256	Feb 10, 2031	U-1674			
ILOPERIDONE - FANAPT							
N 022192 005		8652776	Aug 31, 2030	U-1685			
		8999638	Oct 28, 2030	U-1674			
	>A>	9072742	Jan 16, 2031	U-1674			
	>A>	9074254	Dec 28, 2031	U-1674			
	>A>	9074255	Dec 17, 2030	U-1674			
	>A>	9074256	Feb 10, 2031	U-1674			
ILOPERIDONE - FANAPT							
N 022192 006		8652776	Aug 31, 2030	U-1685			
		8999638	Oct 28, 2030	U-1674			
	>A>	9072742	Jan 16, 2031	U-1674			
	>A>	9074254	Dec 28, 2031	U-1674			
	>A>	9074255	Dec 17, 2030	U-1674			
	>A>	9074256	Feb 10, 2031	U-1674			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ILOPERIDONE - FANAPT							
N 022192 007		8652776	Aug 31, 2030	U-1685			
		8999638	Oct 28, 2030	U-1674			
	>A>	9072742	Jan 16, 2031	U-1674			
	>A>	9074254	Dec 28, 2031	U-1674			
	>A>	9074255	Dec 17, 2030	U-1674			
	>A>	9074256	Feb 10, 2031	U-1674			
INDACATEROL MALEATE - ARCAPTA NEOHALER							
N 022383 001	>A>	8658673	Jun 02, 2020	DS DP U-1168			
INDOMETHACIN - TIVORBEX							
N 204768 001		8992982	Apr 23, 2030	DP			
	>A>	9089471	Apr 23, 2030	U-55			
INDOMETHACIN - TIVORBEX							
N 204768 002		8992982	Apr 23, 2030	DP			
	>A>	9089471	Apr 23, 2030	U-55			
INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH							
N 020986 005		8920383	Jul 17, 2026	DP			
INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH							
N 021536 005		8920383	Jul 17, 2026	DP			
INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR							
N 021081 002		8992486	Jun 05, 2024	DP			
		9011391	Mar 26, 2024	DP			
INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR							
N 206538 001		7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
		7918833*PED	Mar 23, 2028				
		8512297	Sep 15, 2024	DP			
		8556864	Mar 03, 2024	DP			
		8603044	Mar 02, 2024	DP			
		8679069	Apr 12, 2025	DP			
		8992486	Jun 05, 2024	DP			
		9011391	Mar 26, 2024	DP			
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR							
N 021629 003		8992486	Jun 05, 2024	DP			
		9011391	Mar 26, 2024	DP			
INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN							
N 205747 001		6034054	Jun 11, 2018	DP U-1707			
		6034054	Jun 11, 2018	DP U-1708			
		6551992	Jun 11, 2018	DP U-1707			
		6551992	Jun 11, 2018	DP U-1708			
		7291132	Aug 09, 2024	DP			
INSULIN RECOMBINANT HUMAN - AFREZZA							
N 022472 003		6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
		6652885	Jun 29, 2020	U-1535			
		7305986	Jan 16, 2023	DP			
		7464706	Mar 02, 2023	DP			
		7648960	Jun 29, 2020	U-1535			
		7943178	Jun 29, 2020	DP U-1535			
		7943572	Aug 10, 2026	U-1539			
		8119593	Aug 11, 2029	U-1537			
		8146588	Apr 24, 2023	DP			
		8156936	Jan 16, 2023	DP			
		8215300	Nov 24, 2022	DP			
		8258095	Aug 11, 2029	U-1537			
		8389470	Jun 29, 2020	DP U-1697			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN RECOMBINANT HUMAN - AFREZZA						
N 022472 003	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
IPRATROPIUM BROMIDE - ATROVENT HFA						
N 021527 001	8474447	Jan 17, 2030	DP			
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
ISOTRETINOIN - ABSORICA						
N 021951 001	8952064	Sep 21, 2021	DP			
	>A> 9078925	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 002	8952064	Sep 21, 2021	DP			
	>A> 9078925	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 003	8952064	Sep 21, 2021	DP			
	>A> 9078925	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 004	8952064	Sep 21, 2021	DP			
	>A> 9078925	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	>A> 9078925	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	>A> 9078925	Sep 21, 2021	DP			
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 001	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVABRADINE HYDROCHLORIDE - CORLANOR							
N 206143 002		7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
		7361650	Apr 14, 2026	DS DP U-1694			
		7867996	Feb 22, 2026	DS DP U-1694			
		7879842	Feb 22, 2026	DS DP U-1694			
IVACAFTOR - KALYDECO							
N 203188 001		8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
IVACAFTOR - KALYDECO							
N 207925 001		7495103	May 20, 2027	DS DP			
		8324242	Apr 18, 2027	U-1311			
		8354427	Jul 06, 2026	U-1311			
		8410274	Dec 28, 2026	DP			
		8754224	Dec 28, 2026	DS DP			
		8883206	Feb 27, 2033	DP			
IVACAFTOR - KALYDECO							
N 207925 002		7495103	May 20, 2027	DS DP			
		8324242	Apr 18, 2027	U-1311			
		8354427	Jul 06, 2026	U-1311			
		8410274	Dec 28, 2026	DP			
		8754224	Dec 28, 2026	DS DP			
		8883206	Feb 27, 2033	DP			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038 001	>A>	7495103	May 20, 2027	DS DP		>A> NCE	Jul 02, 2020
	>A>	8324242	Apr 18, 2027	U-1311		>A> ODE	Jul 02, 2022
	>A>	8410274	Dec 28, 2026	DP			
	>A>	8507534	Sep 20, 2030	DS DP			
	>A>	8653103	Dec 04, 2028	DP			
	>A>	8716338	Nov 08, 2026	DP U-1718			
	>A>	8741933	Nov 08, 2026	U-1717			
	>A>	8754224	Dec 28, 2026	DS DP			
	>A>	8846718	Dec 04, 2028	U-1717			
	>A>	8993600	Dec 11, 2030	DP			
IVERMECTIN - SOOLANTRA							
N 206255 001		5952372	Sep 18, 2018	U-1631			
		6133310	Apr 26, 2019	U-1631			
		7550440	Apr 22, 2024	DP U-1631			
		8080530	Apr 22, 2024	DP U-1631			
		8093219	Apr 22, 2024	DP U-1631			
		8415311	Apr 22, 2024	DP U-1631			
		8470788	Apr 22, 2024	DP U-1631			
		8815816	Apr 22, 2024	DP U-1631			
	>A>	9089587	Mar 13, 2034	U-1631			
KETOROLAC TROMETHAMINE - ACULAR LS							
N 021528 001		8946281	May 28, 2024	U-1662			
KETOROLAC TROMETHAMINE - ACUVAIL							
N 022427 001		8992952	Aug 05, 2024	DP			
KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA							
N 205388 001		9066856	Oct 23, 2033	DP			
LAMIVUDINE - LAMIVUDINE							
A 203564 001						PC	Sep 01, 2015
LAMIVUDINE - EPIVIR							
N 020564 001		5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
		5905082*PED	Nov 18, 2016				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAMIVUDINE - EPIVIR						
N 020564 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
LAMIVUDINE - EPIVIR						
N 020564 003	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
LAMIVUDINE - EPIVIR						
N 020596 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	6004968	Mar 20, 2018	DP U-248			
	6004968*PED	Sep 20, 2018				
LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-1663			
	7435734	Oct 21, 2022	U-1663			
	7754731	Mar 11, 2029	DS DP U-1663			
	7820660	Apr 25, 2023	DS			
LAMOTRIGINE - LAMOTRIGINE						
A 200828 001					PC	Sep 28, 2015
LAMOTRIGINE - LAMOTRIGINE						
A 200828 002					PC	Sep 28, 2015
LAMOTRIGINE - LAMOTRIGINE						
A 200828 003					PC	Sep 28, 2015
LAMOTRIGINE - LAMOTRIGINE						
A 200828 004					PC	Sep 28, 2015
LAMOTRIGINE - LAMICTAL						
N 020241 001					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 002					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 003					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 004					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 005					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 006					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 001					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 002					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 003					M-159	May 18, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAMOTRIGINE - LAMICTAL CD						
N 020764 004					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 001					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 002					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 003					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 004					M-159	May 18, 2018
LANTHANUM CARBONATE - FOSRENOL						
N 204734 001	8980327	Dec 01, 2030	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 204734 002	8980327	Dec 01, 2030	DP			
LAPATINIB DITOSYLATE - TYKERB						
N 022059 001	8821927	Sep 18, 2029	DS DP			
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 001 >A>	9085573	Mar 21, 2028	DS DP U-1470			
LENALIDOMIDE - REVLIMID						
N 021880 001	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
					ODE	Feb 17, 2022
LENALIDOMIDE - REVLIMID						
N 021880 002	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
					ODE	Feb 17, 2022
LENALIDOMIDE - REVLIMID						
N 021880 003	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
					ODE	Feb 17, 2022
LENALIDOMIDE - REVLIMID						
N 021880 004	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
					ODE	Feb 17, 2022
LENALIDOMIDE - REVLIMID						
N 021880 005	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
					ODE	Feb 17, 2022
LENALIDOMIDE - REVLIMID						
N 021880 006	5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
	9056120	Apr 11, 2023	U-1215		ODE	Feb 17, 2022
LENVATINIB MESYLATE - LENVIMA						
N 206947 001	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			
LENVATINIB MESYLATE - LENVIMA						
N 206947 002	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEUPROLIDE ACETATE - LUPRON DEPOT						
N 020517 003	7429559	Jan 13, 2019	DP			
	8815801	Jun 28, 2022	DP			
	8921326	Feb 05, 2031	DP U-1666			
LEVALBUTEROL HYDROCHLORIDE - XOPENEX						
N 020837 001					M-151	Jan 22, 2018
LEVALBUTEROL HYDROCHLORIDE - XOPENEX						
N 020837 002					M-151	Jan 22, 2018
LEVALBUTEROL HYDROCHLORIDE - XOPENEX						
N 020837 003					M-151	Jan 22, 2018
LEVALBUTEROL HYDROCHLORIDE - XOPENEX						
N 020837 004					M-151	Jan 22, 2018
LEVALBUTEROL TARTRATE - XOPENEX HFA						
N 021730 001					M-156	Mar 12, 2018
LEVETIRACETAM - ELEPSIA XR						
N 204417 001	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Jun 30, 2024	DP			
	8535717	Feb 22, 2026	DP			
LEVETIRACETAM - ELEPSIA XR						
N 204417 002	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Jun 30, 2024	DP			
	8535717	Feb 22, 2026	DP			
LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM						
A 203563 001					PC	Oct 20, 2015
LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM						
A 203563 002					PC	Oct 20, 2015
LEVONORGESTREL - LILETTA						
N 206229 001					NP	Feb 26, 2018
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 001	9006289	Oct 03, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 002	9006289	Oct 03, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 003	9006289	Oct 03, 2032	DP			
LINACLOTIDE - LINZESS						
N 202811 001	8933030	Feb 17, 2031	DP			
LINACLOTIDE - LINZESS						
N 202811 002	8933030	Feb 17, 2031	DP			
LINAGLIPTIN - TRADJENTA						
N 201280 001	8673927	May 04, 2027	U-1503			
	8853156	Mar 05, 2031	U-1642			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINAGLIPTIN - TRADJENTA						
N 201280 001	8673927	May 04, 2027	U-1503			
	8853156	Mar 05, 2031	U-1642			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 001	8673927	May 04, 2027	U-1503			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 002	8673927	May 04, 2027	U-1503			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 003	8673927	May 04, 2027	U-1503			
LINEZOLID - LINEZOLID						
A 078061 001					PC	Dec 19, 2015
LINEZOLID - LINEZOLID						
A 200222 001					PC	Jul 04, 2015
LINEZOLID - ZYVOX						
N 021131 002	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
LINEZOLID - ZYVOX						
N 021131 003	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
LIRAGLUTIDE RECOMBINANT - VICTOZA						
N 022341 001	8846618	Jun 27, 2022	DP			
LIRAGLUTIDE RECOMBINANT - SAXENDA						
N 206321 001	6268343	Aug 22, 2022	DS DP U-1255			
	6458924	Aug 22, 2017	DS DP U-1255			
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 2026	DP			
	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 001					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 002					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 003					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 004					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 005					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 006					I-703	Jan 30, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 007					I-703	Jan 30, 2018
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 001	5712279	Feb 21, 2016	DS U-1317			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 002	5712279	Feb 21, 2016	DS U-1317			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 003	5712279	Feb 21, 2016	DS U-1317			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 004	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 005	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 006	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
LORATADINE - CLARITIN						
N 020641 002	6132758	Jun 01, 2018	DP			
LORCASERIN HYDROCHLORIDE - BELVIQ						
N 022529 001	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
LOXAPINE - ADASUVE						
N 022549 001	8955512	Oct 26, 2021	DP			
	8991387	May 21, 2024	DP			
LULICONAZOLE - LUZU						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 001	RE45573	Jun 23, 2025	DS			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 002	RE45573	Jun 23, 2025	DS			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 003	RE45573	Jun 23, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603 004		RE45573	Jun 23, 2025	DS			
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603 005		RE45573	Jun 23, 2025	DS			
MEGESTROL ACETATE - MEGACE ES							
N 021778 001		9040088	Apr 22, 2024	U-755			
MESALAMINE - APRISO							
N 022301 001		8940328	Apr 20, 2018	DP			
		8956647	Apr 20, 2018	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR							
N 022024 001	>A>	9060941	Sep 19, 2023	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR							
N 022024 002	>A>	9060941	Sep 19, 2023	DP			
METHOTREXATE - OTREXUP							
N 204824 001		8945063	Mar 19, 2030	DP U-1442			
METHOTREXATE - OTREXUP							
N 204824 002		8945063	Mar 19, 2030	DP U-1442			
METHOTREXATE - OTREXUP							
N 204824 003		8945063	Mar 19, 2030	DP U-1442			
METHOTREXATE - OTREXUP							
N 204824 004		8945063	Mar 19, 2030	DP U-1442			
METHOTREXATE - OTREXUP							
N 204824 005		8945063	Mar 19, 2030	DP U-1442			
METHYLPHENIDATE - DAYTRANA							
N 021514 001		9034370	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA							
N 021514 002		9034370	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA							
N 021514 003		9034370	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA							
N 021514 004		9034370	Oct 07, 2025	DP			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121 001		9000038	Jul 31, 2017	U-666			
		9000038	Jul 31, 2017	U-1693			
		9000038*PED	Jan 31, 2018				
		9029416	Jul 31, 2017	DP U-666			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121 002		9000038	Jul 31, 2017	U-666			
		9000038	Jul 31, 2017	U-1693			
		9000038*PED	Jan 31, 2018				
		9029416	Jul 31, 2017	DP U-666			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121	003	9000038	Jul 31, 2017	U-666			
		9000038	Jul 31, 2017	U-1693			
		9000038*PED	Jan 31, 2018				
		9029416	Jul 31, 2017	DP U-666			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121	004	9000038	Jul 31, 2017	U-666			
		9000038	Jul 31, 2017	U-1693			
		9000038*PED	Jan 31, 2018				
		9029416	Jul 31, 2017	DP U-666			
METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR							
N 202100	001	8956649	Feb 15, 2031	DP U-1665			
		9040083	Feb 15, 2031	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831	001	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
		8580310	Apr 12, 2022	DP			
	>A>	9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831	002	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
		8580310	Apr 12, 2022	DP			
	>A>	9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831	003	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
		8580310	Apr 12, 2022	DP			
	>A>	9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831	004	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
		8580310	Apr 12, 2022	DP			
	>A>	9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831	005	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
		8580310	Apr 12, 2022	DP			
	>A>	9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831	006	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
		8580310	Apr 12, 2022	DP			
	>A>	9066869	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 007		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
		8580310	Apr 12, 2022	DP			
	>A>	9066869	Dec 16, 2019	DP			
METRONIDAZOLE - NUVESSA							
N 205223 001		7893097	Feb 19, 2028	DP			
		8658678	Jun 27, 2028	U-1682			
		8877792	Feb 02, 2028	DP			
		8946276	Jun 28, 2032	U-1664			
MIFEPRISTONE - KORLYM							
N 202107 001		8921348	Aug 27, 2028	U-1643			
MINOCYCLINE HYDROCHLORIDE - MINOCIN							
N 050444 001	>A>	9084802	May 12, 2031	U-282			
MINOCYCLINE HYDROCHLORIDE - ARESTIN							
N 050781 001		7699609	Mar 29, 2022	DP			
MINOXIDIL - WOMEN'S ROGAINE							
N 021812 002		6946120	Apr 20, 2019	DP U-702			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 001		9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 002		9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 003		9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 004		9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 005		9072781	Mar 12, 2034	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321 001		8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321 002		8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321 003		8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321 004		8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321 005		8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321 006		8623418	Nov 07, 2029	U-1640			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALOXEGOL OXALATE - MOVANTIK							
N 204760 001		7056500	Jun 29, 2024	DP U-1185			
		9012469	Apr 02, 2032	DS DP			
NALOXEGOL OXALATE - MOVANTIK							
N 204760 002		7056500	Jun 29, 2024	DP U-1185			
		9012469	Apr 02, 2032	DS DP			
NALOXONE HYDROCHLORIDE - EVZIO							
N 205787 001		8926594	Mar 31, 2026	DP			
		8939943	Feb 28, 2031	DP			
		9022022	Feb 28, 2031	DP			
		9056170	Nov 23, 2024	DP			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777 001		8969369	May 10, 2022	DP U-1556			
		9056051	May 10, 2022	DP U-1556			
	>A>	9073933	Mar 30, 2025	DS			
	>A>	9084729	May 10, 2022	DP U-1556			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777 002		8969369	May 10, 2022	DP U-1556			
		9056051	May 10, 2022	DP U-1556			
	>A>	9073933	Mar 30, 2025	DS			
	>A>	9084729	May 10, 2022	DP U-1556			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777 003		8969369	May 10, 2022	DP U-1556			
		9056051	May 10, 2022	DP U-1556			
	>A>	9073933	Mar 30, 2025	DS			
	>A>	9084729	May 10, 2022	DP U-1556			
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET							
N 021926 001		6060499	Aug 14, 2017	DP U-867			
		6060499*PED	Feb 14, 2018				
		6586458	Aug 14, 2017	DP U-867			
		6586458*PED	Feb 14, 2018				
		7332183	Oct 02, 2025	DP U-867			
		7332183*PED	Apr 02, 2026				
		8022095	Aug 14, 2017	DP U-867			
		8022095*PED	Feb 14, 2018				
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET							
N 021926 002	>A>	5872145	Aug 14, 2017	DP U-1719		NP	May 14, 2018
	>A>	5872145*PED	Feb 14, 2018			PED	Nov 14, 2018
	>A>	6060499	Aug 14, 2017	DP U-1719			
	>A>	6060499*PED	Feb 14, 2018				
	>A>	6586458	Aug 14, 2017	DP U-1719			
	>A>	6586458*PED	Feb 14, 2018				
	>A>	7332183	Oct 02, 2025	DP U-1719			
	>A>	7332183*PED	Apr 02, 2026				
NEPAFENAC - ILEVRO							
N 203491 001		8921337	Mar 31, 2032	DP			
NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO							
N 205718 001		8951969	Nov 18, 2030	DP			
NICOTINE - NICODERM CQ							
N 020165 004		8999379	Feb 13, 2020	U-1686			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NICOTINE - NICODERM CQ							
N 020165	005	8999379	Feb 13, 2020	U-1686			
NICOTINE - NICODERM CQ							
N 020165	006	8999379	Feb 13, 2020	U-1686			
NICOTINE POLACRILEX - NICORETTE							
N 022360	001	8940772	Apr 30, 2029	DP			
NICOTINE POLACRILEX - NICORETTE							
N 022360	002	8940772	Apr 30, 2029	DP			
NINTEDANIB ESYLATE - OFEV							
N 205832	001	7989474	Apr 06, 2024	U-1677			
NINTEDANIB ESYLATE - OFEV							
N 205832	002	7989474	Apr 06, 2024	U-1677			
OLAPARIB - LYNPARZA							
N 206162	001	7151102	Apr 29, 2022	DS DP		ODE	Dec 19, 2021
		7449464	Oct 11, 2024	DS DP			
		7981889	Oct 11, 2024	DS DP			
		8143241	Aug 12, 2027	U-1634			
		8247416	Sep 24, 2028	DS			
		8859562	Aug 04, 2031	U-1634			
		8912187	Mar 12, 2024	U-1634			
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT							
N 206756	001	5964416	Oct 04, 2016	DP		NC	May 21, 2018
		6149054	Dec 19, 2016	DP		NCE	Jul 31, 2019
		6176442	Oct 04, 2016	DP			
		6453795	Dec 05, 2016	DP			
		6726124	Oct 04, 2016	DP			
		6846413	Aug 28, 2018	DP			
		6977042	Aug 28, 2018	DP			
		6988496	Feb 23, 2020	DP			
		7056916	Dec 07, 2023	DS DP			
		7104470	Oct 04, 2016	DP			
		7220742	May 12, 2025	DS DP U-1703			
		7246615	May 31, 2016	DP			
		7284474	Aug 26, 2024	DP			
		7396341	Oct 10, 2026	DP			
		7491719	Nov 10, 2023	DS DP			
		7727984	Nov 10, 2023	DS			
		7786111	Nov 10, 2023	DP			
		7802568	Feb 26, 2019	DP			
		7837235	Mar 13, 2028	DP			
		7896264	May 26, 2025	DP			
		7988001	Aug 04, 2021	DP			
		8034809	May 12, 2025	U-1702			
		8044046	Nov 10, 2023	U-1702			
		8733341	Dec 16, 2029	DP			
		9027967	Mar 31, 2027	DP			
		RE39820	Jan 30, 2018	DS DP U-1702			
OLOPATADINE HYDROCHLORIDE - PAZEO							
N 206276	001	8791154	May 19, 2032	DP U-1680		NP	Jan 30, 2018
						PED	Jul 30, 2018
OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE							
N 207931	001	>A> 6037157	Jun 26, 2016	U-1635	>A>	NCE	Dec 19, 2019
		>A> 6037157*PED	Dec 26, 2016		>A>	NP	Jul 24, 2018
		>A> 6703403	Jun 26, 2016	U-1635			
		>A> 6703403*PED	Dec 26, 2016				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE							
N 207931	001	>A> 7148359	Jul 19, 2019	DP			
		>A> 7148359*PED	Jan 19, 2020				
		>A> 7364752	Nov 10, 2020	DP			
		>A> 7364752*PED	May 10, 2021				
		>A> 8268349	Aug 25, 2024	DP			
		>A> 8268349*PED	Feb 25, 2025				
		>A> 8399015	Aug 25, 2024	DP			
		>A> 8399015*PED	Feb 25, 2025				
		>A> 8420596	Apr 10, 2031	DS DP			
		>A> 8420596*PED	Oct 10, 2031				
		>A> 8642538	Sep 10, 2029	DS DP U-1638			
		>A> 8686026	Jun 09, 2031	DP			
		>A> 8691938	Apr 13, 2032	DS DP			
		>A> 9006387	Jun 10, 2030	U-1687			
		>A> 9044480	Apr 10, 2031	U-1638			
OMEGA-3-CARBOXYLIC ACIDS - EPANOVA							
N 205060	001	9012501	Feb 07, 2025	DP U-1511			
		9050308	Jan 04, 2033	U-1511			
		9050309	Jan 04, 2033	DS			
OMEPRAZOLE - OMEPRAZOLE							
N 022032	001	9023391	Aug 16, 2025	DP			
OSPEMIFENE - OSPHENA							
N 203505	001	8642079	Jul 09, 2028	DP			
OXYBUTYNIN CHLORIDE - GELNIQUE							
N 022204	001	8920392	Mar 26, 2031	U-1644			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	001	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
		>A> 9073933	Mar 30, 2025	DS			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	002	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
		>A> 9073933	Mar 30, 2025	DS			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	003	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
		>A> 9073933	Mar 30, 2025	DS			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	004	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
		>A> 9073933	Mar 30, 2025	DS			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	005	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
		>A> 9073933	Mar 30, 2025	DS			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	006	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
		>A> 9073933	Mar 30, 2025	DS			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	007	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
		>A> 9073933	Mar 30, 2025	DS			
PALBOCICLIB - IBRANCE							
N 207103	001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
		7208489	Jan 16, 2023	DS DP			
		7456168	Jan 16, 2023	U-1658			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALBOCICLIB - IBRANCE						
N 207103 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
PALBOCICLIB - IBRANCE						
N 207103 002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
PALBOCICLIB - IBRANCE						
N 207103 003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 001	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 002	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 003	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 004	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
PALONOSETRON HYDROCHLORIDE - ALOXI						
N 021372 001 >A>	9066980	Jan 30, 2024	DP U-528			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PAROXETINE MESYLATE - BRISDELLE						
N 204516 001	8946251	Aug 04, 2026	DS DP U-904			
PERAMPANEL - FYCOMPA						
N 202834 001					I-710	Jun 19, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PERAMPANEL - FYCOMPA						
N 202834 002					I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 003					I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 004					I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 005					I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 006					I-710	Jun 19, 2018
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 001	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 002	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 003	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 004	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PIRFENIDONE - ESBRIET						
N 022535 001	7696236	Dec 18, 2027	U-1601			
POMALIDOMIDE - POMALYST						
N 204026 001	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
POMALIDOMIDE - POMALYST						
N 204026 002	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
POMALIDOMIDE - POMALYST						
N 204026 003	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
POMALIDOMIDE - POMALYST						
N 204026 004	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 001	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 002	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 003	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
POSACONAZOLE - NOXAFIL						
N 205596 001	9023790	Jul 04, 2031	DP U-1698			
PREDNISONE - RAYOS						
N 202020 001	9040085	Apr 23, 2024	U-1362			
PREDNISONE - RAYOS						
N 202020 002	9040085	Apr 23, 2024	U-1362			
PREDNISONE - RAYOS						
N 202020 003	9040085	Apr 23, 2024	U-1362			
REGADENOSON - LEXISCAN						
N 022161 001	9045519	Jun 22, 2019	DP			
REGORAFENIB - STIVARGA						
N 203085 001	8637553	Feb 16, 2031	DS DP			
	8680124	Jun 02, 2030	U-1506			
RIFAXIMIN - XIFAXAN						
N 022554 001	6861053	Aug 11, 2019	U-1707		I-709	May 27, 2018
	6861053	Aug 11, 2019	U-1708			
	7452857	Aug 11, 2019	U-1707			
	7452857	Aug 11, 2019	U-1708			
	7605240	Aug 11, 2019	U-1707			
	7605240	Aug 11, 2019	U-1708			
	7718608	Aug 11, 2019	U-1707			
	7718608	Aug 11, 2019	U-1708			
	7915275	Feb 23, 2025	U-1707			
	7915275	Feb 23, 2025	U-1708			
	7935799	Aug 11, 2019	U-1707			
	7935799	Aug 11, 2019	U-1708			
	8193196	Sep 02, 2027	DS DP U-1707			
	8193196	Sep 02, 2027	DS DP U-1708			
	8309569	Jul 18, 2029	U-1707			
	8309569	Jul 18, 2029	U-1708			
	8741904	Feb 27, 2026	DS U-1526			
	8741904	Feb 27, 2026	DS U-1707			
	8741904	Feb 27, 2026	DS U-1708			
	8946252	Jul 24, 2029	U-1481			
	8969398	Oct 02, 2029	U-1481			
RISEDRONATE SODIUM - RISEDRONATE SODIUM						
A 077132 001					PC	Nov 28, 2015
RISEDRONATE SODIUM - RISEDRONATE SODIUM						
A 077132 002					PC	Nov 28, 2015
RISEDRONATE SODIUM - RISEDRONATE SODIUM						
A 077132 003					PC	Nov 28, 2015
ROFLUMILAST - DALIRESP						
N 022522 001	5712298	Jan 27, 2016	DS DP U-1115			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192 001	>A>	9079912	Dec 12, 2026	U-1573			
	>A>	9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192 002	>A>	9079912	Dec 12, 2026	U-1573			
	>A>	9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192 003	>A>	9079912	Dec 12, 2026	U-1573			
	>A>	9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192 004	>A>	9079912	Dec 12, 2026	U-1573			
	>A>	9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192 005	>A>	9079912	Dec 12, 2026	U-1573			
	>A>	9079912	Dec 12, 2026	U-1721			
SACUBITRIL; VALSARTAN - ENTRESTO							
N 207620 001	>A>	7468390	Nov 27, 2023	DP		>A> NCE	Jul 07, 2020
SACUBITRIL; VALSARTAN - ENTRESTO							
N 207620 002	>A>	7468390	Nov 27, 2023	DP		>A> NCE	Jul 07, 2020
SACUBITRIL; VALSARTAN - ENTRESTO							
N 207620 003	>A>	7468390	Nov 27, 2023	DP		>A> NCE	Jul 07, 2020
SIMEPREVIR SODIUM - OLYSIO							
N 205123 001		9040562	Jul 28, 2026	DS DP U-1467			
SIROLIMUS - RAPAMUNE							
N 021083 001						>A> ODE	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110 001						>A> ODE	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110 002						>A> ODE	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110 003						>A> ODE	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110 004						>A> ODE	May 28, 2022
SODIUM OXYBATE - XYREM							
N 021196 001		8952062	Dec 22, 2019	U-1101			
		8952062	Dec 22, 2019	U-1102			
		9050302	Mar 15, 2033	U-1532			
SOFOSBUVIR - SOVALDI							
N 204671 001	>A>	9085573	Mar 21, 2028	DS DP U-1470			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148 008		8920383	Jul 17, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148 009		8920383	Jul 17, 2026	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148 010		8920383	Jul 17, 2026	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148 011		5849700	Dec 15, 2015	U-1041			
		5849704	Dec 15, 2015	DS DP U-1041			
		6899699	Jan 02, 2022	DP			
		7686786	Aug 03, 2026	DP			
		8672898	Jan 02, 2022	DP			
		8684969	Oct 20, 2025	DP			
		8841252	Dec 26, 2017	DP			
		8920383	Jul 17, 2026	DP			
SONIDEGIB PHOSPHATE - ODOMZO							
N 205266 001						>A> NCE	Jul 24, 2020
SORAFENIB TOSYLATE - NEXAVAR							
N 021923 001	>A>	8124630	Jan 12, 2020	U-1459			
		8841330	Jan 12, 2020	U-1696			
SPINOSAD - NATROBA							
N 022408 001		6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
SUMATRIPTAN SUCCINATE - ZECUITY							
N 202278 001		8983594	Nov 19, 2030	DP U-1328			
TACROLIMUS - ENVARSUS XR							
N 206406 001						>A> ODE	Jul 10, 2022
TACROLIMUS - ENVARSUS XR							
N 206406 002						>A> ODE	Jul 10, 2022
TACROLIMUS - ENVARSUS XR							
N 206406 003						>A> ODE	Jul 10, 2022
TASIMELTEON - HETLIOZ							
N 205677 001		9060995	Jan 25, 2033	U-1710			
TEDUGLUTIDE RECOMBINANT - GATTEX KIT							
N 203441 001		5789379	Apr 14, 2016	DS DP U-1320			
	>A>	9060992	Nov 01, 2025	U-1320			
TESTOSTERONE - AXIRON							
N 022504 001		8435944	Sep 27, 2027	U-1390			
		8993520	Jun 02, 2026	U-1390			
TIGECYCLINE - TYGACIL							
N 021821 001		8975242	Oct 24, 2028	DP			
TOPIRAMATE - TROKENDI XR							
N 201635 001		8992989	Nov 16, 2027	DP U-1675			
TOPIRAMATE - TROKENDI XR							
N 201635 002		8992989	Nov 16, 2027	DP U-1675			
TOPIRAMATE - TROKENDI XR							
N 201635 003		8992989	Nov 16, 2027	DP U-1675			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - TROKENDI XR								
N 201635	004		8992989	Nov 16, 2027	DP		U-1675	
TOPIRAMATE - QUDEXY XR								
N 205122	001	>A>	9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR								
N 205122	002	>A>	9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR								
N 205122	003	>A>	9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR								
N 205122	004	>A>	9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR								
N 205122	005	>A>	9101545	Mar 19, 2033	DP			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST								
N 204114	001		8703781	Oct 15, 2030	DS DP		U-1712	
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST								
N 204114	002		8703781	Oct 15, 2030	DS DP		U-1712	
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST								
N 204114	003		8703781	Oct 15, 2030	DS DP		U-1712	
TRANEXAMIC ACID - LYSTEDA								
N 022430	001		8957113	Mar 04, 2025	DP		U-1182	
			9060939	Mar 04, 2025	DP			
TRAZODONE HYDROCHLORIDE - DESYREL								
N 018207	001	>A>	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL								
N 018207	002	>A>	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL								
N 018207	003	>A>	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL								
N 018207	004	>A>	8133893	Mar 13, 2029	DS DP			
TREPROSTINIL DIOLAMINE - ORENITRAM								
N 203496	001		7417070	Jul 30, 2026	DS			
			9050311	May 24, 2024	DS DP			
TREPROSTINIL DIOLAMINE - ORENITRAM								
N 203496	002		7417070	Jul 30, 2026	DS			
			9050311	May 24, 2024	DS DP			
TREPROSTINIL DIOLAMINE - ORENITRAM								
N 203496	003		7417070	Jul 30, 2026	DS			
			9050311	May 24, 2024	DS DP			
TREPROSTINIL DIOLAMINE - ORENITRAM								
N 203496	004		7417070	Jul 30, 2026	DS			
			9050311	May 24, 2024	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRETINOIN - RETIN-A-MICRO						
N 020475 003	5955109	Sep 21, 2016	DP U-134			
ULIPRISTAL ACETATE - ELLA						
N 022474 001	8962603	Jun 12, 2030	U-1657			
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA						
N 203975 001	8511304	Jun 14, 2027	DP U-1476			
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE						
N 021304 001					D-148	Apr 23, 2018
					NPP	Apr 23, 2018
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE						
N 022257 001					D-148	Apr 23, 2018
					NPP	Apr 23, 2018
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 001					D-146	Mar 16, 2018
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 002					D-146	Mar 16, 2018
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 003					D-146	Mar 16, 2018
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 001	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 002	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 003	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 004	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm